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Abstract 
 
This dissertation addresses several contemporary health challenges affecting the US 
population, drawing on methods and perspectives from health services research, social 
demography, and medical sociology. Paper 1 examines the pathways from educational 
attainment to difficulty with activities of daily living (ADLs) and instrumental activities of daily 
living (IADLs), helping to elucidate the means by which education shapes health outcomes 
throughout life. Less educated individuals experience higher rates of disability than those with 
higher educational attainment, and this disparity appears to be growing at both middle and older 
ages. Yet the mechanisms underlying it are not well understood. In this study, I use nationally 
representative data from the Panel Study of Income Dynamics to estimate the contributions of 
three mediators—excess body mass index (BMI), cigarette smoking, and manual labor—to 
educational disparities in ADL/IADL disability incidence. Disparities are evident in both 
younger and older adults (33-64 years, 65-96 years) and larger in women. At younger ages, these 
factors account for an estimated 60-70% of disparities in disability incidence between the most 
and least educated. Among women ages 65 and over, they account for nearly 40% of that 
disparity. Estimates in older men are more variable, suggesting an explanatory power of 20 to 
60%.  
Papers 2 and 3 speak to the US opioid crisis, which resulted in nearly 47,000 deaths in 
2018. Paper 2 centers on unequal treatment in pain management. Research has shown that black 
and Hispanic chronic pain patients are less likely than their white counterparts to receive opioid
 xii 
prescriptions, and there is evidence that provider bias contributes to this disparity. Using Optum 
healthcare claims data, I investigate whether the 2016 CDC Guideline for Prescribing Opioids 
for Chronic Pain influenced seven measures of opioid prescribing—and, if so, whether these 
changes varied by patient race/ethnicity, thereby influencing preexisting disparities. Across 
racial/ethnic groups, the guideline is associated with a gradual decline in the frequency of opioid 
prescribing, the average daily dose prescribed, and the frequency of high-dose prescribing. 
However, point estimates suggest these declines may have tended to be sharper in black and 
Hispanic patients, potentially amplifying black/white and Hispanic/white disparities in 
prescribing. While the guideline aimed to provide clinicians an evidence-based framework to 
inform opioid prescribing decisions, its emphasis on providers’ use of personal judgment to 
determine each patient’s prescribing needs may have increased reliance on racial stereotypes and 
bias amid clinical uncertainty. 
Finally, Paper 3 asks how the scarce resources available to reduce opioid-related deaths 
can be allocated for maximum health benefit. Distribution of naloxone for reversing opioid-
related overdose reduces mortality, but it is not known whether distribution remains cost-
effective in the context of rising naloxone prices and fentanyl-related overdose rates. Moreover, 
it is unclear whether distribution to people likely to witness or experience overdose 
(“laypeople”), police and firefighters, or emergency medical services (EMS)—as well as 
combinations of these—are equally cost-effective strategies. I conduct a cost-effectiveness 
analysis examining these questions and find that high distribution to all three target groups 
minimized overdose deaths, averting 21% of fatalities compared to “bare minimum” distribution. 
This strategy is highly cost-effective from a health sector perspective, cost-saving from a societal 
perspective, and robust to hypothetical moral hazard. The results suggest that communities with 
 xiii 
insufficient resources for distributing to all three groups should prioritize distribution to 
laypeople and EMS.
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Chapter 1 - Introduction 
 
In recent years, surveillance studies have documented alarming trends in the health status of the 
U.S. population. A long secular decline in age-adjusted disability prevalence during the 1980s 
and 1990s appeared to end in the early 2000s (Choi et al., 2016; Freedman et al., 2002, 2004, 
2012, 2013; Lakdawalla et al., 2004; Manton et al., 2006; Martin et al., 2010b; R. F. Schoeni et 
al., 2008; Seeman et al., 2010) and, after rising for more than fifty years, U.S. life expectancy fell 
each year between 2014 and 2017 (Woolf & Schoomaker, 2019).  
 
Americans in midlife have been particularly affected by these adverse developments. Trends in 
disability prevalence have flattened among those at older ages, while they have been rising 
among Americans under age 70 (Choi et al., 2016; Freedman et al., 2012, 2013; Lakdawalla et 
al., 2004; Martin et al., 2010b; Seeman et al., 2010). And, over the past decade, all-cause 
mortality among those ages 25-64 increased from 328.5 deaths per 100,000 population to 348.2 
per 100,000 (Woolf & Schoomaker, 2019). A sharp rise in rates of fatal overdose, driven in large 
part by opioid-related overdose, has been a key contributor to these worsening mortality trends 
(Scholl et al., 2018; Woolf & Schoomaker, 2019).  
 
This dissertation draws on methods and perspectives from health services research, social 
demography, and medical sociology to investigate three aspects of these contemporary health 
challenges, with an emphasis on their sociodemographic dimensions. Paper 1 examines the 
pathways to educational disparities in U.S. disability, while Papers 2 and 3 center on two
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elements of the 21st century opioid crisis: racial disparities in opioid prescribing amid efforts to 
reduce unsafe prescribing (Paper 2) and the allocation of scarce resources to ensure naloxone 
distribution enables the greatest gains for population health (Paper 3). 
 
Paper 1 - Pathways to educational disparities in disability incidence: The contributions 
of excess BMI, smoking, and manual labor involvement 
In Paper 1, I work to elucidate the pathways that make less educated Americans more likely to 
experience difficulty conducting activities of daily living (ADLs) and instrumental activities of 
daily living (Iezzoni et al., 2014; Robert F. Schoeni et al., 2005). ADLs and IADLs include 
everyday behaviors like bathing, walking, using the toilet, preparing meals, and conducting 
housework, and reporting difficulty with at least one of these activities is often used as an 
indicator of disability (LaPlante, 2010; Palmer & Harley, 2012). The educational gradient in 
difficulty with ADLs and IADLs appears to be growing among adults at both older and middle 
ages (Montez et al., 2017; Robert F. Schoeni et al., 2005; Zajacova & Lawrence, 2018), yet the 
mechanisms producing it have received limited attention in the academic literature (Iezzoni et 
al., 2014). 
 
Educational attainment shapes health throughout the life course via a complex set of pathways 
(Link & Phelan, 1995; Phelan et al., 2010; Zajacova et al., 2012; Zajacova & Lawrence, 2018). 
Higher educational attainment enables greater access to flexible resources, such as knowledge, 
power, money, and advantageous social connections, that can be deployed in any setting for the 
benefit of health (Link & Phelan, 1995). These resources operate at both the individual and 
contextual levels, influencing the individual behaviors that shape health, such as diet, exercise, 
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and smoking, as well as the contexts an individual occupies, such as work environment—all of 
which can in turn influence the risk of experiencing difficulty with ADLs and IADLs (Phelan et 
al., 2010; Zajacova & Lawrence, 2018). 
 
This study estimates the contributions of excess BMI, cigarette smoking, and manual labor 
involvement to educational disparities in the incidence of difficulty with activities of daily living 
(ADLs) and instrumental activities of daily living (IADLs). While the majority of studies on 
trends and disparities in ADL/IADL difficulty rely on prevalence as a main outcome, I take 
advantage of longitudinal nationally representative data from the Panel Study of Income 
Dynamics (PSID) to study incidence—thereby overcoming several methodological challenges 
associated with the study of prevalence.  
 
In addition to ADL/IADL difficulty in later life, this study sheds light on that arising among 
adults at middle ages, which has received comparatively little attention in the literature. I thus 
estimate the population-level proportion of disparities attributable to each mediator for four 
separate groups: women under age 65 years, men under age 65, women ages 65 and over, and 
men ages 65 and over. This allows me to account for variation by age, cohort, and gender in the 
educational disparities of interest and the processes contributing to them. Finally, I take 
advantage of earlier-life measures to more accurately characterize the causal pathways among 
the measures of interest: to account for likely confounding of the education-ADL/IADL 
difficulty relationship, I control for childhood socioeconomic status; and, to measure excess BMI 
and manual labor involvement more completely than in many prior studies, I use earlier-life BMI 
and occupation data in addition to contemporaneous data. 
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Paper 2 – Racial/ethnic disparities in opioid prescribing to chronic pain patients: The role 
of the 2016 CDC Guideline to reduce unsafe prescribing 
Nearly 48,000 Americans died of opioid overdose in 2017, reflecting a steady increase in opioid-
related mortality from 2.9 deaths per 100,000 population in 1999 to 14.9 deaths per 100,000 in 
2017 (Kaiser Family Foundation, 2019; Scholl et al., 2018). This public health crisis was 
accompanied by and has often been attributed to increases in rates of opioid prescribing for pain 
management, which reached a peak of 81.3 opioid prescriptions per 100 population in 2012 
before beginning a consistent decline (Centers for Disease Control and Prevention, 2020). 
Indeed, prescription opioid use increases the risk of non-medical opioid use and opioid-related 
mortality, particularly at higher doses and number of days supplied (Bohnert et al., 2011; Edlund 
et al., 2013).(Edlund et al., 2007; Mason, 2017) In 2006, for example, prescription opioid misuse 
accounted for an estimated 37 percent of all poisoning deaths (Warner et al., 2009). And while 
opioid prescribing decreased after 2012, the “second wave” of the opioid epidemic—beginning 
in earnest in 2010 and characterized by a sharp rise in heroin-related overdose—has been 
attributed in large part to a transition from prescription opioids to heroin (Centers for Disease 
Control and Prevention, 2020; Ciccarone, 2019). 
 
In an effort to stem the flow of people developing dependence on or addiction to opioids, much 
of the policy response to the present opioid crisis has centered on opioid prescribing. In March 
2016, for example, the U.S. Centers for Diseases Control and Prevention (CDC) released the 
Guideline for Prescribing Opioids for Chronic Pain. This document offered a series of 
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recommendations regarding the initiation, titration, and termination of opioid prescribing to 
chronic pain patients, and emphasizes the clinician’s role in tailoring pain management to each 
patient’s specific circumstances. Early research suggests that the guideline accelerated the 
ongoing decline in opioid prescribing at the national level (Bohnert et al., 2018; Dayer et al., 
2019), but there is evidence that it has at times been misapplied, potentially resulting in the 
undertreatment of pain and/or unsafe discontinuation of prescribing for some patients (Dowell et 
al., 2019).  
 
Black and Hispanic chronic pain patients are at particularly high risk of such misapplication, 
given the well-documented racial/ethnic disparities in pain management—especially for pain that 
is less easily observed and measured (Cleeland, 1997; Meghani et al., 2012; Ng et al., 1996; 
Todd et al., 1993, 2000; Won et al., 1999). Clinicians may be disproportionately likely to suspect 
black and Hispanic patients of so-called drug-seeking behavior, and to in turn prescribe fewer 
opioids, take more precautionary measures such as urinalysis, and reduce prescribed doses 
despite a lack of clinical indication (Becker & Turner, 2011; Buonora et al., 2018; Gaither et al., 
2018; Meghani et al., 2012; Moskowitz et al., 2011).  
 
Using a large repository of administrative health care data, this study examines whether the CDC 
Guideline’s estimated effect on prescribing patterns varied by race/ethnicity, in turn exacerbating 
or ameliorating preexisting disparities in opioid prescribing for chronic pain patients. By 
providing a framework for deciding when to prescribe opioids, in what dose, and over what time 
period—as well as guidance for avoiding high-risk co-prescribing with other medications—the 
guideline may have reduced clinical uncertainty. The provision of these clinical guideposts may 
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have mitigated clinicians’ tendency to rely on racist or race-specific priors in decision-making 
about opioid prescribing, resulting in larger declines in prescribing intensity among white 
patients compared to black and/or Hispanic patients—and in turn lessening racial/ethnic 
disparities in pain management.  
 
Alternatively, the guideline could have contributed to a widening of racial/ethnic disparities in 
prescribing. In stressing the dangers of unsafe prescribing while emphasizing provider discretion 
in evaluating the risks and benefits for each patient, it may have actually increased clinical 
uncertainty, prompting greater reliance on racist priors to assess a patient’s “legitimate” need for 
prescription opioids. That is, the guideline may have led clinicians to decrease prescribing 
intensity more strongly in black and/or Hispanic patients compared to white patients, in turn 
exacerbating existing disparities in opioid receipt. 
 
This address this question, I examine the association of passage of the CDC guideline with rates 
and levels of opioid prescribing, as well as benzodiazepine co-prescribing, in chronic, non-
cancer pain patients with osteoarthritis and fibromyalgia. To study trajectories and disparities in 
prescribing in a large sample of individuals from all fifty states, and to enable association of 
chronic pain diagnoses with subsequent prescription receipt, I use health care claims data from 
OptumInsight’s Clinformatics Data Mart. In an effort to assess disparities arising from provider 
decision-making rather than issues of socioeconomic status, access, or pain prevalence, I 
examine prescribing outcomes of clinical encounters with patients who are insured and have 
received diagnoses that meet my criteria for chronic, non-cancer pain.  
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Paper 3 - Cost-effectiveness analysis of alternative naloxone distribution strategies: First 
responder and lay distribution in the United States 
While Paper 2 focuses on policies to address initiation of nonmedical opioid use, Paper 3 
addresses a different dimension of the opioid crisis: efforts to reduce mortality among people 
already at risk of opioid-related overdose. Ensuring access to naloxone, a safe and effective 
opioid antagonist, is a key component of such work. If administered in time and in sufficient 
dosage, naloxone can reverse opioid-related overdose, extending a person’s life and providing 
additional opportunity to pursue treatment for opioid use disorder. 
 
Prior research has shown distribution of naloxone to people using opioids to be highly cost-
effective—i.e., to provide substantial health benefits at a low cost to the health care system and 
society (Coffin & Sullivan, 2013a). However, it is not clear how this strategy of distribution to 
laypeople (those likely to witness or experience overdose) compares to first responder 
distribution. Law enforcement officers, firefighters, and emergency medical services (EMS) are 
increasingly equipped with naloxone, enabling earlier administration than when the medication is 
first available at the emergency department—and thus potentially saving more lives (Belz et al., 
2006; C. S. Davis, Ruiz, et al., 2014; Gulec et al., 2018). 
 
However, resources to address the opioid crisis are scarce, and a number of factors may increase 
or diminish the cost-effectiveness of naloxone distribution to each of the three potential target 
groups: laypeople, police and fire, and EMS. In many rural areas, for example, police and fire 
may arrive to an overdose scene considerably earlier than an ambulance, saving precious time if 
these first responders are equipped with naloxone (C. S. Davis, Ruiz, et al., 2014). Yet many 
 8 
overdose witnesses do not call 911 out of fear of legal or other repercussions, potentially 
reducing the effectiveness of distribution to first responders (Galea et al., 2006). While family 
and friends of an overdose victim are often the “true” first responders—and despite a body of 
evidence to the contrary—many policymakers fear that lay naloxone distribution results in moral 
hazard, increasing opioid use and in turn worsening health outcomes at the population level. 
 
In the context of these intertwining forces, I estimate and compares the cost-effectiveness of 
naloxone distribution to each of three target groups, both individually and in combination. To do 
so, I use a mathematical modeling approach that is robust to the limitations in data regarding 
people who use opioids, particularly in the context of a rapidly evolving crisis. This enables 
extensive sensitivity analyses that speak to a range of real-life circumstances, providing the 
means to make evidence-based policy decisions in the face of incomplete data and urgent human 
need.
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Chapter 2 - Pathways to Educational Disparities in Disability Incidence: The Contributions 
of Excess BMI, Smoking, and Manual Labor Involvement 
 
INTRODUCTION 
In the United States, difficulty with activities of daily living (ADLs) and instrumental activities 
of daily living (IADLs) is starkly patterned by education (Iezzoni et al., 2014; Robert F. Schoeni 
et al., 2005). ADLs and IADLs include everyday behaviors like bathing, walking, using the 
toilet, preparing meals, and conducting housework. Reported difficulty conducting at least one of 
these activities independently is frequently used as an indicator of disability (Burkhauser et al., 
2006; Iezzoni et al., 2014; LaPlante, 2010; Martin & Schoeni, 2014; Palmer & Harley, 2012). 
Disability is defined here as one’s ability, due to a combination of physical, cognitive, 
environmental, and societal attitudinal factors, to carry out everyday life activities (Palmer & 
Harley, 2012; Verbrugge & Jette, 1994).  
 
In a nationally representative study of adults ages 45 to 89, 21.5% of those without a high school 
degree reported experiencing ADL difficulty, compared to just 4.9% of those with a college 
degree or more (Montez et al., 2017). This gradient seems to be growing in adults at both older 
and middle ages (Montez et al., 2017; Robert F. Schoeni et al., 2005; Zajacova & Lawrence, 
2018), yet the mechanisms producing it are not well understood (Iezzoni et al., 2014). Compared 
to disparities in mortality, educational disparities in disability have received little attention. In
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particular, few empirical studies have examined potential mediators of the relationship between 
education and disability and their respective contributions to disparities. 
 
Educational attainment shapes health throughout the life course via a multifarious and complex 
set of pathways (Link & Phelan, 1995; Phelan et al., 2010; Zajacova et al., 2012; Zajacova & 
Lawrence, 2018). Higher educational attainment enables greater access to flexible resources, 
such as knowledge, power, money, and advantageous social connections, which can be deployed 
in any setting for the benefit of health (Link & Phelan, 1995). These resources operate at both the 
individual and contextual levels, influencing the individual behaviors that shape health, such as 
diet, exercise, and smoking, as well as the contexts an individual occupies, such as work 
environment—all of which can in turn influence disability risk (Phelan et al., 2010; Zajacova & 
Lawrence, 2018). 
 
While there is evidence that excess BMI and smoking partially mediate the education-disability 
relationship (Cutler & Lleras-Muney, 2010; Sainio et al., 2007), such research is scarce and has a 
number of important limitations. First, a third mediator and likely confounder, involvement in 
manual labor (defined here as working as an operative or laborer), has received little attention 
(Cutler & Lleras-Muney, 2010). Manual labor can increase disability risk through repetitive 
stress and other mechanisms (Bang & Kim, 2001; Leigh & Fries, 1992; Marmot et al., 1997).  
 
Second, prior research has focused predominantly on older adults, overlooking disparities in 
disability at middle ages. Yet these groups may exhibit important differences in the trends and 
consequences of disability. Disability can have a range of adverse consequences for individual 
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well-being, influencing mental health, everyday task independence, role fulfillment, social 
relationships, finances, and other outcomes (Carr, 1999; Darling, 1987). Its occurrence among 
those under retirement age may be of particular concern, interfering with the ability to work, take 
care of children and aging parents, save for retirement, and engage in other activities important 
in middle life. Moreover, trends in earlier-life disability may differ in direction and magnitude 
from those in older adults (Martin & Schoeni, 2014; Robert F. Schoeni et al., 2008). Between 
1997 and 2010, for example, ADL/IADL disability prevalence increased among adults under age 
65, while decreasing among those ages 65 and over (Iezzoni et al., 2014; Martin & Schoeni, 
2014). A more thorough understanding of the trends in and processes underlying earlier-life 
disability is needed. 
 
Moreover, the respective roles of excess BMI, smoking, and manual labor in explaining 
educational disparities in disability incidence likely vary by age, cohort, and gender—due to 
variation both in the prevalence of the mediators by group, and in the associations among 
education, the mediators, and disability. For example, smoking prevalence among women and 
educational disparities in smoking are greater in more recent cohorts (Escobedo & Peddicord, 
1996; Link & Phelan, 2009; Pampel, 2009). In addition, the association between education and 
BMI is more pronounced in women (Brunello et al., 2013; Y.-J. Kim, 2016), and we might 
expect the effects of manual labor on disability to manifest predominantly during working ages. 
These variations suggest that age-gender groups will differ in the pathways underlying 
educational disparities. 
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Finally, by examining disability prevalence rather than incidence, existing research raises the 
specters of Neyman bias and reverse causation (Grimes & Schulz, 2002; Mehta, 2015). In 
Neyman bias, for example, smoking-related mortality results in a healthier observed population 
of smokers, reducing smoking’s estimated effect on disability (Grimes & Schulz, 2002). In 
reverse causation, disability may lead to reductions in excess BMI or manual labor involvement, 
making these mediators appear protective in prevalence studies (Mehta, 2015). In addition, 
related research has typically estimated only mediation percentages, rather than accounting for 
the mediators’ prevalence in the population and, in turn, estimating the percent of disparities they 
explain at the population level. 
 
To address these gaps in the literature, this study uses the Panel Study of Income Dynamics 
(PSID) to estimate the contributions of excess BMI, smoking, and manual labor to disparities in 
incident ADL/IADL difficulty at the population level, stratifying by age and gender. In doing so, 
I take advantage of life course factors including childhood socioeconomic status, earlier-life 
BMI, and historical occupation data. 
 
Educational disparities in disability 
Education influences health-related outcomes like disability via a variety of biomedical, 
environmental, and social pathways, including economic circumstances, social support and 
influence, health behaviors, stress, environmental exposures, and health care access (Link & 
Phelan, 1995; Zajacova & Lawrence, 2018). The association between education and self-rated 
health appears stronger among women, who also experience higher rates of disability overall 
(Montez et al., 2017; Zajacova & Montez, 2017). 
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Measures of ADL/IADL difficulty suggest that educational disparities in disability prevalence 
may be growing. While the prevalence of ADL/IADL difficulty among adults ages 70 and older 
fell for all educational groups during the 1980s and 1990s, the least educated experienced the 
smallest decline (Robert F. Schoeni et al., 2005). Between 2000 and 2015, prevalence of 
ADL/IADL difficulty among those ages 45-64 stabilized among the most educated and increased 
among other educational groups (Zajacova & Montez, 2017). 
 
Education, excess BMI, and disability 
A strong association between educational attainment and BMI, particularly among women, is 
well-documented (Brunello et al., 2013; Y.-J. Kim, 2016). Using sibling data, for example, Kim 
(2016) finds that those with a college degree have an estimated 0.7-unit lower body mass index 
(BMI) than high school graduates with no college attendance (Y.-J. Kim, 2016). Less educated 
groups gain weight more rapidly during adulthood, such that educational disparities in BMI 
widen throughout much of the life course (Clarke et al., 2009). There is also evidence that BMI 
can influence educational attainment (Karnehed et al., 2006).  
 
Mediators between education and BMI include health literacy and resources for deploying it, 
exposure to norms and social support, and stress related to social status, sense of control, and 
socioeconomic security, among others (for an overview, see Zajacova & Lawrence, 2018). 
Health conditions mediating the excess BMI-disability relationship include higher risk of 
diabetes, coronary artery disease, and osteoarthritis—all of which can undermine mobility and 
independence (Samper-Ternent & Al Snih, 2012). The rising prevalence and duration of obesity 
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in the U.S. population may partly explain rising rates of ADL/IADL difficulty, particularly in 
recent cohorts (Iezzoni et al., 2014; Martin & Schoeni, 2014). 
 
Reverse causation, in which illness causes weight loss, can mask the BMI-disability relationship 
by making higher BMI look protective—particularly in older age, when health declines are more 
common (Stokes & Preston, 2016). Measurement of BMI at multiple points in the life course 
may therefore help capture the effects of excess BMI on health (Abdullah et al., 2011; Mehta, 
2015). 
 
Education, smoking, and disability 
More educated groups may have more economic, cognitive, social, and cultural resources to 
avoid or quit smoking (Link & Phelan, 1995; Pampel, 2009). While smoking was not clearly 
patterned by educational status in the 1950s, an educational gradient emerged in the wake of the 
Surgeon General’s Report on Smoking and Health and subsequent attention to smoking’s 
adverse effects. Educational disparities grew as smoking rates declined earlier and more rapidly 
among the more educated (Escobedo & Peddicord, 1996; Link & Phelan, 2009; Pampel, 2009).  
 
The strong educational gradient in smoking may be due in part to effects of educational 
attainment on smoking, and in part to common causes such as early-life exposures. Net of 
familial factors, however, individuals with less than a high school degree appear to make fewer 
quit attempts and be less likely to quit smoking (Gilman et al., 2008). 
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Disability rates in more recent cohorts would likely have risen more sharply absent declines in 
smoking in those groups (Martin & Schoeni, 2014). Smoking predicts disability via greater 
incidence of musculoskeletal injury (Altarac, 2000), higher probability of progression from 
injury to disability (Lincoln et al., 2003), contribution to cardiovascular and respiratory diseases 
(Murray & Lopez, 1997), and other pathways (Manouchehrinia et al., 2013). There is evidence 
of a dose-response relationship between smoking and disability incidence (Claessen et al., 2010), 
and evidence that cessation can reverse or diminish some adverse health consequences (Lincoln 
et al., 2003; Manouchehrinia et al., 2013). In addition to the causal effects of smoking on 
disability, these factors may have common causes, such as health consciousness and underlying 
mental health (Claessen et al., 2010). 
 
Education, manual labor, and disability 
Manual labor involvement may be a third key mediator of the education-disability relationship 
(Cutler & Lleras-Muney, 2010). Occupation is starkly patterned by education: less educated 
individuals have fewer career options and are disproportionately likely to be unemployed or 
conduct manual labor (Leigh & Fries, 1992). In addition to the likely causal effect of educational 
attainment on manual labor involvement, these factors may be influenced by common causes 
such as family socioeconomic status and structural factors that channel educational groups into 
distinct vocations. 
 
Manual laborers experience higher rates of disability than their counterparts, although research in 
U.S. populations is limited (Abdullah et al., 2011; Cutler & Lleras-Muney, 2010; Leigh & Fries, 
1992; Li, 2000; Mansson, 1998). In the U.S., for example, disability is most common among 
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machine operators, farm workers, and laborers (Cutler & Lleras-Muney, 2010; Leigh & Fries, 
1992). Manual labor often entails more occupational hazards and repetitive movements than 
other work, contributing to musculoskeletal injuries and disability (Leigh & Fries, 1992). Some 
forms of manual labor may also entail limited job control, which can contribute to disability by 
increasing stress, a risk factor for cardiovascular disease (Marmot et al., 1997; Rahkonen et al., 
2006; Warren et al., 2004). Manual labor may also increase disability risk by perpetuating low 
socioeconomic status: lower wages and status may impede individuals’ ability to invest in their 
health and to transition to a more health-conducive job. 
 
The pathways between manual labor and disability may also include interactions with excess 
BMI and smoking. Smoking prevalence is higher in manual labor and related jobs (Bang & Kim, 
2001), likely reflecting social network effects among other factors (Christakis & Fowler, 2008). 
Conversely, the physical activity involved in manual labor may promote lower BMI and prevent 
other adverse effects of more sedentary lifestyles (Rydwik et al., 2013).  
 
Aims 
I examine the proportion of educational disparities in the incidence of ADL/IADL difficulty 
(“incidence”) explained by excess BMI, smoking, and manual labor, independently and jointly. I 
use nationally representative, longitudinal data with up to seven waves of follow-up, and take 
advantage of earlier-life measures of socioeconomic status, body mass index (BMI), and 
occupation. I compare actual disparities in incidence to their estimated counterfactuals in the 
absence of excess BMI, smoking, and manual labor, enabling estimation of the percentage of 
disparities explained by each mediator of interest. 
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I address several important gaps in the literature. To my knowledge, this is the first study to 
estimate the population-level contributions of three key mediators underlying the relationship 
between education and difficulty with ADLs and /IADLs. To account for distinct processes in 
men and women at middle versus older ages, I stratify by gender and age at exposure to the 
mediators. Third, whereas prior studies have examined predictors of ADL/IADL prevalence, I 
study incidence, reducing the risks of Neyman bias and reverse causation. 
 
METHODS 
Study population  
The PSID is a nationally representative survey that followed participants and their descendants 
annually from 1968-1997 and biennially thereafter (Appendix A-1). Individuals were eligible for 
the analytic sample if they participated in PSID in 1986 (the earliest wave in which height and 
weight were reported) and at least two consecutive waves between 2003 and 2015. 
 
Measures 
In line with existing literature and PSID recommendations, ADL/IADL difficulty was defined as 
difficulty with at least one ADL or IADL (Burkhauser et al., 2006; Cutler & Lleras-Muney, 
2010; Iezzoni et al., 2014; Laditka & Laditka, 2016; Martin et al., 2010a; Martin & Schoeni, 
2014; Robert F. Schoeni et al., 2005). Since 2003, PSID has asked about difficulty conducting a 
standard set of ADLs and IADLs without assistance or special equipment. The assessed ADLs 
include: difficulty bathing or showering; dressing; eating; getting in or out of a bed or a chair; 
walking; getting outside; and using or getting to the toilet. The assessed IADLs include: 
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difficulty preparing meals; shopping for toiletries or medicines; managing money; using the 
telephone; doing heavy housework; and doing light housework. Incidence with ADL/IADL 
difficulty was defined as a switch from no difficulty in wave t-1 to any difficulty in wave t 
(Appendix A-2). 
  
Excess BMI was measured using two continuous indicators, calculated using self-reported height 
and weight: 1986 (“earlier-life”) BMI and time-varying (“contemporaneous”) BMI between 
2003 and 2015. To examine associations between excess BMI and incident ADL/IADL 
difficulty, these were equal to absolute BMI minus 25 (Mehta et al., 2014; Preston et al., 2013) 
(Appendix A-3). Smoking history (never, former, current smoker) was time-varying. The manual 
labor variable was binary and indicated ever having been an “operative” or “laborer” between 
1968 and 2001. Appendix A-4 details construction of this variable and discusses the associations 
between each type of manual labor and incidence. 
 
Because people may obtain education between waves, this variable was time-varying (less than 
high school, high school degree, college degree). Obtaining a GED, attending some college, 
receiving non-academic training after high school, and obtaining an Associate’s degree were 
coded as “high school degree”. Appendix A-5 details the reasoning behind this categorization. 
 
I controlled for sociodemographic factors likely to be independently related to education, 
ADL/IADL difficulty, and the mediators: age (continuous), gender, childhood socioeconomic 
circumstances (“Were your parents poor when you were growing up, pretty well off, or what?”: 
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“poor”, “average/it varied”, “pretty well off”), race/ethnicity (non-Hispanic white, black, 
Hispanic non-black, and non-Hispanic other), and year (categorical) (Appendix A-5). 
 
Statistical analysis 
Regression models 
Analyses were conducted in Stata 15.0. Logistic regressions, stratified by gender and age at 
exposure to the time-varying predictors (under 65 years old vs. 65 and above), predicted 
incidence of ADL/IADL difficulty for up to seven waves of follow-up, between 2003 and 2015 
(Appendix A-6). Waves in which a respondent was at risk for incident ADL/IADL difficulty 
(i.e., did not currently report any difficulty) were included in regression analyses, with an 
indicator of whether incidence occurred in the following wave. Individuals could experience 
incidence multiple times. 950 observations were excluded due to covariate missingness or 
extreme values of BMI (less than 15 and greater than or equal to 50), driven predominantly by 
missing mediator data (Appendix A-5). To alleviate reverse causation, all time-varying 
predictors were lagged one wave. Appendix A-7 discusses and tests the assumption, implicit in 
these regression models, that the associations between the mediators and incident ADL/IADL 
difficulty do not vary by educational attainment.  
 
Percent of disparities explained by mediators 
Following regression, I calculated predictive margins and educational disparities by age-gender 
group, using the observed distribution of covariates to estimate incident ADL/IADL difficulty in 
each age-gender-educational category. Educational comparisons included college versus no high 
school degree; high school versus no high school degree; and college versus high school degree. 
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I used the same approach to estimate incidence and disparities in each subgroup under four 
counterfactual scenarios: (a) no excess BMI in the population, in 1986 or contemporaneously; (b) 
no smoking; (c) no involvement in manual labor; and (d) none of the three risk factors in the 
population. That is, I set the indicator of the corresponding mediator(s) to zero for the entire 
sample and calculated the corresponding predictive margins, holding the values of all other 
covariates as observed. I compared the observed and counterfactual disparities to estimate the 
percentage of observed disparities explained by the mediators, individually and jointly. 
Confidence intervals were calculated using the delta method (Oehlert, 1992; Phillips & Park, 
1988). These methods were only able to approximate the causal processes of interest and assume 
no unobserved confounding. For clarity, I use the terms “explained” and “contributed” to 
describe the estimated proportion of disparities attributable to a given mediator, but these cannot 
be interpreted to be true causal effects. 
 
Supplementary analyses 
I conducted a number of supplementary analyses. First, I examined sedentariness in year of study 
entry (more than 10 minutes of heavy exercise per week, or not) as a potential mediator in the 
regressions and re-estimated percentages of disparities explained (Appendix A-8). Concerns 
about reverse causation precluded its inclusion in the main analysis. In a second supplementary 
analysis, I examined the ADL and IADL with which participants most often had difficulty—
walking and heavy housework. The higher frequency of difficulty with these activities could 
suggest that distinct processes underlie the ability to conduct them. Third, I examined persistent 
difficulty, i.e., ADL/IADL difficulty lasting at least two consecutive waves. Appendix A-8 
outlines the frequency of persistent difficulty by age-gender group. Fourth, I examined difficulty 
 21 
with ADLs and IADLs separately. Fifth, I used a method of mediation analysis recently 
developed by Karlson, Holm, and Breen to examine whether the association between manual 
labor and incident ADL/IADL difficulty in younger men was mediated by excess BMI and 
smoking, given that manual labor involvement may influence each of these via effects on 
physical activity, social exposure, and workplace smoking policies (Karlson et al., 2012). 
Finally, I examined whether the association of each mediator with incidence varied by 
educational group (Appendix A-7).  
 
 
RESULTS 
Descriptive statistics 
Table 2-1 displays weighted sample characteristics. Incident ADL/IADL difficulty (i.e., a switch 
from no difficulty to any difficulty in the subsequent wave) was evaluated for 3,129 individuals 
at risk for incident difficulty for an average of 4-5 waves. There were 1,398 cases of incidence. 
Incidence was greater in women (younger women: 4.4 cases per 100 person-years; younger men: 
3.0 per 100 person-years; older women: 9.8 per 100 person-years; older men: 8.3 per 100 person-
years). The sample was predominantly white and most had attained only a high school degree. 
Men were more likely than women to have completed college. 
 
BMI was lower in women than men in 1986 (younger women: 23.0; younger men: 25.2; older 
women: 24.0; older men: 26.1) and at study entry (i.e., the first wave, 2003-2015, present in the 
analytic sample; younger women: 26.6; younger men: 27.7 women; older women: 25.6; older 
men: 27.1). BMI increased between 1986 and study entry. Among older individuals, women 
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were less likely than men to have ever smoked (40% vs. 67%); this difference was less 
pronounced in younger individuals (56% vs. 53%). Across age groups, 29-35% had ever 
participated in manual labor. 
 
Walking was the most prevalent ADL difficulty and performing heavy housework was the most 
prevalent IADL difficulty (Appendix A-9). Others were clustered with similar prevalence. 
Except in women 65 and over, education was positively associated with ever having smoked 
(Table 5-1; Figure 5-2). In women, education was negatively associated with excess BMI; it was 
positively associated with excess BMI in older men. Across groups, education was negatively 
associated with ever participating in manual labor. 
 
Regressions  
Estimated associations between predictors and incident ADL/IADL difficulty varied by age-
gender group (Table 2-2). Age was positively associated with incidence in all groups and being 
black (vs. non-Hispanic white) was associated with incidence in men. With the exception of 
older men, higher education was associated with lower incidence, though estimates were not 
always statistically significant at the p=0.05 level. Similarly, higher childhood socioeconomic 
status was associated with lower incidence in all but older women, but estimates were imprecise. 
Higher 1986 and contemporaneous BMI, as well as smoking, tended to be positively associated 
with incidence. Manual labor was associated with higher odds of incidence in younger men (OR 
= 1.50, 95% CI: 1.08-2.10). 
 
Disparities in incident ADL/IADL difficulty and estimated percent explained 
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Educational disparities in incident ADL/IADL difficulty were evident in both men and women 
(Figure 2-1). With the exception of older men, for whom it was highest among those with a high 
school degree, incidence decreased with greater educational attainment. Larger disparities were 
observed among women than men, and this gender difference was most pronounced among the 
least educated. 
 
Overall, excess BMI, smoking, and manual labor were estimated to explain a greater percentage 
of disparities in younger compared to older adults (younger women: 58-62%; younger men: 65-
72%; younger men; older women: 38-39%; older men: 20-60%), although estimates did not 
reach statistical significance at the p=0.05 level in older men (Table 2-3). In younger women, 
smoking and excess BMI appeared to be the main contributors to disparities (smoking: 21-30%; 
excess BMI: 36-39%), while in younger men the main contributors appeared to be smoking and 
manual labor (smoking: 23-35%; manual labor: 33-38%). In older women, excess BMI appeared 
to be the main contributor to disparities (30%). While estimates for older men were noisy, 
smoking appeared to be the main contributor to disparities. In this group, higher BMI appeared 
to suppress educational disparities, reflecting lower average BMI among the least compared to 
more educated older men. 
 
Tables 5-2 through 5-7 and appendix text provide results of the supplementary analyses. 
 
DISCUSSION 
In this study, I estimated population-level contributions of three key mediators of educational 
disparities in incident ADL/IADL difficulty among both younger and older women and men. I 
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took advantage of seven waves of nationally representative, longitudinal data on ADL/IADL 
difficulty, combined with information on life course factors including childhood socioeconomic 
circumstances, earlier-life BMI, and occupational history. Educational disparities in ADL/IADL 
difficulty were evident among both younger and older adults (under 65, 65 and over) and larger 
in women. Together, excess BMI, smoking history, and manual labor involvement appeared to 
account for roughly 60-70% of disparities in incident ADL/IADL difficulty between the most 
and least educated under age 65. Among women aged 65 and over, these factors tended to 
account for nearly 40% of that disparity. Estimates in older men were more variable, but the 
models indicated an explanatory power of 20-60%. 
 
The stronger contribution of smoking to disparities in younger compared to older women likely 
reflects the growing prevalence and educational gradient in smoking in recent decades (Escobedo 
& Peddicord, 1996; Link & Phelan, 2009; Pampel, 2009). Smoking also appeared to explain 
more of the educational disparity in ADL/IADL difficulty among men, a product of the starker 
educational gradient in smoking among men compared to women. 
 
Conversely, excess BMI appeared to contribute more to educational disparities among women. 
This finding was related to the more consistent relationship between education and BMI among 
women. Indeed, contemporaneous BMI was higher among men with a high school degree than 
among their more and less educated counterparts. This is consistent with prior research (Brunello 
et al., 2013; Y.-J. Kim, 2016), and may relate to findings that education predicts exercise and 
employment more strongly in women, factors inversely related to excess BMI (Brunello et al., 
2013). Moreover, larger educational disparities in smoking—which is inversely related to 
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weight—among men may suppress an educational gradient in BMI in this group (Rydwik et al., 
2013). 
 
Ever conducting manual labor appeared to be a key driver of disparities in young men. While 
estimates were imprecise, it appeared to contribute less in older adults. The apparent differential 
by age may suggest that manual labor’s effect on ADL/IADL difficulty is most pronounced 
during working ages, although my study is not conclusive in this regard. While prevalence of and 
educational disparities in manual labor involvement were considerable in younger women, 
manual labor’s estimated contribution to disparities in incident ADL/IADL difficulty was not 
significantly different from zero. This may suggest that women and men coded as “laborers” or 
“operatives” conduct substantively distinct types of work, with differential consequences for 
difficulty with ADLs and IADLs. More research on the contribution of manual labor to 
ADL/IADL difficulty by gender and throughout the life course is warranted. 
 
The three mediators of interest appeared to explain less of the disparities in the older group than 
in the younger group. Differential ability to manage biological frailty may serve as an additional 
mediator, explaining residual disparities at older ages: more educated individuals, who on 
average have more financial and other resources, may be better able to adapt to growing frailty at 
older ages—e.g., installing home infrastructure to prevent falls and, when a fall does occur, 
obtaining support to reduce the risk of developing ADL/IADL difficulty. Because each age 
group comprised individuals from different birth cohorts, both age and cohort effects are likely 
combining to produce the patterns observed here. Research examining multiple birth cohorts as 
they age is needed to untangle these effects. 
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Reflecting the unique disadvantage of not obtaining a high school degree, disparities between the 
most and least educated were largest, followed by those between the middle and least educated. 
Moreover, despite strong associations between education and the mediators, substantial 
disparities were left unexplained after accounting for them—a product of the myriad pathways 
by which limited education can influence health, and which I was unable to account for. These 
might include persistent stress, environmental exposures, neighborhood resources, social 
influence, unstable housing, unemployment, unstable employment, and others (Bambra & 
Eikemo, 2008; Baum et al., 1999; Burgard et al., 2012; Christakis & Fowler, 2008; Glass et al., 
2006). Therefore, while successful behavioral interventions may reduce disparities in disability, 
they alone are not sufficient. Broad-based policies that improve access to quality education are 
also needed (Link & Phelan, 1995). 
 
Separate examination of ADLs, IADLs, and the two most common manifestations of ADL/IADL 
difficulty (difficulty walking and conducting heavy housework) did not meaningfully change my 
conclusions. In a supplementary analysis of persistent difficulty, defined as ADL/IADL 
difficulty lasting at least two waves, the estimated percentage of disparities explained in women 
grew, driven in younger women by a larger estimated contribution of manual labor. Exposure to 
manual labor may be associated with musculoskeletal injuries that contribute to earlier-life and 
prolonged spells of difficulty with ADLs and IADLs. Finally, supplementary examination of 
potential additive interactions between education and the mediators revealed that education is a 
likely effect modifier of the association between smoking and ADL/IADL difficulty, particularly 
in women. Further research is needed to confirm these findings and to elucidate both the 
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mechanisms underlying them and their consequences for the pathways to educational disparities 
in ADL/IADL difficulty. 
 
This study has limitations. First, comparisons of percent of disparities explained between 
mediators and across age-gender groups were complicated by imprecise estimates, particularly in 
older adults. I reported apparent trends between groups or mediators, but was often unable to 
reject the null hypothesis of no difference at an alpha of 0.05. Despite the strengths afforded by 
my longitudinal data and earlier-life measures, reverse causation remains a challenge. I 
attempted to address this by including 1986 BMI in addition to contemporaneous BMI, providing 
a measure less related to concomitant health decline. As my analyses reflected, earlier-in-life 
BMI predicts health outcomes independent of baseline or contemporaneous BMI (Abdullah et 
al., 2011; Mehta et al., 2014). To further address reverse causation, I lagged BMI and smoking 
by one wave (two years), and fixed the measure of ever having participated in manual labor to 
2001, the wave prior to initiation of analysis. Reverse causation concerns precluded inclusion of 
one potential mediator of disparities: unemployment. Unemployment is strongly related to 
disability (Leigh & Fries, 1992; Mansson, 1998), but much of this relationship may be due to the 
effects of disability on unemployment. 
 
In addition, the links between education and my mediators may in part be explained by common 
causes such as early-life exposures and personality factors, rather than reflecting a pure causal 
effect of education on smoking behavior, excess BMI, and manual labor participation (Claessen 
et al., 2010; Gilman et al., 2008). As a result, the mediators I examined may mediate not only the 
relationship between education and difficulty with ADLs and IADLs, but also the relationship 
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between these common causes and disability. I attempted to minimize this bias by controlling for 
childhood socioeconomic status, but data limitations precluded controlling for other early-life 
exposures or individual traits. Nonetheless, my findings help elucidate the extent to which 
educational disparities in incident ADL/IADL difficulty would shrink if the mediators were 
eliminated in the population. 
 
My measure of whether the participant had ever conducted manual labor was imperfect. I likely 
underestimated manual labor involvement among the older group due to incomplete data on their 
working years: when PSID began in 1968, individuals in the older group were already 30-58 
years old, so some manual labor involvement was likely missed. Second, my measure of manual 
labor involvement does not capture physically demanding domestic labor. This could lead to 
underestimation of ADL/IADL difficulty related to manual labor, particularly in women (Leigh 
& Fries, 1992). Third, missingness in the occupation variable may have resulted in 
misclassification of some individuals as “never manual”; this would also result in conservative 
estimates of manual labor’s contribution to disparities. 
 
While evidence suggests excess BMI can itself contribute directly to difficulty with ADLs and 
IADLs (Samper-Ternent & Al Snih, 2012), it may also function as a proxy for other important 
risk factors such as exercise. However, in the supplementary analysis in which sedentariness in 
the year of study entry was included as a potential mediator, the estimated contribution of excess 
BMI to disparities fell by only 0-4 percentage points, suggesting my main estimates for excess 
BMI are not merely capturing the effects of sedentariness on ADL/IADL difficulty. 
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This study examined disparities in difficulty with at least one of 13 standard ADLs and IADLs, a 
measure frequently used as an indicator of disability (Iezzoni et al., 2014; Martin & Schoeni, 
2014; Palmer & Harley, 2012; Samper-Ternent & Al Snih, 2012). A social-relational model of 
disability acknowledges that disability results from an interaction between physical impairment 
and social and environmental conditions—i.e., that the consequences of physical impairment for 
one’s ability to carry out everyday life activities are shaped by the environmental structures and 
resources available to the person (Reindal, 2008). As a result, disability may often be 
ameliorated by contextual changes—such as ramps, Braille signage, health aides, and many 
others—without change to the body itself.  
 
Within this context, ADL and IADL measures are useful indicators of disability in that they 
assess one’s ability to conduct higher-order activity, which is the product of both biomedical and 
socioenvironmental processes. However, because PSID’s ADL and IADL measures ask about 
trouble conducting the activity without assistance or special equipment, their specificity as 
measures of disability is likely constrained. That is, they may be prone to false positives, in 
which individuals with physical impairment who report ADL/IADL difficulty are able to make 
use of adaptive measures and consequently do not actually experience disability. Because access 
to such adaptive measures is likely greater among more educated people, my estimates of 
disparities in ADL/IADL difficulty probably underestimate disparities in disability as defined in 
the social-relational model. Longitudinal data evaluating ADL/IADL difficulty both with and 
without adaptive measures are needed. 
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Against a backdrop of population aging and widening educational disparities in disability, this 
study provides important insight into the mechanisms underlying those gaps. My findings 
suggest that excess BMI, smoking, and manual labor explain 20-70% of disparities in incident 
ADL/IADL difficulty, and that the mediators driving them vary by age-gender group. Further 
research is needed to account for the proportion of disparities left unexplained, and to better 
characterize the ways in which the mediators of interest translate into health conditions and, 
ultimately, difficulty conducting activities core to everyday life. 
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Table 2-1. Sample characteristics by age group and gender 
  Under 65 65 and older 
 Women Men Women Men 
  Est. 95% C.I.. Est. 95% C.I.. Est. 95% C.I.. Est. 95% C.I.. 
Unique 
individuals 1,352 -- 
        
1,106  -- 382 -- 289 -- 
Waves at risk 
for disability, 
mean 
4.0 --             4.2  -- 4.5 -- 5.1 -- 
Incidence, cases 492 --            300  -- 354 -- 252 -- 
Incidence, per 
100 person-
years 
4.4 (3.9 to 4.9) 3.0 (2.6 to 3.5) 9.8 (8.7 to 11.0) 8.3 (7.1 to 9.4) 
Characteristics 
at study entry 
            
Age, mean, 
years 50.2 (49.7 to 50.6) 50.4 (49.9 to 50.8) 73.9 (73.2 to 74.6) 72.5 (71.8 to 73.2) 
Body mass 
index (BMI) in 
1986, kg/m2 
            
   Mean 23.0 (22.8 to 23.3) 25.2 (25.0 to 25.5) 24.0 (23.6 to 24.5) 26.1 (25.7 to 26.6) 
   Overweight 
   or obese, % 23.0 (20.5 to 25.7) 48.6 (45.3 to 51.9) 30.1 (25.3 to 35.3) 60.1 (54.1 to 65.8) 
Obese, %  7.3 (5.8 to 9.1) 9.5 (7.7 to 11.6) 7.0 (4.7 to 10.2) 11.5 (8.2 to 15.8) 
BMI at study 
entry kg/m2 
            
Mean 26.6 (26.3 to 27.0) 27.7 (27.5 to 28.0) 25.6 (25.1 to 26.1) 27.1 (26.6 to 27.5) 
Overweight 
or obese, % 
(BMI ≥ 25.0) 
52.7 (49.6 to 55.8) 76.0 (73.1 to 78.7) 47.0 (41.6 to 52.5) 66.2 (60.4 to 71.6) 
Obese, %  23.4 (20.9 to 26.1) 24.8 (22.1 to 27.7) 13.3 (10.0 to 17.4) 19.2 (14.8 to 24.5) 
Smoking, %             
Never 54.2 (51.0 to 57.3) 47.2 (43.9 to 50.5) 59.8 (54.3 to 65.1) 32.5 (27.2 to 38.4) 
Former 26.4 (23.7 to 29.3) 28.9 (26.1 to 32.0) 31.6 (26.7 to 37.0) 61.6 (55.7 to 67.3) 
Current 19.4 (17.1 to 22.1) 23.9 (21.2 to 26.8) 8.5 (5.9 to 12.2) 5.8 (3.6 to 9.2) 
Manual labor, % 32.4 (29.5 to 35.4) 35.3 (32.3 to 38.5) 28.9 (24.2 to 34.1) 25.2 (20.4 to 30.6) 
Race/ethnicity, 
% 
            
   Non- 
   Hispanic  
   white 
79.9 (77.3 to 82.2) 88.7 (86.5 to 90.5) 85.1 (80.6 to 88.7) 88.7 (83.9 to 92.2) 
Black 13.9 (12.0 to 16.0) 7.6 (6.2 to 9.2) 9.7 (6.9 to 13.3) 4.0 (2.2 to 7.1) 
Hispanic 
non-black 4.2 (3.0 to 5.9) 2.1 (1.2 to 3.5) 3.0 (1.5 to 6.0) 3.1 (1.5 to 6.2) 
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Non- 
Hispanic 
other 
2.0 (1.3 to 3.2) 1.7 (0.9 to 3.2) 2.2 (0.9 to 5.3) 4.3 (2.1 to 8.3) 
Educational 
attainment, % 
            
Less than 
high school 8.2 (6.7 to 10.0) 7.3 (5.9 to 9.1) 17.4 (13.5 to 22.1) 16.8 (12.9 to 21.7) 
High school 
degree 66.3 (63.3 to 69.2) 59.2 (55.9 to 62.3) 63.6 (58.1 to 68.8) 54.0 (48.0 to 59.8) 
College 
degree 25.5 (22.8 to 28.3) 33.5 (30.5 to 36.7) 19.0 (15.0 to 23.7) 29.2 (24.1 to 35.0) 
Childhood SES             
Poor 28.8 (26.1 to 31.7) 19.5 (17.1 to 22.2) 47.0 (41.5 to 52.5) 46.8 (40.9 to 52.8) 
Average/it 
varied 52.6 (49.5 to 55.7) 49.6 (46.4 to 52.9) 43.0 (37.7 to 48.5) 39.3 (33.6 to 45.2) 
Well off 18.6 (16.3 to 21.2) 30.8 (27.9 to 33.9) 10.1 (7.1 to 14.0) 13.9 (10.3 to 18.6) 
Calendar year, 
mean 2003.6 (2003.5 to 2003.7) 2003.3 
(2003.2 
to 2003.4) 2004.0 
(2003.8 
to 2004.2) 2003.6 
(2003.4 
to 2003.8) 
 
Note: Estimates are weighted. Overweight refers to BMI greater than or equal to 25.0 and obese 
to BMI greater than or equal to 30.0. 
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Table 2-2. Odds ratios, logistic regressions on disability incidence, age-stratified 
 Under 65 65 and older 
 Women Men Women Men 
  OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
BMI, contemporaneous 
1.049** 1.028 1.150*** 1.02 
(1.017, 1.082) (0.988, 1.069) (1.086, 1.217) (0.952, 1.094) 
BMI, 1986 
1.077** 1.089*** 0.951 1.063 
(1.023, 1.134) (1.036, 1.144) (0.874, 1.035) (0.987, 1.145) 
Smoking     
Never Ref. Ref. Ref. Ref. 
Former 
1.343* 1.096 1.357 1.643** 
(1.001, 1.801) (0.754, 1.594) (0.984, 1.871) (1.143, 2.361) 
Current 
1.851*** 1.638* 1.145 2.015 
(1.307, 2.621) (1.102, 2.436) (0.638, 2.056) (0.923, 4.399) 
Manual 
1.05 1.504* 1.162 1.111 
(0.784, 1.407) (1.075, 2.104) (0.819, 1.647) (0.734, 1.680) 
Age 
1.052*** 1.042** 1.103*** 1.088*** 
(1.028, 1.076) (1.014, 1.071) (1.076, 1.130) (1.058, 1.119) 
Race/ethnicity     
Non-Hispanic, white Ref. Ref. Ref. Ref. 
Black 
1.148 1.794** 0.657 3.114** 
(0.833, 1.582) (1.193, 2.697) (0.369, 1.170) (1.355, 7.154) 
Hispanic, non-black 
1.815 0.304 0.646 1.469 
(0.902, 3.655) (0.043, 2.156) (0.202, 2.068) (0.557, 3.871) 
Non-Hispanic, other 
0.624 2.189 0.666 0.716 
(0.207, 1.879) (0.979, 4.894) (0.243, 1.823) (0.247, 2.078) 
Education     
Less than high school Ref. Ref. Ref. Ref. 
High school degree 
0.727 0.708 0.753 0.98 
(0.454, 1.165) (0.400, 1.251) (0.455, 1.245) (0.605, 1.588) 
College degree 0.565* 0.525* 0.694 1.375 
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(0.324, 0.986) (0.276, 0.997) (0.385, 1.251) (0.756, 2.503) 
Childhood SES     
Poor Ref. Ref. Ref. Ref. 
Average/varied 
0.879 0.926 1.004 0.785 
(0.662, 1.167) (0.641, 1.336) (0.731, 1.380) (0.547, 1.126) 
Well off 
0.746 0.762 1.111 0.460* 
(0.514, 1.082) (0.471, 1.235) (0.669, 1.844) (0.246, 0.859) 
Year     
2003 Ref. Ref. Ref. Ref. 
2005 
0.826 1.051 0.776 0.895 
(0.576, 1.184) (0.656, 1.684) (0.483, 1.245) (0.541, 1.482) 
2007 
0.802 1.046 1.084 0.832 
(0.564, 1.142) (0.660, 1.657) (0.693, 1.694) (0.526, 1.317) 
2009 
1.014 1.266 0.953 0.793 
(0.712, 1.444) (0.804, 1.996) (0.597, 1.522) (0.478, 1.316) 
2011 
1.000 1.707* 1.036 0.667 
(0.677, 1.476) (1.027, 2.838) (0.649, 1.652) (0.392, 1.133) 
2013 
0.850 1.419 0.854 0.915 
(0.538, 1.343) (0.832, 2.423) (0.512, 1.424) (0.552, 1.517) 
Constant 
0.007*** 0.005*** 0.000*** 0.000*** 
(0.002, 0.025) (0.001, 0.026) (0.000, 0.001) (0.000, 0.003) 
Observations 5,388 4,615 1,704 1,461 
 
Note: * p<0.05, ** p<0.01, *** p<0.001. OR=odds ratio.  
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Figure 2-1. Disability incidence by age, gender, and education 
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Table 2-3. Percent of educational disparities explained by smoking, excess BMI, and manual 
labor 
Under 65 Women (95% CI) Men (95% CI) 
  
Most vs. 
least 
Middle vs. 
least 
Most vs. 
middle 
Most vs. 
least 
Middle vs. 
least 
Most vs. 
middle 
Observed disparity (per 100 
PY) 
4.8 
(1.6, 7.9) 
3.5 
(0.4, 6.5) 
1.3 
(0.3, 2.4) 
3.0 
(0.6, 5.3) 
1.7 
(-0.7, 4.0) 
1.3 
(0.5, 2.2) 
Percent explained       
Smoking 23.1  (9.3, 36.8) 
20.5  
(6.2, 34.8) 
29.8 
(8.9, 50.6) 
29.5  
(2.3, 56.7) 
34.5  
(-2.0, 70.9) 
23.2  
(-2.3, 48.8) 
Excess BMI 37.8  (18.3, 57.2) 
38.6 
(13.6, 63.5) 
35.6  
(14.4, 56.9) 
15.0  
(2.0, 28.0) 
5.6  
(-19.3, 30.6) 
26.7  
(10.4, 42.9) 
Manual 
4.0 
(-19.5, 
27.5) 
3.8 
(-18.3, 25.9) 
4.5  
(-22.8, 31.8) 
35.1  
(5.9, 64.3) 
32.7 
(1.3, 64.0) 
38.2 
(4.8, 71.6) 
All 58.2  (33.3, 83.0) 
56.8  
(29.9, 83.8) 
61.8  
(25.2, 98.4) 
64.7  
(36.0, 93.4) 
68.9 
(26.7, 91.0) 
72.0  
(37.6, 106.4) 
       
65 and over Women (95% CI) Men (95% CI) 
  
Most vs. 
least 
Middle vs. 
least 
Most vs. 
middle 
Most vs. 
least 
Middle vs. 
least 
Most vs. 
middle 
Observed disparity (per 100 
PY) 
6.1 
(1.8, 10.4) 
3.7 
(-0.4, 7.7) 
2.4 
(-0.2, 5.0) 
1.5 
(-2.0, 5.1) 
2.3 
(-1.1, 5.6) 
-0.7 
(-3.2, 1.8) 
Percent explained       
Smoking 0.0 (-7.2, 7.1) 
-2.0 
(-13.6, 9.6) 
3.0  
(-8.1, 14.2) 
56.3 
(-40.7, 
153.2) 
20.5  
(-2.6, 43.5) N/A 
Excess BMI 29.9  (5.0, 54.8) 
30.1 
(-6.5, 66.8) 
29.5  
(1.5, 57.6) 
-17.3 
(-81.2, 
46.6) 
13.4 
(-52.7, 25.8) N/A 
Manual 
10.2 
(-14.1, 
34.4) 
11.7 
(-17.7, 41.2) 
7.8 
(-11.3, 26.9) 
27.2 
(-93.2, 
147.5) 
11.2 
(-33.5, 55.9) N/A 
All 38.3 (8.3, 68.3) 
38.7 
(-2.1, 79.6) 
37.7 
(5.8, 69.6) 
60.4 
(-58.0, 
178.7) 
19.9 
(-27.5, 67.3) N/A 
 
Note: PY = person-years
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Chapter 3 - Racial/Ethnic Disparities in Opioid Prescribing to Chronic Pain Patients 
 
 
INTRODUCTION  
Unequal medical treatment across racial and ethnic groups that is unexplained by differences in 
socioeconomic status and access to health care has been extensively documented (Goonesekera 
et al., 2015; Goyal et al., 2015; Johansen et al., 2015; McKinlay et al., 2012; Rangrass et al., 
2014; Schulman et al., 1999; Van Ryn et al., 2006). Differential pain management is one notable 
manifestation of these disparities: disproportionate undertreatment of pain in non-white and 
Hispanic patients has been observed, for instance, in emergency departments (Todd et al., 1993, 
2000), nursing homes (Won et al., 1999), postoperative settings (Ng et al., 1996), and in 
management of cancer-related pain (Cleeland, 1997)—despite similar medical conditions across 
the compared groups. A 2012 meta-analysis found that, while black and Hispanic patients with 
traumatic, surgical, or non-traumatic/non-surgical pain were as likely to receive non-opioid 
analgesics as their white counterparts, they were less likely to receive opioids (Meghani et al., 
2012). In addition, nonwhite pain patients may be less able to access the pain medications 
prescribed for them: several studies have found that pharmacies in predominantly non-white 
neighborhoods are less likely to carry a sufficient supply of opioid analgesics than those in white 
neighborhoods (C. R. Green et al., 2005; Morrison et al., 2000). 
 
Consequences of disparities in pain management may not only include disproportionate suffering 
and functional impairment; they may also reduce trust in health care providers, a key factor in
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patients’ decisions to seek treatment and preventive care and to adhere to medical 
recommendations (Anderson et al., 2009; Benkert et al., 2006; Boulware et al., 2003; Cintron & 
Morrison, 2006; Shavers et al., 2010; Williams & Mohammed, 2009). 
 
America’s ongoing opioid crisis, which killed nearly 48,000 people in 2017 (Scholl et al., 2018), 
has brought pain management decisions to the forefront of many clinicians’ minds. Unsafe 
prescribing of opioid analgesics has received much of the blame for the steep rise in opioid-
related morbidity and mortality, although more upstream social, economic, and demographic 
processes are also likely at play (Dasgupta et al., 2018). In March 2016, the U.S. Centers for 
Disease Control and Prevention (CDC) released the Guideline for Prescribing Opioids for 
Chronic Pain, offering twelve recommendations to reduce unsafe prescribing while emphasizing 
the clinician’s role in tailoring pain management to each patient’s specific circumstances. 
 
Early evidence suggests that, at the US population level, the 2016 guideline accelerated the 
preexisting decline in opioid prescribing.  (Bohnert et al., 2018). However, it is not clear whether 
this shift was equally distributed across racial/ethnic groups. Instead, it may have widened or 
narrowed disparities in pain management—for instance by amplifying or reducing clinicians’ 
reliance on racial/ethnic stereotypes in making prescribing decisions. This study thus examines 
whether publication of the 2016 guideline was associated with subsequent opioid prescribing for 
two chronic pain conditions and, if so, whether this association varied by race/ethnicity. 
 
Pathways to unequal treatment in healthcare 
 
A number of pathways likely contribute to racial/ethnic disparities in the health care encounter 
over and above issues of access to care, which are also pervasive (Chen et al., 2016; Waidmann 
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& Rajan, 2000). Broadly, providers may possess implicit and explicit bias regarding the clinical, 
behavioral, and social features of a given racial/ethnic group, which may in turn influence their 
interpretation of the clinical information a patient shares and the medical recommendations they 
make (Balsa & McGuire, 2003b; van Ryn & Fu, 2003). In addition, both stereotype-driven 
beliefs and the mere fact of racial/ethnic discordance between provider and patient may influence 
provider interpersonal behavior (Balsa & McGuire, 2003b; van Ryn & Fu, 2003). This can in 
turn affect the patient’s understanding of their health condition or status, as well as the questions 
they ask, the follow-up care they pursue, and the treatments they request and/or adhere to 
(Benkert et al., 2006; Boulware et al., 2003; van Ryn & Fu, 2003; Williams & Mohammed, 
2009). 
 
Unequal treatment may be more likely in the context of greater clinical uncertainty: in such 
cases, providers may turn to more subjective factors to inform their decision-making, including 
their priors regarding different racial and ethnic groups (Balsa & McGuire, 2003a; Merrill et al., 
2002). These stereotype-driven priors may be most likely to be activated when the beliefs map 
closely onto one or more of the potential health outcomes—such as nonmedical opioid use or 
development of dependence, in the case of opioid prescribing. 
 
Both clinical uncertainty and racial/ethnic stereotypes may thus play an important role in 
decisions to prescribe opioids for chronic pain. Pain is a subjective, difficult-to-measure 
phenomenon, and chronic pain may be more difficult for providers to evaluate than acute 
traumatic or surgical pain (Meghani et al., 2012; Singhal et al., 2016). This results in clinical 
uncertainty about a patient’s subjective experience and need for pain management. In an effort to 
reconcile this uncertainty, and amid concern about opioids’ potential for misuse and overdose, 
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clinicians may call on racial and ethnic stereotypes regarding so-called drug-seeking behavior. 
For example, one study of low-income HIV patients and their primary care providers found that, 
despite equivalent rates of reported nonmedical drug use across racial/ethnic groups, providers 
exhibited less trust in non-white patients (Moskowitz et al., 2011).  
 
Trust, in turn, is a key factor in decisions about chronic pain management (Merrill et al., 2002). 
For example, while Hispanic and non-Hispanic black individuals experience lower rates of 
prescription opioid overdose than whites (Bohnert et al., 2011; Paulozzi, 2012) and are equally 
or less likely to report nonmedical opioid use when receiving prescription opioid therapy (Han et 
al., 2017), they may be more likely to receive urine testing and other precautionary measures 
(Becker & Turner, 2011; Gaither et al., 2018). In addition, a recent study found that black 
patients receiving long-term opioid therapy were more likely than their white counterparts to 
experience a dose reduction during two years of follow-up (Buonora et al., 2018). In contrast, 
two clinical factors associated with higher risk of addiction and overdose—high baseline dosage 
and receipt of a concurrent benzodiazepine prescription—were not positively associated with 
dose reduction in those patients (Buonora et al., 2018). Racial and ethnic stereotypes around 
patient deception and likelihood of nonmedical use are likely rooted in part in decades of less 
sympathetic, less humanized representation of nonwhite people who use opioids compared to 
their white counterparts (Netherland & Hansen, 2016). 
 
Aims 
Clinical uncertainty, in combination with stereotype-driven priors, may thus contribute to the 
persistence of racial/ethnic disparities in opioid prescribing for pain. Indeed, Meghani et al. 
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(2012) found that racial/ethnic disparities in opioid prescribing were larger when the source of 
pain was non-traumatic and non-surgical—i.e., when it was less easily identified and appraised 
(Meghani et al., 2012). The CDC’s 2016 Guideline on Opioid Prescribing for Chronic Pain may 
have reduced clinical uncertainty by providing a framework for deciding when to prescribe 
opioids, in what dose, and over what time period—as well as how to avoid high-risk co-
prescribing with other medications. This framework could thus serve to reduce providers’ 
reliance on priors regarding their patient’s race and/or ethnicity, thereby alleviating disparities in 
opioid prescribing among chronic pain patients.  
 
Alternatively, the guideline could have contributed to a widening of racial/ethnic disparities in 
prescribing. In stressing the dangers of unsafe prescribing while emphasizing provider discretion 
in assessing the risks and benefits for each patient, the guideline may have prompted greater 
reliance on racist priors to assess a patient’s “legitimate” need for prescription opioids. A study 
of benzodiazepine prescribing suggests that such disparate intervention impacts do occur. 
Examining the effects of a New York State triplicate law, Pearson, Soumerai, Mah, et al. (2006) 
found that, while patients in predominantly white neighborhoods exhibited the highest rates of 
overall benzodiazepine use and of potentially problematic use, prescribing decreases attributable 
to the law were sharpest in predominantly black neighborhoods (Pearson et al., 2006). 
 
I examine whether the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain was 
associated with an overall change in opioid prescribing for chronic pain and, if so, whether this 
change varied by racial/ethnic group. It also assesses whether any disparate changes served to 
narrow or widen existing racial/ethnic disparities. To accomplish this, I examine frequency and 
 42 
level of opioid prescribing and co-prescribing with benzodiazepines—outcomes directly related 
to the guideline’s recommendations—in two groups: osteoarthritis patients and fibromyalgia 
patients. Opioids may slightly improve function and reduce pain related to osteoarthritis (Cepeda 
et al., 2006; da Costa et al., 2014), although recent evidence suggests they are not superior to 
non-steroidal anti-inflammatory drugs (Krebs et al., 2018). Still, in 2012, the American College 
of Rheumatology strongly recommended opioids for use in patients with pharmacologic 
treatment-refractory osteoarthritis who could or would not undergo total joint arthroplasty 
(Hochberg et al., 2012). In contrast, experts have generally agreed that opioids are not indicated 
for fibromyalgia, despite being frequently prescribed (Häuser et al., 2017; Macfarlane et al., 
2017). I therefore study racial disparities in opioid prescribing for one condition for which 
opioids were considered appropriate in some patients, and a second for which they were 
consistently not recommended. If the CDC guideline led prescribers to more critically evaluate 
their opioid prescribing decisions, then opioid prescribing for fibromyalgia may have declined 
more sharply than that for osteoarthritis. 
 
I use healthcare claims data from OptumInsight’s Clinformatics Data Mart, allowing evaluation 
of trajectories and disparities in prescribing in a large sample of people with chronic pain from 
all fifty states. In an effort to assess disparities arising from provider decision-making rather than 
issues of socioeconomic status, access, or pain prevalence, I examine rates and levels of 
prescribing during clinical encounters with patients who are insured and have received diagnoses 
of osteoarthritis or fibromyalgia. 
 
METHODS 
Data 
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Optum administrative healthcare data comprise deidentified outpatient, inpatient, and pharmacy 
claims for individuals with commercial insurance plans from UnitedHealthcare. These data are 
similar to the commercially insured population in the United States and enable longitudinal 
observation of diagnosis and prescription receipt in 12.4 to 14 million unique individuals per 
year (Jeffery et al., 2018; University of Michigan Institute for Healthcare Policy and Innovation, 
2016). The dataset provides information on socioeconomic status and race/ethnicity but does not 
provide local geographical data such as zip code.  
 
Periods of analysis and cohort inclusion criteria 
The CDC Guideline was released in March 2016. The period of analysis comprised a 24-month 
baseline comparison period (March 2014-November 2015) and an 18-month post-intervention 
comparison period (July 2016-December 2017;  
Figure 3-1). The three months prior to and after guideline implementation were excluded from 
analysis to account for potential anticipatory and lagged effects of the policy (“implementation 
period”; December 2015-June 2016). A six-month “washout” period (September 2013-February 
2014) was used to establish cohort eligibility, as discussed below. 
 
The analytic cohort consisted of adults ages 18-64 who were continuously enrolled in a 
UnitedHealthcare insurance plan for 24 months, including the six-month washout period and 18 
months of the 24-month baseline comparison period. Included individuals must have received at 
least one diagnosis of the condition of interest during the first half of the baseline analytic period 
(March 2014-February 2015). Because the CDC guideline was intended for patients outside of 
active cancer treatment, palliative care, and end of life care, those who received a cancer 
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diagnosis or palliative care during any of the three observation periods were excluded from the 
sample. To capture new opioid prescribing, individuals who filled an opioid prescription prior to 
their first observed pain-related visit were excluded. 
 
Outcomes 
Dispensing data served as a proxy for prescribing. In line with a recent validation study, 
dispensing was assumed to be prescribed at a visit for the condition of interest if it occurred 
within 15 days of the visit (Rowan et al., 2017). All outcomes were evaluated at the month level.  
 
The four primary outcomes included: (1) percentage receiving any prescription opioid (binary); 
(2) average daily morphine-equivalent dose of prescribed opioids (continuous); (3) percentage 
receiving an average daily morphine-equivalent dose of 90 milligrams or more (binary); and (4) 
percentage receiving concurrent prescriptions of opioids and benzodiazepines (binary). The first 
outcome corresponds to the guideline’s first and fifth recommendations, which state that 
alternatives to opioids are preferred for chronic pain and that clinicians should initiate opioid 
prescribing at the lowest effective dosage. The 90 morphine milligram equivalent (MME) 
threshold corresponds to the guideline’s fifth recommendation, that prescribers “avoid increasing 
dosage to 90 MME or more per day or carefully justify a decision to titrate dosage to 90 MME or 
more per day.” Assessment of concurrent opioid/benzodiazepine prescribing corresponds to the 
11th recommendation, “Clinicians should avoid prescribing opioid pain medication and 
benzodiazepines concurrently whenever possible.” The three secondary outcomes, all of which 
were count variables, included: total days of opioids supplied, total number of opioid fills 
obtained, and the number of days of concurrent opioid and benzodiazepine prescriptions.  
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Covariates 
Sociodemographic measures 
Optum populates sociodemographic data from a combination of sources, including directly from 
the patient at the point of care, via imputation from the U.S. Census, and via internal modeling. 
All sociodemographic variables except age were modeled as categorical, as provided by Optum. 
Race/ethnicity categories included black, white, Hispanic, Asian, and other. “Other” was 
excluded from analysis due to insufficient sample and difficulty of interpretation; Asian patients 
were included in the analysis, but due to small sample and noisy estimates, the corresponding 
results are not discussed here. Age was continuous and ranged from 18 to 64 years. Gender 
comprised female and male. Educational attainment categories included high school degree or 
less; less than college; and college degree. Household income categories included less than 
$40,000 per year; $40,000-$59,999; $60,000-$74,999; $75,000-$99,999; $100,000 or more per 
year.  
 
Clinical measures 
I included several indicators of clinical circumstances that may influence opioid prescribing 
decisions and could vary by race/ethnicity. First, I calculated the monthly number of visits 
related to the diagnosis of interest (osteoarthritis or fibromyalgia) and the number of days since 
the last such visit. Second, I included an indicator of having received another pain-related 
diagnosis in the given month (binary); given its length, the list of ICD codes used to make this 
determination is not included here but is available upon request. Third, I included four time-
varying indicators of any diagnosis of the following conditions since cohort entry: substance use 
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disorder; anxiety disorder or post-traumatic stress disorder; major depression; and psychotic and 
bipolar disorders. ICD codes used to identify these diagnoses are provided in Table 5-8 (Haffajee 
et al., 2019; Heslin et al., 2012). Finally, I calculated a longitudinal Elixhauser comorbidity index 
to obtain the number of distinct comorbidities diagnosed for a given individual in a given month 
(Elixhauser et al., 1998; Manitoba Centre for Health Policy, 2019). 
 
Time 
The secular time trend, ranging from March 2014 through December 2017, with the exception of 
the implementation period, was continuous and, based on visual inspection of the data, was 
estimated as linear. 
 
Analytic strategy 
Generalized estimating equations (GEEs) were used to estimate racial/ethnic differences in the 
association between the guideline and opioid prescribing. GEEs extend generalized linear models 
to data with correlated observations, as in longitudinal data (Wang, 2014). Unlike mixed models, 
GEEs use a quasi-likelihood function to estimate population-averaged effects of the parameters; 
this approach is preferred when the overall treatment effect, rather than individual-level effects, 
is of primary interest (Hubbard et al., 2010; Wang, 2014).  
 
Analyses were conducted at the month level. In each month, observations were only included in 
the analysis if the individual had at least one encounter related to the pain-related condition of 
interest (i.e., osteoarthritis or fibromyalgia). This enabled comparison of opioid prescribing rates 
among individuals who had had the opportunity to receive a prescription. Analysis of all 
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outcomes except “any opioid receipt” was conditioned on having received any opioid fill in the 
given month. Analysis of the final outcome, number of days of concurrent opioid and 
benzodiazepine prescriptions, was conditioned on any concurrent prescription in the given 
month.  
 
Model specification 
Modeling was conducted in two stages: the first stage examined overall associations between 
guideline release and each outcome, regardless of race/ethnicity; the second stage examined 
whether these associations differed by race/ethnicity. 
 
The regression models in Stages I and II took the following general forms, respectively:   
 
(1) !(#($!,#)) 	= 	($ 	+ ∑ (%+,-.!,&'&(% + ()/01.!,# 	+ 	('2345!,# 	+ 	(*/01.!,#2345!,# 	+	6!,# + 	7!,#; and 
(2) !(#($!,#)) 	= 	($ 	+ ∑ (%+,-.!,&'&(% + ()/01.!,# +∑ ('/01.!,#+,-.!,&'&(% 	+ 	(*2345!,# +	∑ (+2345!,#+,-.!,&'&(% +	(,2345!,#/01.!,# +∑ (-/01.!,#2345!,#+,-.!,&'&(% 	+ 	6!,# + 	7!,#; 
 
where g() refers to the link function relating the mean of the outcome, E(Yi,t), to the predictors. 
The link function varied by outcome: binary outcome variables were generally modeled using 
the logit link or (in cases of nonconvergence) the identity link, continuous variables using the 
identity link, and count variables using the negative binomial link function. In addition, i,t 
denotes individual i in month t, and j indicates time-invariant racial/ethnic group (black, 
Hispanic, or Asian, with white as the reference group). Time denotes time, in months, since the 
start of the observation period, and the interaction with Race allows the background secular trend 
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to vary by racial/ethnic group. Post is a binary variable indicating whether the observation 
occurred before or after release of the guideline. The coefficient on Post describes an 
instantaneous (level) change in the outcome following guideline release in March 2016. The 
coefficient on the !"#$!,#%&'(!,# interaction term, which indicates the number of months since 
guideline release, describes a trend (slope) change in the outcome following release. In the Stage 
II models, the interaction terms describe any variation in the level and trend changes by 
racial/ethnic group. Xi,t is a vector of the sociodemographic and clinical covariates described 
above.  
 
For each outcome, Pan’s quasi-likelihood information criterion (QIC) was used to select the 
structure of correlations among intra-individual observations (Cui, 2007; Pan, 2001). 
Unstructured correlation is maximally flexible, allowing the correlation between each pair of 
intraindividual observations to vary, while exchangeable structure assumes constant correlation 
among intraindividual observations. Autoregressive correlation structures that allow a decay in 
correlation with increasing temporal distance were not feasible due to unequally spaced 
observations. As long as the mean response is correctly specified, GEE models provide 
consistent parameter estimates when the correlation structure is misspecified; however, correct 
specification of correlation structure may increase efficiency of the parameter estimates (Cui, 
2007; Wang, 2014). The structure associated with the lowest QIC value was selected (Table 5-9). 
A structure was disqualified if the corresponding model did not converge. When the model failed 
to converge regardless of correlation structure, specification of the link function and 
distributional family were amended: for binary outcomes, the link function was changed to 
identity and family to Gaussian (Table 5-9). Because the meaning of coefficients varies by link 
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function, average marginal effects are reported for all models—i.e., the estimated change in the 
dependent variable associated with a one-unit change in the predictor. 
 
Predicted means and disparities 
To examine differences in prescribing associated with the guidelines, I generated predicted 
means (i.e., average predictive margins) for each outcome variable in the observed (guideline) 
scenario and in the counterfactual (no guideline) scenario for December 2017, the latest month 
observed. Predicted means in each scenario were generated using the observed distribution of 
covariates and were compared in both the full sample (Stage I) and within each racial/ethnic 
group (Stage II). For outcomes that appeared to be influenced by the guideline by December 
2017, I generated predicted racial/ethnic disparities in the observed and counterfactual scenarios 
in that month, allowing me to examine whether the guideline appeared to widen or narrow 
disparities in prescribing. 
 
Sensitivity analyses 
I conducted three sensitivity analyses. In the first, the implementation period was narrowed to 
span November 2015, when the draft guideline was first released for public comment, through 
March 2016, when the final guideline was released. That is, the post-release analytic period 
began in April, immediately after guideline release, in this analysis. In the second sensitivity 
analysis, I excluded observations occurring during or after October 2017, when President Trump 
declared the opioid crisis a public health emergency, to account for the possibility that this 
national event altered the slope of post-guideline trends. In the third sensitivity analysis, the main 
analysis was the same, but average predictive margins were generated for October 2017 through 
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December 2017 (rather than December 2017 alone), in an attempt to reduce noise in those 
estimates. Each of these analyses was conducted for the four main outcome variables, in both 
pain conditions, and using the Stage I (non-interacted) models.  
 
 
RESULTS 
Sample characteristics  
Complete data on all predictors were available in 65% of observations in the osteoarthritis cohort 
(1,284,468 observations) and 62% in the fibromyalgia cohort (855,371 observations). 
Race/ethnicity information was the primary source of missingness (missing for 22% of 
osteoarthritis observations and 26% of fibromyalgia observations), followed by income (missing 
for 18% of osteoarthritis observations and 19% of fibromyalgia observations). After excluding 
observations with incomplete data, the osteoarthritis cohort comprised 87,982 distinct patients 
with a mean of 18.3 observed months involving osteoarthritis-related visits (Table 3-1). The 
fibromyalgia cohort comprised 56,299 distinct individuals with a mean of 18.9 months involving 
fibromyalgia-related visits (Table 3-1). 10,771 individuals appeared in both cohorts 
(corresponding to 12% of the osteoarthritis cohort and 19% of the fibromyalgia cohort). In both 
cohorts, there was a mean of 32.9 months between the first and last observed diagnosis of 
interest. 
 
In both cohorts, individuals were predominantly white, female, and ages 45 years or older, 
although women comprised a larger proportion of the fibromyalgia cohort (Table 3-1). The 
majority had attended at least some college. Compared to white patients, black and Hispanic 
patients tended to be less educated and earn lower household income (Tables 5-10 and 5-11). 
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Black patients were more likely than their white counterparts to be women, more likely to have 
received a diagnosis of substance use disorder, and less likely to have received a mental health 
diagnosis. In the fibromyalgia cohort, black patients had also been diagnosed with more 
comorbidities on average. 
 
Individuals with missing race/ethnicity data were more likely than their counterparts to be 
missing education and income data, to have received a mental health diagnosis, to fill an opioid 
prescription following a pain-related visit, and to receive concurrent opioid/benzodiazepine 
prescriptions (Table 5-12). They also tended to be younger, have more comorbidities, have more 
monthly pain-related visits, receive higher opioid dosages, and fill more opioid prescriptions per 
month.  
 
Overall, patients filled at least one opioid prescription following 15.1% of osteoarthritis-related 
visits and after 16.3% of fibromyalgia visits (Table 3-1). When at least one opioid prescription 
was filled, the median daily dosage was 45 MMEs and the mean number of monthly fills was 1.3 
for both conditions; the mean number of days supplied per month was 28.0 in the osteoarthritis 
cohort and 30.7 in the fibromyalgia cohort. The dosage was above 90 MMEs in 22.9% of filled 
opioid prescriptions for osteoarthritis and 24.4% for fibromyalgia. In the osteoarthritis cohort, a 
concurrent benzodiazepine prescription was filled in 26.4% of cases in which an opioid 
prescription had been filled; this occurred in 32.2% of cases in the fibromyalgia cohort. When 
concurrent opioid and benzodiazepine prescriptions were filled, they overlapped for a mean of 
7.5 days in the osteoarthritis cohort and 29.0 days in the fibromyalgia cohort. Figure 3-2 depicts 
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unadjusted trends in each primary outcome variable by condition for black, Hispanic, and white 
patients. 
 
Regression results 
Stage I. Overall associations of racial/ethnic group and guideline release with prescribing 
Tables 5-13 and 5-14 provide estimated marginal effects of the main predictors in Stage I of 
modeling, which examined overall level and trend changes associated with the guideline. In both 
osteoarthritis and fibromyalgia, and after controlling for likely confounders, Black and Hispanic 
patients were less likely than their white counterparts to fill an opioid prescription, received 
lower doses on average, were less likely to receive a dose of greater than 90 MMEs, received 
fewer fills, and were less likely to receive concurrent opioid and benzodiazepine prescriptions. 
All else equal, black osteoarthritis patients were 1.3 percentage points less likely than white 
patients to fill an opioid prescription (95% CI: -1.70, -0.821) and Hispanic patients were 2.0 
percentage points less likely (95% CI: -2.48, -1.58). All else equal, the doses that black and 
Hispanic osteoarthritis patients received were roughly 10 MMEs lower than those white patients 
received (black: -9.9; 95% CI: -11.48, -8.36; Hispanic: -10.4; 95% CI: -12.20, -8.62). Black and 
Hispanic osteoarthritis patients were roughly 4 percentage points less likely to receive high-dose 
prescriptions (black: -4.2; 95% CI: -5.05, -3.34; Hispanic: -4.2; 95% CI: -5.13, -3.19). Estimates 
for fibromyalgia were similar but tended to be smaller. Black patients also received fewer days 
supplied and experienced fewer days of concurrent prescriptions.  
 
Using an alpha of 0.05 as a detection threshold, and for both conditions, negative trend but not 
level changes associated with the guideline were apparent in three of the four main outcomes. 
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These included a trend change in the percentage receiving any opioid fill (marginal effect in 
osteoarthritis: -0.031 percentage points, 95% CI: -0.056, -0.006; fibromyalgia: -0.059 percentage 
points, 95% CI: -0.090, -0.028), the average daily dose (marginal effect in osteoarthritis: -0.563 
MME, 95% CI: -0.716, -0.411; fibromyalgia: -0.569 MME, 95% CI: -0.751, -0.387), and the 
percentage receiving a high dose (marginal effect in osteoarthritis: -0.229 percentage points, 95% 
CI: -0.317, -0.140; fibromyalgia: -0.237 percentage points, 95% CI: -0.350, -0.124). In 
osteoarthritis, a negative trend change in number of fills and number of days supplied was also 
detected (fills: -0.001, 95% CI: -0.003, -0.0007; days supplied: -0.038, 95% CI: -0.074, -0.002). 
In fibromyalgia, a positive level change in number of fills was detected (0.019 fills, 95% CI: 
0.0001, 0.039).  
 
Table 3-2 presents predicted means for December 2017—the latest post-guideline month 
observed—in the observed and counterfactual (i.e., no guideline) scenarios, holding all other 
predictors as observed. In both osteoarthritis and fibromyalgia, the guideline appeared to be 
associated with a roughly 1 percentage point lower rate of receiving any opioid prescription in 
December 2017, although the difference was marginally significant given an alpha of 0.05. It 
was also associated with a lower average dose of roughly 10 MMEs and a roughly 4 percentage 
point lower rate of high-dose prescriptions among those who received opioids. While point 
estimates of number of days supplied, number of fills, rate of concurrent opioid-benzodiazepine 
prescribing, and days of concurrent prescribing were also lower in the observed compared to the 
counterfactual scenario, the corresponding 95% confidence intervals overlapped (Table 3-2). 
 
Stage II. Changes associated with guideline release by race/ethnicity 
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In the Stage II models, the background secular trend and the guideline exposure variables were 
interacted with race/ethnicity. Table 3-3 and Table 3-4 show the estimated marginal effects of 
race/ethnicity as well as racial/ethnic group-specific marginal effects of the secular trend and 
guideline exposure variables. Tables 5-15 and 5-16 show marginal effects for the complete set of 
model predictors. Estimated main effects of race/ethnicity, as well as overall level and trend 
changes, were highly consistent with Stage I models. In both osteoarthritis and fibromyalgia 
patients, consistent positive predictors of overall and high-risk opioid prescribing included a 
history of diagnosis with substance use disorder, diagnosis with at least one other pain condition, 
number of comorbidities, and number of visits per month related to the condition of interest 
(Tables 5-15 and 5-16). A history of diagnosis with mental health disorder was often positively 
associated with prescribing and high-risk prescribing. Women tended to be less likely to receive 
opioids or high-risk prescriptions, with the exception that they were more likely to receive 
concurrent opioid and benzodiazepine prescriptions. Patients with higher income tended to be 
less likely to receive opioids or high-risk prescriptions; those with higher education were less 
likely to receive any opioid fill; when they did receive a prescription, they received higher 
average doses, more fills, and fewer days supplied. Secular trends were not consistent across 
outcomes. In both conditions, the probability of any fill increased throughout the analytic period 
and the probability of concurrent prescriptions decreased. In fibromyalgia, the average number of 
days supplied appeared to decrease.  
 
Estimated associations of the guideline with prescribing varied by race/ethnicity, although 
smaller sample sizes resulted in less precise estimates for black and Hispanic patients. In 
osteoarthritis, and at an alpha of 0.05, the guideline was associated with a lower percentage 
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receiving any opioid fill in white patients. In December 2017, 21 months after its release, the 
guideline was associated with an estimated 1.0 percentage point lower percentage receiving any 
fill in white patients compared to the counterfactual, “no guideline” scenario (Table 3-5).  
 
Among those who received opioids, the guideline was associated with a lower average dose in 
white, black, and Hispanic osteoarthritis patients. By December 2017, this corresponded to an 
estimated difference of 9.5 MME, 11.4 MME, and 23.5 MME, respectively. The guideline was 
also associated with a decline in the percentage receiving high-dose opioid prescriptions in white 
and black patients. By December 2017, this corresponded to an estimated difference of 4.0 
percentage points in white patients and 5.5 percentage points in black patients. In fibromyalgia 
patients, the guideline was associated with: a lower percentage receiving any fill in white 
patients (estimate difference of 1.2 percentage points in December 2017); a lower average dose 
in white and black patients (estimated difference of 9.8 MME in white patients, 10.9 MME in 
black patients in December 2017); and a lower percentage receiving high-dose prescriptions in 
white patients (estimated difference of 3.6 percentage points in December 2017). While 
associations between guideline release and the main outcome variables were less consistently 
statistically significant in black and Hispanic patients, point estimates were often similar or 
larger in size compared to white patients. 
 
Figure 3-3 and Figure 3-4 depict predicted means with and absent the guideline for the three 
main outcome variables with which guideline release was associated. While the patterns of the 
predicted means are similar to those for the raw means, the models tend to underestimate the 
average dose and the average percentage receiving a high dose. 
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Table 3-6 shows estimated racial/ethnic disparities, both with and without the guideline, in 
December 2017 for the three main outcomes with which guideline release was associated: 
percentage receiving any fill, average daily dose, and percentage receiving a high-dose 
prescription. While there were differences in the observed and counterfactual point estimates, the 
confidence intervals in the two scenarios consistently overlapped. Point estimates of the 
Hispanic/white disparity were generally larger in the “guideline” compared to the “no guideline” 
scenario, and this difference was most marked in the average daily dose among osteoarthritis 
patients: on average, Hispanic osteoarthritis patients received an estimated 14.67 MME (95% CI: 
8.97, 20.37) lower dose than white patients in December 2017; absent the guideline, this 
difference was estimated to be only 0.68 MME (95% CI: -11.10, 12.45). Similarly, estimated 
black/white disparities in average dose and percentage receiving high dose were larger in the 
“guideline” scenario, but differences were small. In contrast, and in both conditions, because the 
guideline was associated with a (not statistically significant) increase in percentage of black 
patients receiving any fill in December 2017, the guideline was associated with a widening 
black/white disparity in which a larger percentage of black patients received any opioid fill 
compared to white patients. 
 
Sensitivity analyses 
Changing the implementation period to cover November 2015 through March 2016 (i.e., the 
period between release of the draft guideline and release of the final guideline) and initiating the 
post-guideline analytic period in April 2016 did not affect the substantive results (Table 5-17). In 
the second sensitivity analysis, I shortened the post-guideline analytic period to end in September 
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2017, prior to President Trump naming the opioid epidemic a public health emergency. In this 
analysis, the estimated differences in observed and counterfactual predicted means for September 
2017 were smaller than those for December 2017 in the main analysis, as expected; in the 
sensitivity analysis, these differences tended to be 55-85% the size of those in the main analysis 
(Table 5-18). If President Trump’s announcement had had no effect on prescribing, the 
September estimates would be expected to be 86% of the December estimates, suggesting the 
guideline’s effects may have been slightly smaller than estimated in the main analysis. In the 
third analysis, generating predicted means for October through December 2017, rather than 
December 2017 alone, had little influence on estimate precision and did not change the 
overarching pattern of results (Table 5-19). 
 
DISCUSSION 
 
To my knowledge, this study is the first to examine the association of release of the 2016 CDC 
Guideline for Prescribing Opioids for Chronic Pain with subsequent overall and high-risk opioid 
prescribing in the population it targeted: people with chronic, non-cancer pain. In addition, it is 
the first to assess whether these associations varied by patient race/ethnicity, and if so whether 
this contributed to a widening or narrowing of racial/ethnic disparities in opioid prescribing for 
chronic pain. To do this, I took advantage of longitudinal healthcare claims data from all fifty 
states that are similar to the US commercially insured population and that allow linkage of 
clinical diagnosis and pharmacy information (Jeffery et al., 2018; University of Michigan 
Institute for Healthcare Policy and Innovation, 2016).  
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In two closed cohorts—one comprised of osteoarthritis patients, the other of fibromyalgia 
patients—the guideline was associated with an overall decline in the percentage of patients 
receiving opioids and, among those who received opioids, with a decline in average daily dose 
and the percentage of patients receiving a high dose (>90 morphine milligram equivalents, or 
MME). These declines manifested not as instantaneous changes following the guideline’s 
release, but as gradual decreases. By December 2017, 21 months after release of the guideline, 
these apparent effects corresponded to an estimated one percentage point difference in the 
percent of the sample receiving any opioid prescription each month, a 10 MME difference in 
average daily dose, and a roughly 4 percentage point difference in the percentage receiving a 
high dose. In osteoarthritis patients, the guideline was also associated with a small decrease in 
the number of opioid fills and days supplied per month. While no statistically significant 
associations between guideline release and concurrent opioid/benzodiazepine prescribing were 
detected, point estimates tended to be negative. Together, these results are in line with a recent 
study of opioid prescribing trends at the national level (Bohnert et al., 2018) and another 
examining rates of prescribing in a single emergency department (Dayer et al., 2019). Overall, 
my findings did not support the hypothesis that the guideline would more strongly influence 
opioid prescribing for fibromyalgia, for which opioids are categorically not recommended, 
compared to osteoarthritis (Häuser et al., 2017; Macfarlane et al., 2017). 
 
In both conditions, associations with the guideline were consistently detectable in white patients 
at an alpha of 0.05. In addition, statistically significant declines in average daily dose were 
detected in black and Hispanic patients. And in osteoarthritis, the guideline was associated with 
reduced high-dose prescribing in black patients and with fewer fills in Hispanic patients. 
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However, lack of statistical significance corresponding to other outcomes may primarily be due 
to insufficient power: point estimates suggested that black and Hispanic patients were generally 
estimated to experience the same or larger declines as white patients. For example, by December 
2017, the guideline was estimated to have reduced average daily dose by nearly 10 MME in 
white patients, compared to more than double that in Hispanic patients. While these differences 
were never statistically significant, point estimates of racial/ethnic disparities with and absent the 
guideline suggest it may have contributed to a widening of black/white and Hispanic/white 
disparities in prescribing (with the exception of the black/white disparity in percentage receiving 
at least one opioid prescription). To help distinguish the consequences of insufficient power from 
true null effects on disparities, an extension to this study will examine the same relationships in a 
pooled cohort of patients with osteoarthritis, chronic back and neck pain, fibromyalgia, and 
chronic headache. 
 
Despite imprecise estimates, there was little evidence to suggest a narrowing of disparities due to 
the guideline. This may indicate that, despite providing clinicians a framework for deciding 
when to prescribe opioids and in what dose, the CDC guideline did not diminish racial/ethnic 
disparities in prescribing. That is, these findings do not appear to support the hypothesis that the 
guideline reduced clinical uncertainty and, in turn, the tendency to use racial/ethnic stereotypes 
or bias to inform prescribing decisions. Instead, the guideline may have affected white, black, 
and Hispanic pain patients similarly; or it may have disproportionately affected patients of color, 
and particularly Hispanic patients. The latter scenario could result from an increase in clinical 
uncertainty due to the guideline, in which the recommendations’ encouragement that providers 
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use personal judgment to determine each patient’s prescribing needs led to increased reliance on 
stereotypes and bias.  
 
In line with prior studies, I found that, after accounting for an array of likely confounders 
including socioeconomic status, access to health care, the presence of comorbidities, and the 
frequency of pain-related clinical encounters, black and Hispanic chronic pain patients received 
less overall and high-risk opioid prescribing on average than their white counterparts. In contrast 
with other examples of unequal treatment in health care, some have argued that disparate opioid 
prescribing has had a protective effect, accounting for the lower rates of opioid-related overdose 
mortality in black and Hispanic Americans in recent decades (Alexander et al., 2018; Frakt & 
Monkovic, 2019; Kaiser Family Foundation, 2019). Moreover, the medical consensus that 
opioids are not indicated for fibromyalgia, along with growing evidence that they are no more 
effective than lower-risk analgesics in some other conditions, may suggest that patients of color 
are benefiting from receiving fewer opioids. However, for any problem racial/ethnic 
discrimination in opioid prescribing avoids, it creates many more. Unequal treatment can reduce 
trust in health care providers, a key factor in decisions to seek treatment and preventive care and 
to adhere to medical recommendations (Benkert et al., 2006; Boulware et al., 2003; Williams & 
Mohammed, 2009). In addition, experiences of discrimination may increase depression and 
feelings of helplessness, and may even worsen the pain experience (Shavers et al., 2010). 
 
Moreover, racial/ethnic disparities in opioid prescribing may result in disproportionately high 
rates of untreated pain in black and Hispanic patients. In this study, I was unable to examine 
whether chronic pain patients not receiving opioids received alternative forms of pain 
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management—for example, lower-risk analgesics such as acetaminophen, physical therapy, or 
cognitive behavioral therapy. However, a meta-analysis found that black pain patients were less 
likely than white patients to receive any analgesic, while no difference between Hispanic and 
white patients was detected (Meghani et al., 2012). That is, black/white disparities in opioid 
prescribing likely reflect a disparity in medication-based pain management overall. Chronic, 
unmanaged pain can influence quality of life and mental health, and can interfere with one’s 
ability to work and conduct activities of daily living (Shavers et al., 2010). It may also increase 
the risk of illicit opioid use for pain management, which could have particularly severe adverse 
consequences in the context of a growing illicit fentanyl supply (Rothstein, 2017; Zoorob, 2019).  
 
The finding that the CDC guideline influenced prescribing intensity across racial/ethnic 
groups—and particularly the sizeable decline in average daily dose among those prescribed 
opioids—suggest that clinical guidelines in which compliance is entirely voluntary may result in 
clinically significant shifts in prescribing behavior. At the same time, the relatively small 
decrease in percent receiving at least one opioid fill per month may allay concerns that the 
guideline led to widespread inappropriate discontinuation of pain management among chronic 
pain patients in need (Rothstein, 2017). For more clarity on this issue, an extension to this study 
will examine the association of the guideline’s release with the percentage of chronic pain 
patients on opioid therapy who experience abrupt discontinuation.  
 
In an attempt to examine provider racial/ethnic discrimination in opioid prescribing before and 
after release of the CDC guideline, I studied a sample of patients who had received an 
osteoarthritis or fibromyalgia diagnosis, who had health insurance, and who, in a given month, 
had a pain-related healthcare visit. In this way, I was able to rule out many alternative 
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explanations for disparate rates of opioid use, such as variations in chronic pain prevalence by 
race/ethnicity and disparities in rates of insurance and other aspects of access to care. 
 
However, I was unable to fully rule out a demand-side explanation—i.e., that black and Hispanic 
patients may be less likely to accept any or high-dose opioid prescribing than their white 
counterparts. For example, one qualitative study found that many black cancer patients chose 
unmanaged pain over opioids or higher doses of opioids, due to aversion to “masking” the pain, 
concern about unpleasant side effects or developing dependence on opioids, discomfort with the 
stigma associated with opioid use, fear of doctors considering their pain illegitimate, and other 
factors (Meghani & Keane, 2007). Variations in these demand-side processes by race/ethnicity 
have not, to my knowledge, been studied. However, dissemination of the CDC guideline 
specifically targeted clinicians, suggesting that disparate effects of the guideline by race/ethnicity 
are unlikely to be fully attributable to differences in demand. 
 
There may be other unobserved confounders. For example, while claims data by definition 
allowed us to control for access to a clinician, white patients may have greater access to or be 
more likely to see pain specialists, who in turn may be more likely to prescribe opioids. 
However, one study found no association between race/ethnicity and pain specialist use 
(Meghani & Cho, 2009). Alternatively, because I was only able to observe filled prescriptions, 
disparities in opioid receipt may result not from discrimination in prescribing but from disparate 
access to pharmacies that stock prescription opioids (Morrison et al., 2000). However, this would 
not explain disparities in dose, and it is not in line with research that has observed opioid 
prescribing directly (Meghani et al., 2012).   
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The absence of a comparison group in this study raises the possibility that the observed 
associations were caused by other forces. In late October 2017, President Trump declared the 
opioid crisis a public health emergency, potentially increasing prescriber awareness of opioid 
overprescribing (The White House, 2018). Analysis excluding the months following this 
declaration resulted in slightly lower estimated effects of the guideline than in the main analysis, 
suggesting that the main results may have marginally overestimated the true effects. I was unable 
to identify any other co-occurring national policies or events that would be expected to cause the 
observed trend changes. Major state-level policy changes that influenced opioid prescribing, 
such as widespread implementation of prescription drug monitoring programs, predominantly 
occurred prior to the analytic period or prior to guideline release (Prescription Drug Abuse 
Policy System, 2017).  
 
Optum data reflect the age-sex structure of the commercially insured population, a more 
educated and higher-income group than the US as a whole (Jeffery et al., 2018; University of 
Michigan Institute for Healthcare Policy and Innovation, 2016). Racial/ethnic disparities in 
prescribing and effects of the CDC guideline may differ in the broader population. For example, 
disparities may be larger in a national population of chronic pain patients if there is an interaction 
between race/ethnicity and socioeconomic status (SES), resulting in a stronger effect of being 
black or Hispanic on prescribing among lower-SES patients. This effect modification could, in 
turn, cause any effect of the guideline on disparities to be larger at the national level. Additional 
research would be needed to compare the associations found in this study with those in a national 
population of chronic, non-cancer pain patients. 
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This study examined whether the CDC Guideline for Prescribing Opioids for Chronic Pain was 
associated with changes in opioid prescribing in its primary target group—patients with chronic, 
non-cancer pain—and whether these associations varied by race/ethnicity. Racial/ethnic 
disparities in opioid prescribing are well-documented and have an array of adverse consequences 
for black and Hispanic people experiencing chronic pain. By providing additional guidance on 
how and when to prescribe opioids, the guideline could have reduced providers’ reliance on 
racial/ethnic stereotypes in medical decision-making and in turn reduced disparities in 
prescribing. Yet while the guideline was associated with overall declines in prescribing and high-
dose prescribing for patients with osteoarthritis and fibromyalgia, it did not appear to decrease 
the effect of race/ethnicity on prescribing decisions. In fact, while estimates were too imprecise 
to draw solid conclusions, the CDC guideline may have contributed to a widening of 
racial/ethnic disparities in opioid prescribing for chronic pain.  
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Figure 3-1. Periods used to establish cohort and compare trends 
 
 
Note: CNCP refers to chronic, non-cancer pain; sample inclusion required newly observed CNCP during the first twelve months of the baseline comparison 
period. “Implem.” refers to the implementation period, i.e., months excluded from analysis to account for potential anticipatory and lagged effects of the policy. 
March 2016, the month of policy implementation, was also excluded from analysis. 
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Table 3-1. Characteristics of sample and filled opioid prescriptions 
  Osteoarthritis Fibromyalgia 
  Estimate 95% CI  Estimate  95% CI 
Distinct individuals 87,982         56,299    
Total monthly observations     1,284,468        855,371    
Months with osteoarthritis visits 18.3 (18.23 to 18.38)            18.9  (18.83 to 19.03) 
Race/ethnicity (%)       
White 77.9 (77.67 to 78.22)            79.5  (79.17 to 79.84) 
Black 11.0 (10.78 to 11.19)               8.4  (8.16 to 8.62) 
Hispanic 9.1 (8.94 to 9.32)               9.6  (9.33 to 9.81) 
Asian 1.9 (1.85 to 2.03)               2.5  (2.41 to 2.67) 
Female (%) 58.6 (58.24 to 58.90)            72.0  (71.60 to 72.34) 
Age (%)       
18-25 0.5 (0.50 to 0.59)               3.9  (3.70 to 4.02) 
25-34 1.7 (1.63 to 1.80)               8.6  (8.39 to 8.86) 
35-44 8.6 (8.39 to 8.76)            20.1  (19.79 to 20.45) 
45-54 34.1 (33.79 to 34.41)            34.6  (34.19 to 34.98) 
55-64 55.1 (54.73 to 55.39)            32.8  (32.42 to 33.20) 
Education (%)       
High school degree or less 30.7 (30.43 to 31.04)            25.4  (25.02 to 25.74) 
Less than college 53.5 (53.16 to 53.82)            55.3  (54.91 to 55.73) 
College degree 15.8 (15.54 to 16.02)            19.3  (18.97 to 19.62) 
Income (%)       
<$40K 20.9 (20.66 to 21.20)            18.6  (18.27 to 18.91) 
$40K-$59K 12.2 (12.00 to 12.43)            11.5  (11.20 to 11.72) 
$60K-$74K 9.6 (9.45 to 9.84)               9.2  (8.96 to 9.44) 
$75K-$99K 17.5 (17.26 to 17.77)            16.6  (16.28 to 16.89) 
$100K+ 39.7 (39.37 to 40.02)            44.2  (43.75 to 44.57) 
Mental health diagnosis, ever       
Anxiety, PTSD 35.3 (35.02 to 35.65)            44.9  (44.51 to 45.33) 
Depression 24.5 (24.19 to 24.76)            30.1  (29.76 to 30.52) 
Psychosis, schizophrenia, bipolar 6.2 (6.05 to 6.37)               7.8  (7.57 to 8.01) 
SUD diagnosis, ever 22.4 (22.13 to 22.68)            23.0  (22.68 to 23.38) 
Other pain-related diagnosis 42.1 (41.76 to 42.41)            36.6  (36.24 to 37.04) 
Elixhauser score (max per month. mean) 0.9 (0.91 to 0.93)               0.7  (0.73 to 0.75) 
Days since last pain visit 43.1 (42.71 to 43.47)            38.3  (37.90 to 38.77) 
Pain visits per month 2.9 (2.85 to 2.88)               2.9  (2.92 to 2.96) 
Months between first and last pain 
diagnosis 32.9 (32.79 to 32.94)            32.9  (32.84 to 33.04) 
Any opioid fill in month (%)       
Overall 15.1 (15.05 to 15.17)            16.3  (16.23 to 16.39) 
First year 14.3 (14.16 to 14.36)            14.9  (14.79 to 15.05) 
Second year 15.1 (15.00 to 15.21)            16.3  (16.17 to 16.44) 
Third year 16.0 (15.81 to 16.17)            17.9  (17.71 to 18.17) 
Fills per month, if any 1.3 (1.25 to 1.25)               1.3  (1.25 to 1.26) 
Days supplied per month, if any 28.0 (27.96 to 28.12)            30.7  (30.56 to 30.76) 
Morphine-milligram equivalents (MME), if any      
Mean (daily) 74.4 (74.03 to 74.73)            78.2  (77.77 to 78.63) 
Median (daily) 45.0 (45.0 to 45.0) 45.0 (45.0 to 45.0) 
Receiving > 90 MME (%) 22.9 (22.73 to 23.10)            24.4  (24.18 to 24.63) 
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Concurrent opioids/benzodiazepines, if any opioid      
  Any overlap (%) 26.4 (26.16 to 26.55)            32.2  (31.97 to 32.46) 
  Days with overlap, if any 28.2 (28.05 to 28.35)            29.0  (28.81 to 29.13) 
 
Note: Sample comprises observations for which there was no missingness on any model predictor. 
Sociodemographic, Elixhauser, and pain visit estimates refer to the individual’s first month in the cohort. Mental 
health and substance use diagnosis refer to diagnosis obtained any time during the observation period. Prescription 
fill estimates refer to all analyzed months in which a visit for the relevant condition (osteoarthritis or fibromyalgia) 
occurred. The Elixhauser comorbidity index indicates the number of distinct comorbidities for which an individual 
had a visit in the month of interest; 30 standard comorbidities were evaluated. 
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Figure 3-2. Unadjusted trends in opioid prescribing by pain condition and race/ethnicity 
A. Osteoarthritis 
 
B. Fibromyalgia 
  
Note: Red line indicates the month of guideline release (March 2016). All outcomes except “any fill” are conditional 
on having received at least one opioid prescription that month related to the condition of interest.
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Table 3-2. Observed and counterfactual predicted means for December 2017, from the Stage I (non-interacted) model  
 Any fill (%) Average dose (MME) High dose (%) 
Concurrent 
prescriptions (%) Days supplied Prescription fills 
Days with 
concurrent 
prescriptions 
Osteoarthritis        
  Guideline 14.0 47.9 11.8 18.9 21.0 1.17 25.0 (13.7 - 14.3) (46.3 - 49.6) (10.9 - 12.7) (18.0 - 19.7) (20.6 - 21.3) (1.16 - 1.18) (24.4 - 25.6) 
  No guideline 14.8 58.9 16.0 19.3 21.6 1.18 25.8 
(14.3 - 15.3) (55.7 - 62.0) (14.2 - 17.7) (17.8 - 20.9) (20.8 - 22.3) (1.16 - 1.21) (24.6 - 27.0) 
Fibromyalgia        
  Guideline 14.6 47.5 11.8 23.6 24.0 1.17 26.4 (14.3 - 15.0) (45.5 - 49.4) (10.8 - 12.9) (22.6 - 24.6) (23.6 - 24.5) (1.15 - 1.18) (25.7 - 27.0) 
  No guideline 
15.7 57.5 15.4 25.4 24.0 1.17 27.4 
(15.1 - 16.4) (53.8 - 61.1) (13.4 - 17.4) (23.7 - 27.1) (23.1 - 24.8) (1.14 - 1.20) (26.1 - 28.8) 
 
Note: MME = morphine milligram equivalents. 95% confidence intervals in parentheses. Bold indicates observed and counterfactual estimates with non-
overlapping confidence intervals. The counterfactual scenario is that in which the guidelines were not released but all other predictors were as observed.
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Table 3-3. Group-specific marginal effects of main predictors from Stage II (interacted) models, 
osteoarthritis 
  Any fill (%) Average dosage (MMEs) High dosage (%) 
Concurrent 
prescriptions  (%) 
Secular trend     
  White 0.0348*** 0.00216 -0.0248 -0.169*** 
(0.0200, 0.0497) (-0.102, 0.106) (-0.0800, 0.0304) (-0.217, -0.122) 
  Black -0.014 0.157 0.042 -0.143* 
(-0.0545, 0.0265) (-0.0461, 0.361) (-0.0824, 0.167) (-0.256, -0.0300) 
  Hispanic 0.0419 0.254 0.0156 -0.261*** 
(-0.00103, 0.0848) (-0.0649, 0.573) (-0.146, 0.177) (-0.409, -0.112) 
  Asian 0.108** 0.627 0.468* 0.197 
(0.0307, 0.186) (-0.235, 1.490) (0.0334, 0.902) (-0.240, 0.635) 
Level change     
  White -0.191 1.625 0.876 0.772 
(-0.564, 0.182) (-0.468, 3.718) (-0.338, 2.089) (-0.362, 1.906) 
  Black 0.323 -0.78 -0.285 -0.331 
(-0.668, 1.313) (-5.164, 3.604) (-3.056, 2.486) (-3.208, 2.545) 
  Hispanic -0.955 -3.333 0.0025 2.239 
(-1.978, 0.0689) (-9.899, 3.233) (-3.620, 3.625) (-1.142, 5.620) 
  Asian -0.812 -0.996 -3.21 -0.992 
(-2.628, 1.005) (-15.19, 13.20) (-10.96, 4.545) (-11.48, 9.494) 
Trend change     
  White -0.0394** -0.527*** -0.223*** -0.061 
(-0.0677, -0.0111) (-0.704, -0.351) (-0.325, -0.121) (-0.151, 0.0292) 
  Black 0.0251 -0.506** -0.246* -0.0162 
(-0.0515, 0.102) (-0.871, -0.141) (-0.475, -0.0182) (-0.218, 0.186) 
  Hispanic -0.0168 -0.958*** -0.226 -0.027 
(-0.0974, 0.0639) (-1.447, -0.469) (-0.521, 0.0682) (-0.289, 0.235) 
  Asian -0.0859 -1.032 -0.567 -0.563 
(-0.229, 0.0570) (-2.689, 0.624) (-1.437, 0.304) (-1.366, 0.240) 
Race/ethnicity     
  White Ref. Ref. Ref. Ref. 
  Black -1.323*** -9.778*** -4.274*** -4.696*** 
(-1.765, -0.880) (-11.337, -8.219) (-5.146, -3.401) (-5.676, -3.717) 
  Hispanic -2.054*** -10.539*** -4.248*** -2.973*** 
(-2.507, -1.601) (-12.324, -8.754) (-5.244, -3.252) (-4.074, -1.871) 
  Asian -3.680*** -4.639 -1.989 -6.716*** 
(-4.443, -2.918) (-9.551, 0.273) (-4.679, 0.702) (-8.988, -4.445) 
Observations 1,284,468 191,970 194,045 194,045 
 
Note: *** p<0.001, ** p<0.01, * p<0.05. MME = morphine milligram equivalents. 95% confidence intervals in 
parentheses. Estimates are racial/ethnic group specific and can be interpreted as a unit change in the outcome 
variable associated with a unit change in the variable of interest for the group of interest. In contrast with the other 
predictors, marginal effects of race/ethnicity are in reference to white patients.
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Table 3-4. Group-specific marginal effects of main predictors from Stage II (interacted) models, 
fibromyalgia 
  Any fill (%) Average dosage (MME) High dosage (%) 
Concurrent 
prescriptions  (%) 
Secular trend     
  White -0.035 -0.0967 -0.035 -0.191*** 
(-0.0971, 0.0271) (-0.217, 0.0234) (-0.0971, 0.0271) (-0.250, -0.132) 
  Black -0.0352 0.0152 -0.0352 -0.250** 
(-0.202, 0.132) (-0.266, 0.296) (-0.202, 0.132) (-0.417, -0.0838) 
  Hispanic -0.011 -0.125 -0.011 -0.281*** 
(-0.210, 0.188) (-0.513, 0.263) (-0.210, 0.188) (-0.448, -0.115) 
  Asian 0.11 0.271 0.11 -0.545* 
(-0.395, 0.615) (-0.730, 1.273) (-0.395, 0.615) (-0.989, -0.100) 
Level change     
  White 1.093 2.415 1.093 -0.435 
(-0.360, 2.545) (-0.0372, 4.866) (-0.360, 2.545) (-1.797, 0.926) 
  Black -1.108 -0.56 -1.108 0.394 
(-4.880, 2.664) (-6.672, 5.551) (-4.880, 2.664) (-3.629, 4.418) 
  Hispanic 1.998 1.473 1.998 -0.0963 
(-2.086, 6.082) (-5.324, 8.270) (-2.086, 6.082) (-4.085, 3.892) 
  Asian -1.004 -5.307 -1.004 0.895 
(-11.03, 9.018) (-28.71, 18.10) (-11.03, 9.018) (-8.065, 9.854) 
Trend change     
  White -0.241*** -0.581*** -0.241*** -0.0937 
(-0.367, -0.115) (-0.787, -0.375) (-0.367, -0.115) (-0.200, 0.0129) 
  Black -0.157 -0.495* -0.157 -0.0499 
(-0.505, 0.190) (-0.989, -0.000199) (-0.505, 0.190) (-0.347, 0.247) 
  Hispanic -0.268 -0.538 -0.268 -0.0485 
(-0.689, 0.153) (-1.165, 0.0883) (-0.689, 0.153) (-0.355, 0.258) 
  Asian -0.413 -0.787 -0.413 0.698 
(-1.557, 0.732) (-2.336, 0.761) (-1.557, 0.732) (-0.109, 1.505) 
Race/ethnicity     
  White Ref. Ref. Ref. Ref. 
  Black -1.150*** -9.184*** -2.677*** -4.812*** 
(-1.815, -0.486) (-11.413, -6.956) (-4.053, -1.302) (-6.316, -3.307) 
  Hispanic -1.865*** -7.421*** -3.419*** -3.587*** 
(-2.455, -1.275) (-9.922, -4.920) (-4.806, -2.032) (-5.090, -2.083) 
  Asian -3.850*** -2.936 -1.844 -7.991*** 
(-4.725, -2.974) (-10.174, 4.301) (-5.475, 1.788) (-11.408, -4.574) 
Observations 855,371 137,984 137,984 139,484 
Note: *** p<0.001, ** p<0.01, * p<0.05. MME = morphine milligram equivalents. 95% confidence intervals in 
parentheses. Estimates are racial/ethnic group specific and can be interpreted as a unit change in the outcome 
variable associated with a unit change in the variable of interest for the group of interest. In contrast with the other 
predictors, marginal effects of race/ethnicity are in reference to white patients. 
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Table 3-5. Observed and counterfactual predicted means for December 2017, from the Stage II (interacted) model 
  Any fill (%) Average dose (MME) High dose (%) Concurrent prescriptions (%) 
  Guideline No guideline Guideline No guideline Guideline No guideline Guideline No guideline 
Osteoarthritis         
  White 14.1 15.1 50.0 59.5 12.6 16.4 19.5 20.0 (13.76, 14.39) (14.54, 15.65) (48.12, 51.87) (55.87, 63.03) (11.54, 13.69) (14.46, 18.37) (18.51, 20.50) (18.30, 21.73) 
  Black 14.9 14.0 43.4 54.8 8.8 14.3 17.3 18.0 (14.04, 15.69) (12.51, 15.52) (39.56, 47.15) (47.51, 62.01) (6.582, 11.06) (9.793, 18.77) (15.28, 19.40) (13.88, 22.14) 
  Hispanic 12.9 14.2 35.3 58.8 8.4 13.1 16.0 14.4 (12.05, 13.80) (12.64, 15.83) (29.90, 40.76) (47.50, 70.04) (5.221, 11.53) (7.346, 18.92) (13.38, 18.69) (9.034, 19.69) 
  Asian 8.9 11.5 47.4 70.0 12.1 27.2 11.0 23.8 (7.293, 10.47) (8.550, 14.44) (30.95, 63.78) (39.37, 100.7) (2.698, 21.41) (11.61, 42.71) (1.723, 20.28) (7.994, 39.63) 
Fibromyalgia         
  White 14.6 15.8 48.6 58.4 12.3 15.9 24.8 27.2 (14.23, 15.02) (15.14, 16.52) (46.37, 50.86) (54.28, 62.53) (11.16, 13.50) (13.66, 18.06) (23.66, 25.97) (25.10, 29.33) 
  Black 18.1 17.8 44.3 55.2 10.2 14.1 20.9 21.5 (16.80, 19.33) (15.59, 20.00) (38.90, 49.63) (45.38, 65.06) (7.250, 13.19) (8.031, 20.12) (17.87, 23.85) (15.47, 27.56) 
  Hispanic 12.8 14.3 41.2 51.0 9.6 12.8 20.5 21.6 (11.71, 13.79) (12.36, 16.20) (34.79, 47.61) (37.57, 64.49) (6.079, 13.05) (5.599, 20.03) (17.20, 23.83) (15.56, 27.70) 
  Asian 7.8 8.2 42.9 64.7 8.7 18.2 19.7 4.1 (5.979, 9.666) (5.005, 11.48) (26.61, 59.14) (26.18, 103.2) (-1.103, 18.53) (-6.965, 43.42) (11.80, 27.56) (-11.95, 20.22) 
 
Note:  Bold indicates observed (guideline) and counterfactual (no guideline) estimates with non-overlapping confidence intervals. MME = milligram morphine 
equivalents. The counterfactual scenario is that in which the guidelines were not released but all other predictors were as observed. High dose refers to over 90 
MME.
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Table 3-6. Observed and counterfactual predicted disparities for December 2017, from the Stage II (interacted) model 
 
  Any fill (%) Average dose (MME) High dose (%) 
  Guideline No guideline Guideline No guideline Guideline No guideline 
Osteoarthritis           
  Black vs. white 0.8 -1.1 -6.64 -4.68 -3.8 -2.1 (-0.08, 1.67) (-2.67, 0.52) (-10.86, -2.42) (-12.72, 3.35) (-6.27, -1.31) (-7.01, 2.75) 
  Hispanic vs. white -1.2 -0.9 -14.67 -0.68 -4.2 -3.3 (-2.08, -0.22) (-2.54, 0.82) (-20.37, -8.97) (-12.45, 11.10) (-7.57, -0.91) (-9.38, 2.81) 
  Asian vs. white -5.2 -3.6 -2.63 10.59 -0.6 10.8 (-6.81, -3.58) (-6.59, -0.60) (-19.16, 13.89) (-20.29, 41.47) (-9.98, 8.86) (-4.92, 26.42) 
Fibromyalgia           
  Black vs. white 3.44 1.96 -4.35 -3.19 -2.11 -1.78 (2.12, 4.77) (-0.34, 4.27) (-10.13, 1.44) (-13.82, 7.45) (-5.31, 1.09) (-8.20, 4.63) 
  Hispanic vs. white -1.87 -1.55 -7.41 -7.37 -2.76 -3.05 (-2.98, -0.77) (-3.59, 0.49) (-14.19, -0.64) (-21.43, 6.69) (-6.44, 0.91) (-10.59, 4.49) 
  Asian vs. white -6.8 -7.59 -5.74 6.3 -3.62 2.37 (-8.68, -4.92) (-10.89, -4.28) (-22.16, 10.68) (-32.42, 45.03) (-13.51, 6.27) (-22.92, 27.65) 
 
Note: 95% confidence intervals in parentheses. MME = milligram morphine equivalents. High dose refers to over 90 MME. A black/white disparity of -1.1% in 
“any fill” indicates that black patients are an estimated 1.1 percentage points less likely to receive an opioid prescription than their white counterparts. Bold 
indicates an estimated disparity with a 95% confidence interval that does not overlap with zero. 
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Figure 3-3. Osteoarthritis: predicted means with and without the guideline, by race/ethnicity  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Left panel shows predicted means with the guideline, right panel absent the guideline (counterfactual). Ranges 
are 95% confidence intervals. Predicted means were not calculated for the implementation period (November 2015-
July 2016). Vertical line indicates month of guideline release.   
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Figure 3-4. Fibromyalgia: predicted means with and without the guideline, by race/ethnicity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Left panel shows predicted means with the guideline, right panel absent the guideline (counterfactual). Ranges 
are 95% confidence intervals. Predicted means were not calculated for the implementation period (November 2015-
July 2016). Vertical line indicates month of guideline release. 
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Chapter 4 - Cost-Effectiveness Analysis of Alternative Naloxone Distribution Strategies: 
First Responder and Lay Distribution in the United States 
 
 
INTRODUCTION 
In the United States, there were an estimated 48,000 opioid-related overdose deaths in 2017 
(Scholl et al., 2018). While the surge of opioid use disorder (OUD) and overdose has been 
especially severe in the U.S., opioid-related overdose fatalities have been increasing in a number 
of countries, including Canada, Scotland, Wales, and Australia. (National Records of Scotland, 
2018; Roxburgh et al., 2018; Special Advisory Committee on the Epidemic of Opioid Overdoses, 
2019; Substance Misuse Programme, 2017) Ensuring access to naloxone, a safe and effective 
opioid antagonist, is crucial to reducing mortality from opioid overdose (Bird et al., 2016; D. 
Kim et al., 2009; Pitt et al., 2018; A. Y. Walley et al., 2013). A recent cost-effectiveness analysis 
found that increasing naloxone availability may be one of a few cost-effective interventions to 
reduce overdose deaths without causing harm (Pitt et al., 2018). However, prior studies have not 
examined whether cost-effectiveness varies by the group targeted for naloxone distribution.  
 
Target groups of naloxone distribution & distribution prevalence  
Emergency medical services (EMS), police and fire, and laypeople comprise key target groups 
for naloxone distribution. There are potential advantages and disadvantages of distribution to 
each of these groups.  
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EMS distribution 
In many communities, EMS are equipped with naloxone (C. S. Davis, Southwell, et al., 2014). 
This enables administration at the scene of overdose rather than at the hospital, saving precious 
time (Belz et al., 2006). However, in some communities, EMS consists predominantly of 
emergency medical technicians (EMTs) and emergency medical responders—together termed 
basic life support, or BLS, and distinguished from advanced life support (ALS) personnel such as 
paramedics. BLS personnel lack authorization to administer naloxone in many states (C. S. 
Davis, Southwell, et al., 2014). This is the case in many rural areas, lowering the likelihood that 
individuals in these areas will receive naloxone at the scene of an overdose (Faul et al., 2015). 
EMS distribution could be increased by authorizing naloxone administration by BLS personnel. 
Evidence from states that allow this indicates that BLS personnel administer naloxone effectively 
(Belz et al., 2006; C. S. Davis, Southwell, et al., 2014; Gulec et al., 2018); one study found that 
enabling administration by EMTs could reduce time to administration by 6-10 minutes (Belz et 
al., 2006). 
 
Police and fire distribution 
Naloxone can also be administered by nonmedical emergency responders such as law 
enforcement officers and firefighters. Because police and fire are more numerous than EMS in 
many communities, the former may arrive first at an overdose scene (C. S. Davis, Ruiz, et al., 
2014). As a result, distribution to police and/or firefighters (“police and fire”) may further reduce 
time to administration, and thus the likelihood of death or severe hypoxia due to insufficient 
cerebral oxygenation. Distribution to police and fire may be particularly valuable in rural 
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communities, where ambulances may take longer to arrive or EMS may consist of primarily 
BLS.  
 
In the U.S., naloxone distribution to EMS, police, and firefighters has risen significantly (Belz et 
al., 2006; C. S. Davis, Ruiz, et al., 2014; Gulec et al., 2018; North Carolina Harm Reduction 
Coalition, 2018), and overdose reversals by these groups receive considerable media attention 
(Depompei, 2016; Wade, 2018; Zendehnam, 2018). However, the cost-effectiveness of first 
responder distribution strategies has not been studied, and some policymakers have expressed 
concern about their costs (Wootson Jr., 2017; WOWK-TV, 2018). Additionally, there are 
constraints on the effectiveness of naloxone distribution to either of these first responder groups. 
While the majority of overdose events are witnessed (D. Kim et al., 2009; Sherman et al., 2007; 
Strang et al., 1999), many witnesses do not call 911, often fearing legal repercussions due to the 
presence of illicit opioids (Galea et al., 2006). Good Samaritan Laws aim to ameliorate this fear, 
but expansive immunity is not yet universal and initial research is mixed on these laws’ 
effectiveness (Koester et al., 2017; McClellan et al., 2018; National Conference of State 
Legislatures, 2017; Rees et al., 2017; Zadoretzky et al., 2017). 
 
Lay distribution 
A third strategy is to distribute naloxone to laypeople, and in particular those likely to experience 
or witness an overdose. Distributing directly to laypeople may benefit overdose victims whose 
witness will not call 911. Moreover, when the witness does call 911, lay distribution may still 
reduce time to naloxone administration. Naloxone can be distributed to laypeople by community-
based organizations, pharmacies, health care facilities, and other sources to individuals likely to 
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experience or witness overdose (Wheeler et al., 2015). Evidence indicates that trained laypeople 
recognize overdose and administer naloxone effectively (T. C. Green et al., 2013), and that lay 
distribution and training programs have successfully reduced overdose mortality (McClellan et 
al., 2018; McDonald & Strang, 2016). 
 
Lay distribution may also have disadvantages. Because a layperson will likely encounter fewer 
overdoses than a first responder, a naloxone kit distributed to a layperson may be less likely to be 
used than one distributed to a first responder, reducing the cost-effectiveness of lay distribution 
compared to first responder distribution. Some worry that lay naloxone distribution provides an 
overdose safety net, leading individuals to use opioids more intensively and overdose more 
frequently (T. C. Green et al., 2013). This increased risk-taking is known as “moral hazard” in 
the economics literature. Empirical evidence for this hypothesis is lacking: a systematic review 
of 22 observational studies found no evidence that take-home naloxone programs increased 
heroin use (McDonald & Strang, 2016), and a recent econometric analysis found no significant 
association between naloxone access laws and non-medical opioid use (McClellan et al., 2018). 
Indeed, some studies suggest a decline in opioid use following naloxone training (McDonald & 
Strang, 2016; Seal et al., 2005). Nonetheless, because some policymakers and health providers 
continue to cite moral hazard as a concern, it is important to analyze the potential effects of the 
moral hazard hypothesis on cost effectiveness (T. C. Green et al., 2013; Seelye, 2017). 
 
The size and number of lay distribution programs have grown, as community-based programs 
have increasingly offered naloxone and states have issued standing orders for provision by 
pharmacists without individual prescriptions (C. S. Davis et al., 2015; Wheeler et al., 2015). 
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Nonetheless, a recent study found that only 13% of the counties with the highest opioid overdose 
rates had naloxone distribution programs for laypeople (Lambdin et al., 2018). One reason may 
be that lay distribution remains highly controversial (Bachhuber et al., 2015; Blendon & Benson, 
2018). 
 
With the rapid evolution of the opioid crisis, the cost-effectiveness of naloxone distribution to all 
target groups may be shifting. For example, rising prevalence of highly potent opioids like 
fentanyl has increased risk of death due to overdose, requiring earlier naloxone administration 
and/or higher doses, and potentially reducing its cost-effectiveness (Frank & Pollack, 2017). 
Sharply rising naloxone prices have also raised concern (Gupta et al., 2016). Given these 
changing circumstances, the variation in advantages and disadvantages across strategies, and the 
scarcity of resources available to address the crisis, a cost-effectiveness analysis of each 
distribution strategy, both independently and in combination, is needed. 
 
Aims 
I conduct a cost-effectiveness analysis to compare eight strategies that encompass all 
combinations of low and high distribution to laypeople, police and fire, and EMS: low levels of 
distribution to all groups (“minimum distribution”); high distribution to all groups (“maximum 
distribution”); and all other combinations of high and low distribution to the three groups (all 
eight combinations are listed in Table 4-2). Because laypeople likely to experience or witness 
overdose—people with OUD and their friends and family—are more likely than the average 
person to benefit from obtaining naloxone, I specifically consider laypeople likely to witness or 
experience an overdose (henceforth “laypeople”). 
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I examine police and fire separately from EMS for several reasons. First, police and/or fire often 
arrive to an overdose scene before EMS, such that overdose victims can receive naloxone from 
police and fire as well as EMS—i.e., they can function as two separate interventions. Second, 
increasing naloxone distribution to police and fire departments is conceptually distinct from 
authorizing naloxone administration by BLS, a primary means by which EMS naloxone levels 
could be increased. I examine police distribution and fire distribution as one strategy, however, 
because both groups serve a similar function as nonmedical first responders, costs of distribution 
and training to the two groups are similar, there is great heterogeneity in which party arrives first 
at an overdose scene, and because data on any differences in frequency and effectiveness of 
naloxone administration are insufficient to parameterize separate strategies.  
 
METHODS 
I developed a decision analytic model in TreeAge Pro 2018. Outcomes of interest included (a) 
strategy ranking, determined by net monetary benefit, (b) cost-effectiveness, expressed in 
incremental costs per quality-adjusted life year (QALY) gained, and (c) the number of fatal 
overdoses (and percent of fatal overdoses averted compared to the worst-case scenario, or 
minimum, strategy). Net monetary benefit is equal to effectiveness (QALYs) times willingness-
to-pay per QALY, minus cost. A strategy is “preferred” if it maximizes net monetary benefit. I 
used a lifetime time horizon in order to account for both up-front costs of distribution and long-
term benefits (such as less lost productivity) of averted deaths. I employed two reference case 
perspectives: a societal perspective that incorporated productivity and criminal justice system 
costs, and a health sector perspective that did not (Neumann, Sanders, Russell, Siegel, & Ganiats, 
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2016). Costs included the cost of naloxone kits themselves, the cost of training recipients to 
recognize overdose and administer naloxone, the cost of ambulance rides and emergency 
department visits, and (in the societal analysis) the time costs of lay naloxone training, 
productivity costs of OUD and overdose (less consumption), and costs to the criminal justice 
system (Table 5-20; appendix text). Effectiveness is accrued via (a) reductions in mortality and 
(b) improvements in quality of life due to less hypoxia and reduction in misuse, which is 
associated with lower health-related quality of life (Nosyk et al., 2010; Pyne et al., 2011; 
Vanagas et al., 2010). 
 
I modeled a closed cohort of hypothetical individuals with OUD. The average age of first 
use/misuse of heroin and prescription pain relievers is the average age of first use/misuse of 
heroin and prescription pain relievers (Lipari et al., 2017), and the average length of heroin use 
has been found to be about 10 years (Best et al., 2008). Assuming a symmetrical age distribution 
of misuse, I approximated a cross-section of the population with OUD who enter the model at 
age 35 (i.e., at the median age of use). Costs and QALYs were scaled to a hypothetical 
population of 50,000 people in which OUD prevalence is 0.8%, following the 2016 National 
Survey on Drug Use and Health (Center for Behavioral Health Statistics and Quality, 2016). My 
cohort thus comprised 400 individuals with OUD (50,000 x 0.8%). Hypothetical individuals in 
the model could be currently misusing opioids, not currently misusing, or dead. Because prior 
overdose is a strong predictor of future overdose and mortality (Darke et al., 2007), these health 
states were further divided as shown in Figure 4-1. Individuals who survived an overdose could 
suffer from long-term effects of hypoxia. Individuals could transition between states annually, 
via pathways depicted in Figure 4-1. 
 83 
 
Figure 4-2 is a simplified tree of potential events for individuals in a “misusing” health state (the 
complete model is available upon request). In a given year, an individual with OUD may 
experience an overdose, which carries a risk of mortality and a risk of severe hypoxia; these 
probabilities vary depending on the interventions an individual receives. If an overdose occurs, 
there is some probability that it is witnessed, and some probability that a layperson at the scene 
(the victim or a witness) has obtained naloxone—e.g., from a pharmacy or community-based 
program. This parameter varies across strategies. If they have obtained naloxone, whether the 
witness actually administers it depends on a number of factors: whether the witness recognizes 
the event as an overdose, whether the witness is aware of the naloxone (if it belongs to the 
victim), whether the naloxone is at the scene (i.e., not lost or left elsewhere), and whether the 
witness is willing and able to administer. Lay administration of naloxone reduces the risk of 
mortality and severe hypoxia.  
 
Regardless of whether the witness administers naloxone, they may choose to call 911. If 911 is 
called, and if police or fire arrive to the scene before EMS, they may be equipped with naloxone 
(varying across strategies) and may administer it. If not, they may still reduce average mortality 
and hypoxia risk via rescue breathing or ventilation by bag-valve. If police and fire do have and 
then administer naloxone, the reduction in average mortality is larger than if they arrive first but 
do not have naloxone. There is a given probability that EMS arriving on the scene have naloxone 
(varying by strategy). There is an additional probability the EMS administer the naloxone. To 
reflect the capability of EMS to manage breathing and cardiac conditions during an overdose, the 
arrival of EMS on scene results in a reduction in mortality and hypoxia risk regardless of 
 84 
naloxone administration. However, the administration of naloxone by EMS garners further risk 
reduction. If none of the first responders have naloxone, the individual will receive naloxone at 
the hospital. This delay results in a smaller reduction in mortality and hypoxia risk. 
 
In the minimum distribution strategy, the hypothetical community is assumed to have equipped 
no laypeople and no police and fire with naloxone (Table 4-1). The probability that EMS arriving 
at the scene are equipped with naloxone was set to 0.5. This models a community in which 50% 
of 911 calls are responded to by EMS authorized to administer and equipped with naloxone; in 
the other 50% of 911 calls, BLS or other personnel not equipped with naloxone arrive. This 
selection was somewhat arbitrary, but reflects the fact that advanced life support personnel or 
other responders authorized to administer and equipped with naloxone, will comprise some 
proportion of EMS in any given community. In the “high police and fire” and “high EMS” 
strategies, the percentage of each first responder group equipped with naloxone was increased to 
100%. In the “high layperson” strategy, the percentage of overdoses at which a layperson 
(whether victim or witness) has obtained naloxone is increased to 75%; I set the “high 
layperson” value to less than 100% to reflect the challenge of disseminating naloxone to all 
individuals likely to experience or witness overdose.  
 
As an example, the “high layperson, low police and fire, low EMS” strategy would model a 
community in which 75% of individuals likely to witness or experience overdose have obtained 
naloxone, no police and fire who arrive at an overdose scene are equipped with naloxone, and 
50% of 911 calls are responded to by EMS authorized to administer and equipped with naloxone. 
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To gain insight into the optimal target levels of naloxone distribution, sensitivity analyses 
examined variation in the precise definition of the levels for each intervention. 
 
Table 5-21 provides parameter point estimates, ranges, and rationales. Selection of input 
parameters was based on nationally representative data and synthesis of one-off studies. To 
account for the uncertainty inherent in estimates regarding opioid use and overdose events, I 
selected a range within which each parameter value was expected to fall and used these ranges to 
conduct sensitivity analyses. The size of the range reflected the level of uncertainty in the 
parameter. Model calibration was conducted to ensure the model produced results similar to 
those observed in the literature and is described in the appendix text and Table 5-23. 
 
I conducted a tornado analysis to examine the effects of varying each parameter individually on 
model outcomes. For a set of particularly uncertain or potentially influential parameters, I 
conducted threshold analyses to examine whether any value of the parameter (ranging from zero 
to one) would change the model’s conclusions. For example, given uncertainty in the probability 
of overdose death in the presence of each intervention, the corresponding mortality parameters 
were varied from relative risks of zero (no mortality with the given intervention) to one (no 
reduction in mortality compared to receiving no intervention). Sensitivity analysis on mortality 
parameters also enabled examination of the impact of increasing use of highly potent fentanyl-
like products on cost-effectiveness, as this shift may result in greater mortality at traditional 
naloxone doses, and/or entail higher costs when multiple doses are required. I also conducted 
threshold analyses on rising naloxone prices, the effectiveness of subsequent doses of naloxone 
when multiple doses are administered, and hypothetical moral hazard. 
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In a probabilistic sensitivity analysis, I simultaneously varied all parameters in 10,000 iterations 
of a Monte Carlo simulation. This allowed us to evaluate the probability that each strategy would 
be cost-effective compared to the alternatives, given overall, combined parameter uncertainty. 
Table 5-22 details the assumptions about the distribution of each parameter.  
 
I used the Consumer Price Index to adjust costs to 2017 US dollars. I used a 3% discount rate 
applied to both costs and health outcomes (Sanders et al., 2016). I used a threshold for cost-
effectiveness of $50,000 (Ubel et al., 2003). For some comparisons, I compared strategies in 
terms of net monetary benefit, a measure that combines costs and QALYs into a single value 
measure, by valuing QALYs at $50,000 each. 
 
RESULTS 
Results of base case analysis (societal perspective) 
High levels of distribution to all three groups maximized net monetary benefit and minimized the 
number of overdose deaths, while low levels of distribution to all groups entailed the reverse 
outcomes (Table 4-2). For example, maximum distribution entailed 107 overdose deaths, 
compared to 136 in the minimum strategy (21% averted compared to the minimum). This 
strategy would cost a community of 50,000 approximately $40,000 in naloxone training and kits 
in the first year of distribution, and about $100,000 over five years. The top four strategies 
(ranked by net monetary benefit) involved high lay distribution, while the bottom four involved 
low lay distribution.  
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Table 4-3 disaggregates the costs and savings accrued in each strategy. In strategies with higher 
rank, criminal justice system costs and costs due to health care not related to overdose were 
higher because people were kept alive longer; training and kit costs were higher because more 
naloxone was distributed; costs related to overdose also increased as people were kept alive 
longer and had additional opportunities to overdose. However, the increased overall costs of 
naloxone distribution, training, and the societal health and criminal justice costs of individuals 
with OUD living longer were considerably smaller than the productivity gained by averting 
deaths. Every strategy was cost-saving compared to its next-best alternative, and cost savings 
were greatest in the maximum distribution strategy because it minimized deaths (and maximized 
effectiveness). 
 
The second highest-ranking strategy involved high distribution to laypeople and EMS, but low 
distribution to police and fire; there were four more overdose deaths in this strategy. The third 
highest-ranking strategy involved high distribution to laypeople and police and fire, but low 
distribution to EMS, involving five more overdose deaths than in maximum distribution. 
 
Results of health sector analysis 
The results of the health care sector analysis were similar to those from the societal analysis 
(Table 4-2 and Figure 4-3). Rankings based on net monetary benefit of each strategy were the 
same, although some strategies were dominated by extended dominance—i.e., there was a more 
effective strategy with a lower cost-effectiveness ratio (Cantor, 1994). Maximum distribution to 
all groups remained the preferred strategy and undominated; high distribution to laypeople and 
EMS (but not police and fire) remained second most preferred and was undominated. Because 
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societal costs were excluded from this analysis, strategies were no longer cost-saving. However, 
the incremental cost-effectiveness ratio of all undominated strategies fell below $20,000 per 
QALY gained.  
 
Sensitivity analysis 
Societal analysis 
Results were highly robust to uncertainty in the model parameters. For all but one parameter in 
the tornado analysis—the probability that police and fire arrive before EMS—wide variation in 
the parameter estimate did not affect strategy ranking. For example, variation in the probability 
that an overdose is witnessed, the probability that a witness would administer naloxone if 
obtained, and the probability that a witness would call 911 did not influence which strategy was 
preferred. Results also were not sensitive to how “low” distribution levels were defined—i.e., to 
status quo levels in the community—or to variation in training duration, naloxone kit costs 
(within a reasonable range), or trainer/trainee wages. When police and fire arrived first less than 
3.0% of the time 911 was called, high distribution to all groups was no longer preferred; under 
these circumstances, high distribution only to laypeople and EMS maximized net monetary 
benefit (Table 5-24). 
 
Threshold analyses identified thresholds in nine additional parameters: the probability an 
overdose is witnessed, naloxone kit costs, hypothetical moral hazard (represented as an increase 
in the annual probability of overdose associated with lay naloxone distribution), and the 
reduction in mortality associated with each possible intervention (Table 5-24). These thresholds 
occurred at extreme values of each parameter. For example, maximum distribution maximized 
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net monetary benefit as long as naloxone cost less than $1,432 per kit. In the analysis of 
hypothetical moral hazard, high distribution to police/fire and EMS (but not laypeople) was only 
preferred to the maximum strategy if lay distribution increased the probability of overdose by at 
least 23%. 
 
A two-way sensitivity analysis of the effectiveness of subsequent naloxone doses (e.g., 
administered by EMS following administration by police and fire) revealed that maximum 
distribution maximized net benefit even if subsequent doses reduced mortality by as little as 
0.01%. Strategy rankings also did not depend on the effectiveness of subsequent doses. 
Appendix text further details the results of sensitivity analyses. 
 
Figure 4-4 displays results of the probabilistic sensitivity analysis in cost-effectiveness 
acceptability curves, which display the probability that an intervention is preferred to its 
alternatives at a given willingness-to-pay (WTP) (Fenwick et al., 2001). Maximum distribution 
was consistently most likely to be cost-effective; this probability is larger than 0.8 when 
willingness-to-pay is $50,000 or above per QALY. All other strategies were consistently less 
than 20% likely to be preferred to the alternatives. 
 
Health sector analysis 
As in the societal analysis, variation in only one parameter in the health sector tornado analysis 
influenced strategy rankings. If police and fire arrived before EMS less than 7.3% of the time, 
then maximum distribution no longer maximized net monetary benefit; instead, high distribution 
to laypeople and EMS (but not police and fire) was preferred. Threshold analysis indicated that, 
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from this perspective, maximum distribution was preferred as long as a naloxone kit cost less 
than $570; above that, high distribution to laypeople and EMS (but not police and fire) is 
preferred until a kit reaches $2,210. In addition, high distribution to police/fire and EMS (but not 
laypeople) was only preferred to the maximum strategy if hypothetical moral hazard increased 
the probability of overdose rose by at least 20%. 
 
DISCUSSION 
This study is the first to evaluate the cost-effectiveness of naloxone distribution to first responder 
groups individually and in combination with laypeople. The target groups of interest included 
laypeople likely to witness or experience overdose, police and/or firefighters (“police and fire”), 
and EMS personnel not currently equipped, such as basic life support personnel who in many 
states are not authorized to administer naloxone. In both the societal and health sector analyses, 
high distribution to all three target groups minimized overdose deaths and maximized net 
monetary benefit, a measure that takes into account both costs and health gains. Compared to a 
worst-case scenario of minimum distribution to all groups, this strategy averted 21% of overdose 
deaths. High distribution to laypeople and EMS (but not police and fire) ranked second, while 
high distribution to laypeople and police and fire (but not EMS) ranked third. Compared to the 
minimum strategy, these strategies each averted roughly 18% of overdose deaths. 
 
Strategies involving low distribution to laypeople always ranked last. The majority of mortality 
reduction would result from increased lay distribution, because it could benefit a population not 
accessible to first responders: overdose victims whose witness does not call 911. In contrast, first 
responder naloxone benefits victims likely to receive naloxone eventually—if not by first 
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responders equipped with naloxone at the scene (police and fire and/or EMS), then once 
transported to the hospital. The marginal value of lay distribution is thus greater than that of first 
responder distribution. For a similar reason, increased police and fire distribution reduces 
mortality less than EMS distribution. Police and fire can administer naloxone and potentially 
avert fatal overdose when they arrive on scene before EMS. However, because administration by 
police and fire is always followed by EMS care, its benefit relative to the alternative—EMS 
treatment alone—is smaller than the benefit of administration by either of the other groups.  
 
In the societal analysis, which took into account productivity and criminal justice system costs, 
all strategies were cost-saving because the productivity losses averted by keeping a person alive 
longer far outweighed the societal costs of doing so (e.g., added costs to the criminal justice and 
health care systems). In the narrower health sector analysis, undominated strategies were highly 
cost-effective: for example, high distribution to all groups corresponded to an incremental cost-
effectiveness ratio of $15,950 per QALY gained, considerably below a threshold of $50,000.  
 
The cost of naloxone is low compared to many life-saving medications. Even amid rising 
naloxone prices, maximum distribution remained the preferred strategy as long as naloxone kits 
remained below $1,430 in the societal analysis and $570 in the health sector analysis. As rising 
naloxone prices risk making naloxone unaffordable to some individuals, organizations, and local 
governments (Gupta et al., 2016; Wheeler et al., 2015), the medication’s cost-effectiveness 
justifies subsidies or other support to ensure availability. This finding also suggests that, even if 
rising prevalence of synthetic opioid overdose increases the number of doses needed for 
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successful reversal, the corresponding increase in cost per reversal is unlikely to undermine 
naloxone’s cost-effectiveness.  
 
While my results suggest that maximum distribution would be highly cost-effective (health 
sector analysis) or even pay for itself (societal analysis), affordability of up-front costs may 
influence a community's decision. A community of 50,000 would spend about $40,000 on 
naloxone training and kits in the first year of high distribution to all groups, and about $100,000 
over five years. 
 
The results were remarkably robust to sensitivity analysis. Even in threshold analyses (within the 
societal analysis) in which I extended parameter ranges beyond what the literature suggests is 
reasonable, I only saw thresholds at extreme values. In addition, the findings were robust to 
probabilistic sensitivity analysis, and were comparable with results of related studies of lay 
distribution (Coffin & Sullivan, 2013a; Langham et al., 2018; Uyei et al., 2017b). 
 
These findings were not sensitive to large increases in the probability of overdose death and to 
greater need for multiple doses of naloxone—further evidence that, in the context of increased 
use of highly potent opioids such as fentanyl, naloxone distribution will remain cost-effective.  
 
While empirical evidence indicates otherwise (McClellan et al., 2018; McDonald & Strang, 
2016), some decision makers worry that distributing lay naloxone will lead individuals to use 
opioids more intensively, thereby undermining the health benefits of distribution (Seelye, 2017). 
my results suggest that, even if moral hazard were to occur, maximum distribution to all groups 
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would very likely remain preferred. Moral hazard would need to increase the annual probability 
of overdose by 23% in the societal analysis (20% in the health sector analysis) in order for high 
distribution to police/fire and EMS—but not laypeople—to be preferred. Such manifestations of 
moral hazard are inconsistent with prior research (McClellan et al., 2018; McDonald & Strang, 
2016), suggesting that this common concern is not a realistic threat to the value of lay naloxone 
distribution. 
 
This study has limitations. Incomplete and imperfect data produce uncertainty in the parameter 
estimates in my model. Much existing research is limited to individuals using heroin, who may 
differ from individuals who misuse other opioids (Darke et al., 2007; Sumner et al., 2016). 
Studies of overdose witness behavior typically rely on self-reports, raising concern about social 
desirability bias. I use a combination of national statistics and data from smaller-scale studies, 
many of which have occurred in urban areas; more research is needed for greater national 
representativeness. Nonetheless, informed policy decisions are needed now. Given these 
challenges, I selected a mathematical modelling approach that allows for considerable 
uncertainty. Extensive deterministic and probabilistic sensitivity analyses examining wide ranges 
of possible values for each parameter revealed my results to be remarkably robust. Analyses such 
as this one provide means to make evidenced-based, cost-effective policy decisions in the face of 
incomplete or low-quality data.  
 
Community-level heterogeneity may necessitate different distribution approaches in different 
communities. For example, rural and urban areas likely differ in important ways (Faul et al., 
2015; Gonzalez et al., 2009; Kerensky & Walley, 2017; Wunsch et al., 2009). However, 
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insufficient data on rural opioid use and overdose precluded the development of two separate 
models; this is an area for future research. In the meantime, the robustness of my results to 
sensitivity analysis suggests that the highest-ranked strategies are likely to remain cost-saving 
and effective under a wide range of circumstances. Similarly, insufficient data on the frequency 
and effectiveness of naloxone distribution by police officers and firefighters precluded 
examination of distribution to these target groups separately. More empirical research on the 
mortality and morbidity benefits of different forms of first responder naloxone distribution is 
needed. 
 
I defined “high lay distribution” such that, at 75% of overdose events, either the victim or a 
witness would have at some point obtained naloxone (though they may not have or administer it 
at the scene of overdose). I chose this conservative upper bound to reflect the difficulty of 
reaching all individuals likely to experience or witness overdose.  
 
However, I am unable to estimate the proportion of target laypeople who should receive 
naloxone in order to ensure that, at 75% of overdose events, someone has obtained naloxone. 
First, there is some amount of positive spillover of lay distribution, in which a given kit may be 
administered to someone other than the original recipient (Keane et al., 2018). Second, 
nonrandom distribution of naloxone among target laypeople may lead to a nonlinear relationship 
between number of kits distributed and effectiveness. For example, two people at a single 
overdose event may have obtained naloxone (e.g., if they both live near a distribution site or if 
one learned about naloxone from the other), while at another event no one may have obtained 
it—rendering the second layperson kit less able to confer health benefits than if distribution were 
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homogeneous. The data needed to explicitly model these forces are lacking, limiting my ability 
to recommend precise target percentages for lay distribution. Nonetheless, my findings support a 
concerted increase in naloxone distribution to laypeople as well as first responders.    
  
Because naloxone is not randomly distributed among target laypeople, the cost of ensuring that 
naloxone has been obtained by at least one person at 75% of overdose events is likely higher 
than that of distributing naloxone to 75% of laypeople. This may be compounded by a related 
phenomenon, in which, at higher levels of distribution, the remaining laypeople become harder 
and thus more expensive to reach. Insufficient prior research precluded explicit modeling of 
these nonlinearities, potentially resulting in underestimation of lay distribution costs and, in turn, 
overestimation of cost-effectiveness. However, sensitivity analyses demonstrated my key 
findings to be robust to large increases in the costs of lay distribution (Appendix C-6). Still, my 
inability to model these nonlinearities likely renders my precise cost estimates imperfect. Further 
research is needed to better characterize the social networks of individuals with OUD and the 
resulting nonlinearities in naloxone costs and effectiveness.   
 
Opioid-related overdose killed more nearly 48,000 Americans in 2017 alone (Scholl et al., 2018). 
Increasing naloxone access saves lives, reduces morbidity due to severe hypoxia, and costs little. 
Yet naloxone access remains insufficient. my findings support increased naloxone distribution to 
laypeople likely to experience or witness overdose, police and fire, and EMS. Increased 
distribution to and use by EMS could be achieved by, for example, authorizing naloxone 
administration by basic life support personnel in states that currently prohibit it. When resource 
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constraints limit a community’s ability to increase distribution to all three groups, distribution to 
laypeople and EMS should be prioritized.  
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Figure 4-1. Possible health states and transitions 
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Figure 4-2. Tree of potential annual transitions for individuals in a "misusing" health state 
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Table 4-1. Intervention levels in base case analysis 
 Low (%) High (%) 
Lay distribution* 0 75 
Police and fire 
distribution 0 100 
EMS distribution 50 100 
 
Note: All eight combinations of these levels (“strategies”) are examined in the analysis. Sensitivity 
analyses are conducted on each of these levels to examine the effects of defining them differently. 
* Lay distribution level refers to the percentage of overdoses at which at least one of the victim or 
witnesses has obtained naloxone. In such cases, a separate probability determines whether the naloxone is 
available and administered. The “high” value is less than 100% to reflect the challenge of disseminating 
naloxone to all individuals likely to experience or witness overdose. 
  
 100 
 
Table 4-2. Results of societal and health sector analyses 
 
A.  
 Ranka Overdose deaths 
Deaths averted, 
compared to 
minimum (%) 
Costb Effectivenessc Statusd 
High LP, High PF, High EMS 1 107 21 (179.2) 5,230 _______ 
High LP, Low PF, High EMS 2 111 18 (178.9) 5,200 Dominated 
High LP, High PF, Low EMS 3 112 18 (178.5) 5,180 Dominated 
High LP, Low PF, Low EMS 4 117 14 (178.0) 5,140 Dominated 
Low LP, High PF, High EMS 5 125 8 (177.0) 5,080 Dominated 
Low LP, Low PF, High EMS 6 129 5 (176.5) 5,040 Dominated 
Low LP, High PF, Low EMS 7 131 4 (176.1) 5,020 Dominated 
Low LP, Low PF, Low EMS 8 136 _______ (175.4) 4,960 Dominated 
 
B.  
 Ranka Overdose deaths 
Deaths averted, 
compared to 
minimum (%) 
Costb Effectivenessc ICERe 
High LP, High PF, High EMS 1 107 21 61,544 5,230 15,950 
High LP, Low PF, High EMS 2 111 18 61,054 5,200 12,880 
High LP, High PF, Low EMS 3 112 18 61,982 5,180 Dominated (extended) 
High LP, Low PF, Low EMS 4 117 14 60,348 5,140 Dominated (extended) 
Low LP, High PF, High EMS 5 125 8 59,537 5,080 Dominated (extended) 
Low LP, Low PF, High EMS 6 129 5 58,956 5,040 12,000 
Low LP, High PF, Low EMS 7 131 4 58,838 5,020 Dominated (extended) 
Low LP, Low PF, Low EMS 8 136 _______ 58,083 4,960 _______ 
 
a Ranked by net monetary benefit 
b In millions of dollars 
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c In QALYs 
d Because all strategies but one are dominated, incremental cost-effectiveness ratio is not reported 
e Incremental cost-effectiveness ratio. Compared to next-best alternative, where next-best alternative is 
the undominated strategy with the next highest net monetary benefit; in dollars per QALY 
 
Note: Panel A: societal analysis; Panel B: health sector analysis. LP = layperson; PF = police and fire; 
EMS = emergency medical services. Cost and effectiveness values correspond to a hypothetical 
community with a population of 50,000, over a lifetime time horizon.  
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Table 4-3. Disaggregated costs of top three strategies at five years and lifetime (societal 
perspective) 
 
  Five years 
 Rank Training & kits 
Productivity 
(excluding 
consumption) 
Health, -
overdose 
Health, -
other 
Criminal 
justice 
system 
Total 
High LP, high PF, 
high EMS 1 102,000 (94,009,000) 1,629,000 17,299,000 6,879,000 (157,388,000) 
High LP, low PF, 
high EMS 2 63,000  (93,913,000) 1,626,000 17,282,000 6,873,000 (157,266,000) 
High LP, high PF, 
low EMS 3 97,000 (93,866,000) 1,625,000 17,274,000 6,869,000 (157,156,000) 
Low LP, low PF, 
low EMS 8 5,000 (93,122,000) 1,604,000 17,140,000 6,817,000 (156,007,000) 
        
  Lifetime 
 Rank Training & kits 
Productivity 
(excluding 
consumption) 
Health, -
overdose 
Health, -
other 
Criminal 
justice 
system 
Total 
High LP, high PF, 
high EMS 1 281,000 (259,098,000) 5,075,000 56,150,000 18,366,000 (564,054,000) 
High LP, low PF, 
high EMS 2 160,000 (258,187,000) 5,032,000 55,825,000 18,262,000 (561,398,000) 
High LP, high PF, 
low EMS 3 263,000 (257,752,000) 5,012,000 55,671,000 18,213,000 (559,976,000) 
Low LP, low PF, 
low EMS 8 15,000 (250,962,000) 4,707,000 53,333,000 17,467,000 (539,955,000) 
 
Note: All values in dollars. Negative values (savings) in parentheses. A lower value of costs (or larger 
absolute value of savings) is preferred. Top three strategies are included, as well as the minimum strategy 
for comparison. 
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Figure 4-3. Cost-effectiveness planes, societal perspective (A) and health care sector (B) 
A.  
 
 
B.  
 
 104 
Note: Strategy labels are ordered as: layperson (high or low), police and fire (high or low), and EMS 
(high or low). Markers in gray indicate dominated strategies; markers in black and (in panel B) connected 
by the line indicate strategies that are not dominated. The triangle marker indicates the strategy that 
maximizes net monetary benefit. 
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Figure 4-4. Cost-effectiveness acceptability curves 
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Chapter 5 – Conclusion 
 
 
INTRODUCTION 
This dissertation addressed two contemporary challenges in population health: (1) stagnation of 
the downward trends in disability prevalence, combined with growing disparities in disability; 
and (2) the opioid overdose crisis, which led to the deaths of 48,000 people in 2017 and 
contributed to a 0.28 year decline in life expectancy between 2000 and 2015 (Dowell et al., 
2017; Scholl et al., 2018). In Paper 1, I used data from the nationally representative Panel Study 
of Income Dynamics to better characterize the mechanisms underlying educational disparities in 
difficulty with everyday life activities. Papers 2 and 3 centered on two elements of the 21st 
century opioid crisis: racial disparities in opioid prescribing amid efforts to reduce unsafe 
prescribing (Paper 2) and the allocation of scarce resources to equip laypeople and first 
responders with naloxone, in order to ensure the greatest benefits to population health (Paper 3).  
 
PAPER 1 - EDUCATIONAL DISPARITIES IN DISABILITY 
This study estimated the population-level contributions of three key mediators of educational 
disparities in incident difficulty with ADLs and IADLs among both younger and older women 
and men. I took advantage of seven waves of nationally representative, longitudinal data on ADL 
and IADLs, combined with information on life course factors including childhood 
socioeconomic circumstances, earlier-life BMI, and occupational history. Educational disparities 
in incidence of ADL/IADL difficulty were evident among both younger and older adults (under
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65, 65 and over) and larger in women. Together, excess BMI, smoking history, and manual labor 
involvement appeared to account for roughly 60-70% of disparities in disability incidence 
between the most and least educated under age 65. Among women aged 65 and over, these 
factors tended to account for nearly 40% of that disparity. Estimates in older men were more 
variable, but the models indicated an explanatory power of 20-60%.  
 
In younger women, smoking and excess BMI appeared to be the main contributors to disparities, 
while in younger men smoking and manual labor appeared most important. In older women, 
excess BMI appeared to be the main contributor to disparities. Estimates for older men were 
noisy, but smoking appeared to be the main contributor to disparities; higher BMI appeared to 
suppress educational disparities, reflecting lower average BMI among the least compared to 
more educated older men. 
 
What accounts for the disparities left unexplained in this study? The role of imperfectly 
measured and missed mediators  
 
Body mass index (BMI) 
By taking advantage of both earlier-life and lagged contemporaneous measures of excess BMI, I 
was able to improve on studies that use one-time BMI to examine relationships between excess 
BMI and health outcomes. For example, in studies on the association between one-time BMI and 
mortality or morbidity, reverse causation—in which underlying illness contributes to weight 
loss—may downwardly bias the estimated risk of excess BMI (Abdullah et al., 2011; Mehta, 
2015).  
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Due to data limitations, however, my estimates of excess BMI’s contribution to disparities in 
ADL/IADL incidence may still be downwardly biased, particularly for older adults. First, in men 
ages 60 and over, weight loss may begin to accelerate an average of nine years before death 
(with variation by ultimate cause of death) (Alley et al., 2010)—much longer than my one-wave 
lag of excess BMI is able to account for. To the extent that ADL/IADL difficulty is on the causal 
pathway between excess BMI and death—which I would expect for conditions like 
cardiovascular disease and diabetes—this could result in underestimation of excess BMI’s 
contribution to ADL/IADL disparities. 
 
In addition, while the 1986 BMI measure provides valuable earlier-in-life information, it occurs 
relatively late in life for some in my older age group, who ranged from age 65 to 93 years in 
2003. Evidence suggests that accounting for BMI during midlife improves estimates of BMI’s 
association with mortality in older adults (Adams & Mouw, 2006); in my data, however, 22% of 
older respondents were 60 years or older in 1986, while 8% were 65 or older. The 1986 indicator 
may thus be less informative for these respondents, who may be experiencing weight loss due to 
age or chronic disease, resulting in potential underestimates of excess BMI’s contribution to 
disparities. Unfortunately, data limitations precluded use of an earlier-life BMI indicator that 
referred to the same age for all individuals.  
 
Finally, a growing body of work suggests that BMI trajectories predict health risks over and 
above static BMI (Zheng et al., 2013), but I lacked sufficient observations to characterize 
trajectories for my sample. In an analysis of data from the Health and Retirement Study, Zheng 
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et al. (2013) showed that individuals with normal but either increasing or decreasing weight were 
at greater risk of mortality than individuals who were overweight at baseline and whose BMI 
remained stable (Zheng et al., 2013). If I were able to look specifically at the effect of rising 
BMI—but not that of being overweight but stable—I might attribute a greater proportion of 
ADL/IADL disparities to BMI. 
 
Together, these limitations suggest that my estimates of excess (or rising) BMI’s contribution to 
disparities may be conservative. As more waves of PSID and the corresponding BMI data 
become available, research using earlier-in-life BMI and/or trajectories will become more 
feasible. 
 
Smoking 
The time-varying, categorical measure of current and former smoking allows an estimate of the 
average effect of smoking versus not on ADL/IADL difficulty. However, limitations in this 
measure could lead to some bias in those estimates. By not accounting for intensity of smoking 
or years since the respondent last smoked, I may obtain less accurate estimates of smoking’s 
contribution to the incidence of ADL/IADL difficulty than if I were to model number of 
cigarettes smoked and years since last smoked. Moreover, an analysis accounting for these 
factors would enable more nuanced comparisons of smoking’s role in ADL/IADL difficulty by 
age-gender group, further elucidating the reasons for variation in smoking’s role across groups. 
Future research could use existing PSID measures to address these questions. 
 
Manual labor and occupation more broadly 
 110 
Despite similarly sized educational disparities in both men and women at younger ages, manual 
labor only appeared to explain disparities in ADL/IADL difficulty in younger men. This may 
suggest that women and men coded as “laborers” or “operatives” conduct substantively distinct 
types of work, with differential consequences for disability. Alternatively, this difference could 
be a product of varying lengths of time conducting manual labor by gender, which for 
methodological reasons I was unable to account for. More research on the contribution of manual 
labor to disability by gender and throughout the life course is warranted. 
 
A broader approach to the role of work in difficulty with everyday activities may also be 
merited. Involvement in manual labor, defined here as reporting one’s main occupation as 
“laborer” or “operative”, likely influences ADL and IADL difficulty via effects on occupational 
hazards, job control, earnings, and prestige (Caston, 1989; Hayward et al., 1989; Leigh & Fries, 
1992). However, other types of occupation, such as clerical and service work, may also confer 
disadvantages due to one or more of these dimensions (Gallo et al., 2004; Marmot et al., 1997). 
As a result, a more comprehensive, more sociological assessment of occupation would likely 
reveal that work plays a larger role in educational disparities in ADL/IADL difficulty than 
manual labor appears to account for in this study. This would likely be especially true for 
women, who disproportionately perform low-status and low-paying work not captured by my 
measure of manual labor. Future research could better elucidate these pathways and their relative 
contributions to incident difficulty with ADLs and IADLs. 
 
Management of frailty 
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Excess BMI, smoking, and manual labor involvement appeared to explain less of the ADL/IADL 
disparities in the older group than in the younger group. Biological frailty may help explain this 
gap. Increased frailty is a natural consequence of age; increased ADL/IADL difficulty is thus a 
part of the normal aging process. However, older Americans with more education and the 
resources it confers may be better able to manage this frailty, making its consequences less 
severe. For example, frailty increases the risk of falls, which can translate into more severe, 
persistent, and disruptive ADL/IADL difficulty; individuals with more financial and social 
resources may be better able to, e.g., modify their environment to reduce the risk of falling, 
and/or to obtain tools such as medical alert necklaces to reduce a fall’s consequences. For future 
research to account for ability to manage frailty as a mediator of the education-disability 
relationship, data on older individuals’ access to and use of various management strategies would 
be needed. I am not aware of nationally representative studies that collect such data in detail, but 
smaller datasets may exist and be appropriate. 
 
Pathways between educational attainment and the mediators 
Educational attainment shapes excess BMI, smoking, and manual labor via myriad pathways, 
including adult income, neighborhood and social network contexts, marital selection, access to 
preventive services, and numerous others. The regression models in this study did not include 
variables on the causal pathway between education and the mediators, since our objective was to 
estimate the “total effect”—rather than the “controlled direct effect”—of the mediators on 
disability incidence. If controlled for, variables underlying the education-mediator relationship 
would “absorb” some of the total effect of the mediators. For example, health literacy is one 
plausible pathway through which educational attainment relates to smoking behavior. If I 
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included health literacy in the regression models, the estimated association between smoking 
incident ADL/IADL difficulty would reflect only that portion of the education-smoking 
relationship that is not influenced by health literacy. The goal here is not to delineate the 
pathways linking education to the mediators—or, for similar reasons, the pathways linking the 
mediators to disability—but rather to capture smoking’s total effect on the education-disability 
relationship.  
 
Interactions between educational attainment and the mediators 
The regression models assumed independence between education and the mediators, but 
interactions could exist, such that the association between each mediator and incident 
ADL/IADL difficulty varies by educational attainment. For example, excess BMI may be more 
likely to contribute to ADL/IADL difficulty among people with less education, e.g., due to 
higher risk of developing and fewer resources for managing health conditions such as diabetes, 
cardiovascular disease, and arthritis. Alternatively, intensity of current and former smoking may 
vary by educational status, such that these indicators are more strongly associated with incident 
ADL/IADL difficulty in less educated groups.  
 
I tested the assumption of independence by assessing whether additive interactions between 
educational attainment and each mediator existed in each regression model. In a logistic 
regression, additive interactions are more straightforward to calculate than multiplicative 
interactions because the coefficient on the interaction term is not equal to the actual 
multiplicative interaction effect (Ai & Norton, 2003; Norton et al., 2004). In addition, and unlike 
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multiplicative interactions, additive interactions are useful in that they provide direct insight into 
the proportion of people who could benefit from an intervention in one group versus another.  
 
In the present analysis, I found no evidence of varying effects of excess BMI or manual labor on 
incidence across educational groups. However, the association between smoking and incident 
ADL/IADL difficulty appeared to be larger in people with less than a high school degree 
compared to those with a college degree. These results suggest that, in women, interventions that 
reduce smoking could reduce the risk of ADL/IADL difficulty in a larger proportion of people if 
they targeted those with less education. Future research could help to explain these results. 
Women with less education may smoke more cigarettes per day, may have less access to 
cessation resources and thus smoke for a greater duration, and/or may have less access to 
resources for mitigating the effects of smoking on their health. There was also an apparent 
interaction between education and smoking in older men, in which current smoking was more 
strongly associated with incidence in those with a high school degree compared to those without 
one. However, the estimated interaction effect was imprecise, and additional research would be 
needed to confirm this finding. 
 
Because the main regression models do not include an interaction between educational 
attainment and smoking history, the estimated proportions of educational disparities attributable 
to smoking may be biased. Given that, in women, smoking appeared more associated with 
ADL/IADL difficulty in the least compared to the most educated group, the true contribution of 
being a current or former smoker in disparities is likely larger than estimated. In older men, the 
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reverse could be true. However, imprecise estimates of both the interaction and disparities make 
conclusions more difficult to draw for this group.  
 
Population-level research on conditions linking the mediators and incident disability is 
needed, but the requisite longitudinal, nationally representative data are lacking 
Despite robust evidence that excess BMI, smoking, and manual labor involvement contribute to 
disability via conditions such as diabetes, osteoarthritis, cardiovascular disease, respiratory 
diseases, and musculoskeletal injury (Altarac, 2000; Leigh & Fries, 1992; Murray & Lopez, 
1997; Samper-Ternent & Al Snih, 2012), it is unclear what proportion of those relationships can 
be attributed to each of these conditions at the population level. Elucidation of their relative 
contributions to disability and to disparities in disability would aid the targeting of downstream 
efforts to alleviate disability in the U.S. population. While upstream work—improving access to 
quality education; blocking the pathways from education to excess BMI, smoking, and manual 
labor; and targeting those mediators of the education-disability relationship when they do 
occur—is crucial, an understanding of the most prominent disease pathways between these 
mediators and disability would also allow for valuable interventions to prevent the incidence of 
disability. 
 
PSID would be better able to support this research if additional information about the cause of 
ADL and IADL difficulty were collected. For example, the National Health Interview Survey 
(NHIS), a repeated cross-sectional survey that is also nationally representative, asks which health 
conditions have caused any ADL or IADL difficulty that a respondent has reported. PSID does 
ask, “Have you ever been told by a doctor that you have—” regarding an array of conditions, but 
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these measures have important limitations for the present purposes: (1) the potential for temporal 
mismatch with the ADL/IADL difficulty of interest (e.g., the respondent had a given condition 
but no longer does, and the condition did not contribute to the present difficulty), and (2) the 
possibility, likely unequally distributed across education groups, that the respondent would be 
able to report a reason for their difficulty if asked (e.g., a back or neck problem, arthritis, or a 
breathing problem) but has not received a formal diagnosis. Indeed, when I used these PSID 
indicators to conduct a preliminary mediation analysis of the relationships between (a) excess 
BMI, smoking, and manual labor and (b) ADL/IADL difficulty, the results were quite noisy and 
thus challenging to interpret. 
 
Policy and program implications will depend on whether the ADL/IADL difficulty reflects 
a met or an unmet need 
Researchers often use difficulty with ADLs and IADLs as a measure of disability in a population 
(Iezzoni et al., 2014; LaPlante, 2010; Martin & Schoeni, 2014; Palmer & Harley, 2012; Samper-
Ternent & Al Snih, 2012). In PSID, respondents are asked about any difficulty conducting a 
given activity on one’s own and without special equipment. However, the consequences of such 
a difficulty—and in turn the policy and program implications—are a product not only of a 
person’s physical status, but also of the physical and social environments in which they are 
embedded (Clarke & Nieuwenhuijsen, 2009; Reindal, 2008). In some circumstances, the activity 
of interest may be conducted by another person, or special equipment may be available, thereby 
rendering the ADL/IADL difficulty less disruptive. Because PSID does not evaluate whether 
these needs are met, the extent to which my findings reflect disparities in disability—rather than 
disparities in physical status—is unknown. 
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However, the frequency with which ADL/IADL needs are met is likely patterned by educational 
attainment: I would expect education to select into a range of resources that influence once’s 
access to adaptive technologies, social capital, and professional aid—in turn determining the 
disruptiveness of their ADL/IADL difficulty. If ADL/IADL difficulty more frequently translates 
into unmet needs among less educated individuals than among their more educated counterparts, 
then the consequences of disparities in ADL/IADL difficulty would actually be understated by 
my study’s conclusions. Future research should both test this hypothesis and evaluate the 
everyday life needs that are most frequently unmet in less-educated groups. Policies and 
programs to address these gaps, with emphasis on the most socially disadvantaged, are needed.  
 
Policy and program implications will depend on the extent to which the proximal causes 
identified are replaced by alternatives 
This study serves an important descriptive function, helping to elucidate the pathways by which 
educational disparities in ADL/IADL difficulty manifest, as well as how these vary in influence 
by age-gender group. It also offers some prescriptive conclusions, suggesting that resources 
aiming to reduce educational disparities in ADL/IADL difficulty may be best targeted towards 
disparities in: excess BMI and (less so) smoking in younger women; manual labor and smoking 
in younger men; and excess BMI in older women. While estimates in older men were more 
variable, smoking seemed to be the main contributor to disparities; because former but not 
current smoking was associated with ADL/IADL difficulty in this group, interventions would 
likely be needed earlier in life. Although society is often wont to view health problems through a 
biomedical lens, efforts to reduce disparities in these groups should not be limited to the health 
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care system. Upstream interventions, such as evidence-based programs to improve nutrition and 
exercise, workplace smoking policies, and efforts to alleviate occupational hazards are needed. 
 
However, the potential for such interventions to meaningfully and lastingly reduce disparities in 
ADL/IADL difficulty would depend on the extent to which the persistent educational gradient in 
American society—which would not be affected by interventions on the above mediators—
would spawn new pathways to disability-related outcomes as the broader context of risk factors, 
treatment availability, and disease patterning evolve (Link & Phelan, 1995). That is, targeting 
more proximal causes of disparities will not eliminate those disparities if education’s 
consequences for health are transportable to new circumstances and thus manifest via alternative 
pathways. As a result, broad-based efforts to alleviate the educational gradient in American 
society are key to addressing population-level health disparities. 
 
PAPER 2  - DISPARITIES IN OPIOID PRESCRIBING 
This study was the first, to my knowledge, to examine the association of release of the 2016 
CDC Guideline for Prescribing Opioids for Chronic Pain with subsequent overall and high-risk 
opioid prescribing in the population it targeted: people with chronic, non-cancer pain. In 
addition, it is the first to assess whether these associations varied by patient race/ethnicity, and if 
so whether this contributed to a widening or narrowing of racial/ethnic disparities in opioid 
prescribing for chronic pain. I found evidence that, in osteoarthritis and fibromyalgia patients, 
the guideline was associated with a gradual decline in the percentage of patients receiving 
opioids each month and, among those who received opioids, with a decline in average daily dose 
and the percentage of patients receiving a high dose (more than 90 morphine milligram 
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equivalents, or MME). These findings, particularly the decline in average daily dose among 
those prescribed opioids, suggest that clinical guidelines in which compliance is entirely 
voluntary may result in clinically significant shifts in prescribing behavior. At the same time, the 
relatively small decrease in percent receiving at least one opioid fill per month may help to allay 
concerns that the guideline led to widespread inappropriate discontinuation of pain management 
among chronic pain patients in need (Rothstein, 2017).  
 
In both osteoarthritis and fibromyalgia, associations with the guideline were consistently 
detectable in white patients at an alpha of 0.05, while associations were less consistent in black 
and Hispanic patients. However, lack of statistical significance corresponding to other outcomes 
may have primarily been due to insufficient power: point estimates suggested that black and 
Hispanic patients were generally estimated to experience the same or larger declines as white 
patients. And while these differences were never statistically significant either, point estimates of 
racial/ethnic disparities with and absent the guideline suggest it may have contributed to a 
widening of black/white and Hispanic/white disparities in prescribing. There was little evidence 
to suggest a narrowing of disparities due to the guideline, potentially suggesting that, despite 
providing clinicians a framework for deciding when to prescribe opioids and in what dose, the 
CDC guideline did not diminish racial/ethnic disparities in prescribing. That is, my findings do 
not appear to support the hypothesis that the guideline reduced clinical uncertainty and, in turn, 
the tendency to use racial/ethnic stereotypes or bias to inform prescribing decisions. Instead, the 
guideline may have affected white, black, and Hispanic pain patients similarly; or it may have 
disproportionately affected patients of color, and particularly Hispanic patients. The latter 
scenario could result from an increase in clinical uncertainty due to the guideline, in which the 
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recommendations’ encouragement that providers use personal judgment to determine each 
patient’s prescribing needs led to increased reliance on stereotypes and bias.  
 
Limitations of Optum’s race/ethnicity measure 
Optum data offer many strengths for the analysis of opioid prescribing for chronic pain, 
including diagnosis, prescription fill, and sociodemographic data for a large swath of Americans 
in all 50 states. For comparison, another leading provider of commercial claims data, Truven 
Health Analytics, does not provide information on patient race/ethnicity or socioeconomic status. 
However, a key disadvantage of Optum data is the high and unexplained rate of missingness on 
the race/ethnicity variable, which is central to the present analysis. In the osteoarthritis and 
fibromyalgia cohorts studied, race/ethnicity data were missing for 22% and 26% of observations, 
respectively, resulting in their exclusion from the analytic sample. Optum reports that their 
sociodemographic data are obtained via a combination of strategies, including reporting by the 
patient at the point of care, imputation using the Census, and internal imputation based on other 
information such as name and geographic data. However, the respective proportions of 
race/ethnicity obtained via each of these methods are not available.  
 
In the present study, race/ethnicity missingness poses several challenges: it reduces the size of 
the analytic sample, contributing to statistical power constraints, and, by limiting the population 
analyzed, it may result in biased estimates. As Table 5-12 shows, individuals with incomplete 
race/ethnicity data were more likely to have received a mental health diagnosis and tended to 
have more comorbidities and pain-related visits; they also tended to experience higher rates of 
overall and high-risk opioid prescribing. The consequences of this missingness for the study 
 120 
results are difficult to predict. If, for example, race/ethnicity missingness were more common in 
black compared to white patients, then my estimates could overestimate black/white disparities 
in prescribing. But if the differences in opioid prescribing between individuals with and without 
missing data were fully explained by differences in the other covariates—e.g., rates of mental 
health diagnosis, numbers of comorbidities, and frequency of visits—then my estimates may be 
correct even if the “missing” individuals were disproportionately black. Improvements in data 
completeness and transparency in the mechanisms for obtaining these data would enable more 
robust future research. 
 
Future directions for understanding racial/ethnic disparities in management of chronic 
pain 
Collapsing cohorts to improve clarity of trends in disparities 
The present study offered useful preliminary insight into potential consequences of the 2016 
guideline for racial/ethnic disparities in opioid prescribing. Next, prior to submission for 
publication, I will take additional steps to increase statistical power and, in turn, to provide more 
precise estimates of disparities in the “guideline” and “no guideline” scenarios. I will collapse 
osteoarthritis and fibromyalgia patients into a single cohort and will add two additional pain-
related conditions: back and neck pain and chronic headache. Mirroring osteoarthritis and 
fibromyalgia, respectively, prescription opioids have been considered indicated for back and 
neck pain under some circumstances, whereas they are categorically not recommended for 
management of chronic headaches (Eccleston et al., 2017). Therefore, in addition to pooled 
analysis of the four conditions, I will also disaggregate analysis into (1) osteoarthritis and back 
and neck pain, and (2) fibromyalgia and chronic headache—allowing clearer investigation of the 
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hypothesis that the guideline would more strongly influence opioid prescribing for the latter 
group of conditions.  
 
Are the observed racial/ethnic disparities in opioid prescribing offset or amplified by disparate 
rates of non-opioid pain management? 
In this study, I was unable to examine whether chronic pain patients not receiving opioids 
received alternative forms of pain management—for example, lower-risk analgesics such as 
acetaminophen, physical therapy, or cognitive behavioral therapy. However, a meta-analysis 
found that black pain patients were less likely than white patients to receive any analgesic, while 
no difference between Hispanic and white patients was detected (Meghani et al., 2012). That is, 
black/white disparities in opioid prescribing likely reflect disparities in medication-based pain 
management overall. In addition, given limited access to mental health services in black and 
Hispanic populations, disparities in non-medication based therapies that may aid in pain 
management likely exacerbate rather than offset disparities in opioid prescribing (Eccleston et 
al., 2017; Ojeda & McGuire, 2006). Research quantifying access to a more comprehensive range 
of pain management techniques by race/ethnicity, as well as trends in the use of non-opioid 
management following growing concern about the risks of opioid prescribing, would paint a 
more complete picture of racial/ethnic disparities in pain management and their evolution amid 
the opioid crisis. 
 
Policies to reduce unsafe opioid prescribing and discontinuation of opioid therapy 
There is concern that, in the wake of efforts to address unsafe opioid prescribing—such as 
implementation of prescription drug management programs and release of the 2016 CDC 
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guideline—pain patients may have increasingly experienced abrupt discontinuation of opioid 
therapy, which may in turn increase non-medical opioid use, overdose rates, and suicidal ideation 
(Dowell et al., 2019; Kroenke et al., 2019; Rothstein, 2017). In an extension to the present work, 
I plan to assess trends in opioid discontinuation among chronic pain patients, overall and by 
race/ethnicity, before and after release of the CDC guideline—and, if discontinuation increased 
following the guideline, to examine associations with rates of overdose and suicide. 
 
 
A better understanding of changing trajectories of OUD and mortality by race/ethnicity is 
needed 
The narrative surrounding the 21st century opioid crisis has tended to emphasize opioid-related 
morbidity and mortality in white, and particularly rural and/or less educated white, Americans. 
For example, Case and Deaton reported that, between 1999 and 2013, all-cause mortality increased 
for the first time in a subset of the US population, less educated white Americans ages 45-54 years 
(Case & Deaton, 2015), which the authors attribute in part to increases in drug and alcohol poisoning. 
Indeed, opioid-related mortality rates have been persistently lower in black and Hispanic compared 
to white Americans in recent decades (Alexander et al., 2018; Kaiser Family Foundation, 2019). 
However, opioid-related mortality began to increase more sharply among non-Hispanic black and 
Hispanic patients around 2013—coinciding with the sharp increase of illicitly manufactured fentanyl 
in the opioid supply (Alexander et al., 2018; Kaiser Family Foundation, 2019). Moreover, while 
opioid-related mortality among whites decreased between 2017 and 2018, it continued to increase in 
Hispanic and non-Hispanic black Americans (Wilson et al., 2020). These differences appear to have 
been driven by a decrease in prescription opioid and heroin-related overdose in white but not black 
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and Hispanic individuals, while increases in deaths from synthetic opioids such as fentanyl continued 
to increase in all three groups.  
 
Relatively little work has aimed to explain these shifting trends by race/ethnicity, or to anticipate 
how race/ethnicity-specific morbidity and mortality related to opioids and other substances may 
evolve in coming years. One important step is to continue disaggregating policy and program effects 
by race/ethnicity. For example, while Good Samaritan Laws have shown promise in reducing opioid-
related mortality (Rees et al., 2017), it is not clear whether their effects are consistent across 
racial/ethnic groups. Black and Hispanic populations may benefit less from such policies, for 
instance, if they are more reticent than their white counterparts to call 911 and if, when they do, law 
enforcement officers are less likely to adhere to the laws’ requirements. A key goal of my future 
work will be to help alleviate these gaps in the literature.  
 
How prevalent is opioid prescribing for cancer pain, and has this changed amid rising 
concern about the risks of opioid prescribing?  
People living with cancer experience high rates of chronic pain, even in early and intermediate 
stages and following completion of active treatment (Glare et al., 2014; C. R. Green et al., 2011; 
van den Beuken-van Everdingen et al., 2016). Opioids have historically been used to treat many 
forms of cancer-related pain, and national guidelines on opioid prescribing often exclude cancer 
patients from their recommendations (Brown & Farquhar-Smith, 2017). Still, adverse 
consequences such as side effects and risk of dependency remain sources of concern in opioid 
prescribing for cancer-related pain (Brown & Farquhar-Smith, 2017), and the quality of evidence 
on opioids’ effectiveness for reducing pain and improving function in these patients remains low 
(Wiffen et al., 2017). Little research has examined the prevalence of opioid prescribing in cancer 
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patients. In subsequent research, I plan to use Optum data to obtain national estimates of opioid 
prescribing rates overall and by cancer stage (proxied, e.g., by proximity to death) and type. 
More in-depth analyses I would like to conduct in this national sample of cancer patients include: 
trends in prescribing over time and whether these mirrored national trends for non-cancer 
patients, whether the 2016 CDC guideline appears to have influenced prescribing in cancer 
patients despite excluding this population from its recommendations, associations of opioid 
prescribing with incidence of diagnosed opioid use disorder and overdose, and disparities in 
prescribing by race/ethnicity and socioeconomic status. 
 
PAPER 3 - NALOXONE DISTRIBUTION 
Chapter 3, a cost-effectiveness analysis comparing naloxone distribution to three target groups—
laypeople likely to witness or experience overdose, police and fire, and emergency medical 
services (EMS)—found that increasing access to naloxone access reduces morbidity due to 
insufficient brain oxygenation and costs society little. Yet naloxone access remains insufficient. 
My findings support increased naloxone distribution to laypeople likely to experience or witness 
overdose, police and fire, and EMS. Increased distribution to and use by EMS could be achieved 
by, for example, authorizing naloxone administration by basic life support personnel in states 
that currently prohibit it. When resource constraints limit a community's ability to increase 
distribution to all three groups, distribution to laypeople and EMS should be prioritized. 
 
How do we achieve the level of naloxone access this study suggests is needed? 
While evidence shows that naloxone reduces mortality at a low or even negative cost to society, 
and while observational studies have demonstrated the potential for community-based programs 
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and naloxone access laws to achieve these benefits through provision of naloxone kits and 
training to people who use opioids (Bird et al., 2016; Coffin & Sullivan, 2013a; McClellan et al., 
2018; Alexander Y Walley et al., 2013), a more comprehensive understanding of the 
effectiveness of and barriers surrounding efforts to improve naloxone access is needed. 
 
Numerous policy options for increasing naloxone availability and use exist, and they vary in 
strength and scope. For example, most states have enacted standing orders that allow pharmacists 
to dispense naloxone to individuals without a prescription, and most states allow for third-party 
prescribing—i.e., prescribing of naloxone to someone close to the person at risk of overdose (C. 
Davis & Carr, 2017). At least forty states have enacted “Good Samaritan laws” that provide legal 
immunity to individuals who seek medical attention at an overdose event (National Conference 
of State Legislatures, 2017). Several states have passed mandates that opioid prescribers co-
prescribe naloxone to patients deemed at risk of overdose (Sohn et al., 2019), and many states 
authorize law enforcement officers to administer naloxone and to distribute additional kits 
following overdose (C. S. Davis et al., 2015; C. S. Davis, Ruiz, et al., 2014). There is some 
evidence that such policies do improve naloxone access. For example, a recent study found a 
nearly eight-fold increase in the rate of naloxone prescribing per 100,000 population following 
the passage of co-prescribing mandates in West Virginia and Vermont (Sohn et al., 2019). And 
Rees, Sabia, Argys, et al. (2017) found that laws authorizing laypeople and first responders to 
carry and administer naloxone result in a 9-11% reduction in opioid-related mortality, with no 
evidence of concomitant moral hazard (Rees et al., 2017). 
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However, each of these policies may entail a distinct set of barriers to widespread and effective 
implementation, including problems of awareness, funding, personal beliefs, and others. For 
example, despite naloxone access laws, pharmacies often fail to stock naloxone, and pharmacists 
may refuse to dispense it due to lack of awareness of third-party prescribing policies or beliefs 
about inducing moral hazard (Meyerson et al., 2018; Puzantian & Gasper, 2018). In addition, 
some research has found a large proportion of law enforcement personnel to be unfamiliar with 
naloxone access laws in their state and at risk of confiscating the life-saving medication (Banta-
Green et al., 2013). Relatedly, a 2017 survey of prescribers in regional health care systems in 
North Dakota, Minnesota, and Wisconsin found that the majority had never prescribed naloxone 
for overdose prevention, and reported evidence that this was in part due to lack of awareness of 
the relevant state policies (Okoro et al., 2018). And years after West Virginia passed a law 
authorizing law enforcement to carry naloxone, a 2018 study found that less than 2% of police 
departments actually do so (Lurigio et al., 2018). 
 
In order to ensure that naloxone’s potential to reduce mortality and extend opportunity for 
recovery is realized, a more thorough mapping of these policies and programs to their 
consequences is needed. However, rigorous evaluations can be difficult to conduct amid a 
preponderance of observational data. 
 
Naloxone access must be combined with evidence-based treatment for opioid use disorder 
By reversing opioid-related overdose, naloxone provides people who use opioids additional 
opportunity to receive treatment for opioid use disorder, with potential to substantially extend 
life and improve quality of life. For this potential to be realized, however, access to evidence-
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based treatment for opioid use disorder is crucial. Evidence is clear that, compared to inpatient 
detoxification or residential services, intensive and non-intensive behavioral health, and 
treatment with the opioid antagonist naltrexone, methadone and buprenorphine treatment 
effectively reduce opioid-related overdose and serious acute care use (Wakeman et al., 2020). 
 
Yet access to medication for opioid use disorder remains low. In 2016, only 36% of all substance 
use treatment facilities offered at least one of buprenorphine, methadone, or naltrexone 
(naltrexone requires opioid detoxification before treatment can be initiated, rendering it less 
effective than its opioid agonist counterparts) (Mojtabai et al., 2019). Access is particularly 
limited in rural communities, which have been hit particularly hard by opioid addiction and 
overdose. For example, 30% of rural Americans live in a county without a licensed 
buprenorphine provider, compared to just 2% of urban Americans (Andrilla et al., 2019). 
Numerous barriers also limit access to methadone: required daily clinic visits, inadequate 
insurance coverage, and clinics that are limited in geographic distribution—and which, where 
they do exist, may be at or near capacity (Jones et al., 2015). 
 
Urgent action is required to improve access to evidence-based treatment for people with opioid 
use disorder, including those for whom naloxone reversed an otherwise fatal overdose. A recent 
report by the National Academies of Sciences, Engineering, and Medicine recommended an 
array of policies in this vein, including amending the Controlled Substances Act to allow 
methadone prescribing in primary care settings and to eliminate the excessive provider training 
requirements and patient caps that constrain buprenorphine prescribing (National Academies of 
Sciences, Engineering, and Medicine, 2020). Other recommendations included broadening 
 128 
access to telemedicine for treatment of opioid use disorder, particularly in rural areas, and 
making federal funding available to address upstream housing and transportation needs among 
individuals with co-occurring opioid use disorder and infectious disease—factors that, among 
other things, may improve access and adherence to treatment (National Academies of Sciences, 
Engineering, and Medicine, 2020). 
 
Naloxone access and moral hazard: A review of the evidence 
Some worry that lay naloxone distribution provides an overdose safety net, leading individuals to 
use opioids more intensively and overdose more frequently (T. C. Green et al., 2013; Seelye, 
2017). The present cost-effectiveness analysis found that, if this “moral hazard” effect were to 
occur, it would have to cause the overdose rate to increase by at least 20% in order for high 
levels of lay distribution to no longer be a component of the preferred strategy—that is, the 
strategy that allocates scarce resources for maximum health benefit. 
 
Moreover, the bulk of the relevant literature is unable to detect a moral hazard effect at the 
population level. While rigorous large-scale evaluations of naloxone access laws and naloxone 
provision more broadly are rare and needed, a systematic review of 22 observational studies 
found no evidence that take-home (i.e., layperson) naloxone programs increased heroin use 
(McDonald & Strang, 2016). Two more recent studies have supported this conclusion. Using 
data from the National Vital Statistics System and the National Survey on Drug Use and Health, 
McClellan et al. (2018) employed a staggered difference-in-differences design with state random 
effects to examine associations between naloxone access laws and (a) opioid-related overdose 
deaths and (b) nonmedical opioid use (McClellan et al., 2018). The authors report a 14% 
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decrease in opioid-related mortality but no evidence of an effect on nonmedical opioid use. Rees 
and colleagues (2017) took a similar approach using the same data and found a 9-11% decrease 
in opioid-related mortality following the passage of a naloxone access law but, again, no 
evidence of change in nonmedical use. Some research suggests a decline in opioid use following 
naloxone training, perhaps due to increased motivation to or awareness of how to seek treatment 
(McDonald & Strang, 2016; Seal et al., 2005). 
 
One study, which has received considerable media attention, reported conflicting findings. A 
2018 working paper reported that naloxone access laws resulted in increased opioid-related 
emergency department visits and crime while failing to reduce mortality (Doleac & Mukherjee, 
2018). The authors’ methods have been critiqued by others in the field (Frank et al., 2018). The 
study is at risk of confounding, for instance, by sharp, concurrent increases in fentanyl-related 
mortality in states that expanded naloxone access laws. In addition, and in contrast with Rees et 
al. (2017), the authors used a single treatment variable to examine the association between any of 
several naloxone access laws and Good Samaritan laws (GSLs) and their main outcome variables 
(opioid-related emergency visits, opioid-related mortality, and opioid-related theft). Doleac and 
Mukherjee were thus unable to disentangle the effects of each policy, which may vary in 
strength. Indeed, Rees et al. (2017) found variation in the magnitude and precision of effect 
estimates across types of policy (Rees et al., 2017). Naloxone ends a high and induces sudden 
withdrawal symptoms, outcomes that people who use opioids generally want to avoid. There 
may be individuals who increase opioid use given access to naloxone, but the preponderance of 
evidence suggests that, at the population level, such effects on either use or mortality are not 
detectable.
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Appendix A. Supplementary Material for Chapter 2 (Educational Disparities) 
 
Appendix A-1. Panel Study of Income Dynamics  
The Panel Study of Income Dynamics (PSID) is the world’s longest-running household panel 
survey and collects data on myriad social, behavioral, and health indicators. It was initiated in 
1968 with a nationally representative sample of over 18,000 individuals (5,000 households) and 
an oversample of low-income families. PSID followed core sample members and their decedents 
annually until 1997 and then biennially thereafter. Response rates in PSID have equaled or 
exceeded response rates in other panel studies globally (McGonagle et al., 2012). More details 
are provided in the PSID User Manual (Institute for Social Research, 2019).  
 
Appendix A-2. Defining disability incidence 
An individual was defined as experiencing incident disability in wave t if they reported disability 
in that wave and had been at risk for disability in the prior wave (“t-1”). Individuals were 
considered at risk if they reported no difficulty on any ADL/IADL in wave t-1; were in the panel 
during waves t-1 and t; and had no missing ADL/IADL data in either wave. When an individual 
indicated that they “did not do” a given ADL or IADL, they were considered to have no 
difficulty rather than be missing on this indicator. 
 
I assumed that an individual reporting an ADL/IADL disability in two consecutive waves 
experienced that disability throughout the two-year period. I also assumed a uniform distribution 
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of changes in disability status and treated any switch as occurring at the midpoint of the adjacent 
waves. 
 
The modelling strategy accounted for the possibility that an individual experience more than one 
incident disability event. I used this approach for two reasons. First, given fluctuation in 
disability status throughout the life course, I wanted to capture both new and subsequent 
disability events. Second, since PSID began asking about ADLs and IADLs in 2003, I could not 
observe difficulty with ADLs/IADLs before 2003. This left truncation precluded assumptions 
that any observed incidence represented “first incidence”. 
 
Appendix A-3. BMI measures 
Contemporaneous and 1986 BMI were left-truncated at 25, such that only excess BMI 
contributed to the models (Mehta et al., 2014; Preston et al., 2013). This decision was based on 
the finding that, when running the main model with BMI splines, BMI values of 25-30 and 30+ 
contributed to disability risk. 
 
Appendix A-4. Construction of manual labor variable  
This variable was fixed rather than time-varying to minimize the risk of confounding by a 
common cause like illness. The measure was based on PSID’s “main occupation” variable, 
which was categorized using three-digit occupation codes from the 1970 Census of Population. 
From this taxonomy, I considered the following three groups manual laborers: “operatives, 
except transport”; “laborers, except farm”; and “farm laborers and farm foremen” (Cutler & 
Lleras-Muney, 2010; Leigh & Fries, 1992).  
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Occupation information was available for all PSID household heads and spouses between 1982 
and 2001. In addition, roughly 65% of the PSID sample provided retrospective occupation 
information for 1968-1980. To enable use of occupation data for 1968-1980 without excluding 
those who had not reported retrospectively, I coded participants as “1” if they had ever 
participated in manual labor, and “0” if they had never reported participating in manual labor—
even if occupation information was missing in some years. Excluding those who were ever 
missing occupation data resulted in too small a sample for analysis. 
 
The health consequences of agricultural and non-agricultural labor may vary. In this dataset, 
76% percent of manual labor observations corresponded to “operatives” (N=4,377); 4% 
corresponded to “farm laborers and farm foremen” (N=252), and 20% to “laborers” (N=1,135). 
To preliminarily assess differences in the implications of each type of manual labor for disability 
incidence in young men—the group in which I observed the clearest association between manual 
labor and disability—I constructed indicators of ever having participated in each type and 
included them in the regression model instead of the grouped indicator of manual labor 
participation. While all estimated odds ratios were greater than one, estimates on “ever laborer” 
and “ever farmer” were noisy, likely due to limited power (ever operative: OR=1.434, 95% CI: 
1.017-2.021; ever laborer: OR=1.035, 95% CI: 0.702-1.526; ever farmer: OR=1.807, 95% CI: 
0.873-3.739). Although the estimated odds ratio for ever laborer appears potentially smaller than 
that for the other types of manual labor, an adjusted Wald test of equality unable to reject the null 
hypothesis of equality among the three coefficients (p=0.329). 
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Appendix A-5. Additional detail on model covariates and missingness 
In the main analysis, respondents with some college, technical training, and associate’s degrees 
were grouped with those who obtained only a high school degree. However, there is evidence 
that these individuals experience a distinct set of health outcomes from high school graduates 
(Rogers et al., 2010; Zajacova et al., 2012; Zajacova & Lawrence, 2018). To examine whether 
they differ in risk of disability incidence, I conducted a regression in which these groups were 
separated (high school degree only; some college, technical training, or associate’s degree) and 
conducted a Wald test of a difference between the corresponding coefficients. In each of the 
younger groups and in older men, I was unable to reject the null hypothesis that they were 
equivalent (younger women: F=0.43, p=0.514; younger men: F=0.35, p=0.554; older men: 
F=0.02, p=0.896). In older women, however, there was a potential difference in (a) the 
association between obtaining a high school degree and disability (OR=0.823, 95% CI=0.493-
1.375, compared to no high school degree) and (b) the association between completing additional 
education, but not college, and disability (OR=0.577, 95% CI=0.324-1.027, compared to no high 
school degree) (F=3.18, p=0.075). Despite this potential difference in one of the age-gender 
groups, I maintained the three-category variable for several key reasons: (1) concerns about 
insufficient power, particularly in the older age group; (2) additional complexity of calculating 
disparities among all combinations of four rather than three educational groups; and (3) 
preliminary evidence that the differences in health outcomes by group do not operate through 
obesity or smoking (to my knowledge, manual labor has not been examined; Zajacova et al. 
2012). 
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Age was calculated using birthdate and date of interview. I combined Hispanic and non-Hispanic 
black participants into one category due to evidence that health tends to be poorer among 
Hispanic black individuals compared to Hispanic non-black individuals (Chinn & Hummer, 
2016; Elo et al., 2011). 
 
Conservative imputation was conducted to reduce missingness. Missing values of model 
predictors were imputed if sandwiched between two waves of identical values. In addition, I used 
PSID’s continuous “years of education” variable to reduce missingness in the education variable 
(0.5% of analytic sample observations; n=60). Fewer than 12 years of education was coded as 
“less than high school”, 12-14 years as “high school degree”, and 16 or more years as “college 
degree”. A report of 15 years of education was not used for imputation, since it could result from 
not completing college or from completing college in three years. Finally, remaining missingness 
on covariates that were unlikely to change values between waves—childhood SES, 
race/ethnicity, and educational attainment—was imputed using available data from previous (and 
then subsequent) waves if available. There was no missingness on age, gender, or year. 
 
Appendix A-6. Regression model 
Equation 1 details the regression model, which was conducted separately for each age group; X 
is a vector of covariates (age, gender, childhood socioeconomic circumstances, race/ethnicity, 
and year). 
 log $ %!"1 − %!"( = *# + *$,-.!"%$ + *&/.012. + *'1986678! + *(678!"%$ + *)9:;;.<=!"%$ 
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+	**/?;0.;!"%$ +	*+@A.;71<:12! +B*,-@C:D1=E?<!- +.-/$ B*$#0F1D./@=ℎ<!0&0/$
+ B *$$09ℎE2CI@I!1.1/$ 	+B*$.J.1;!"%$*"/.  
where it denotes individual i at t years since 2003, and %!" is the individual-level annual 
probability of experiencing a disability incidence. Age is age in single years. 1986678! is BMI 
in 1986 and 678!" is time-varying BMI (contemporaneous BMI). 9:;;.<=!" and /?;0.;!"	are 
time-varying current and former smoking status. @A.;71<:12!" denotes ever having 
participated in manual labor. 	@C:D1=E?<!- are the indicators for educational attainment, F1D./@=ℎ<!0 for race/ethnicity, and 9ℎE2CI@I!1for childhood socioeconomic circumstances. J.1;!" is calendar year between 2003 and 2015. 
 
Longitudinal population weights provided by PSID were adjusted to address selective attrition. 
Attrition was defined as leaving the panel after 2003 and not returning. For each year between 
2003 and 2015, a logistic regression was run to predict non-attrition in the subsequent year, using 
the previous wave’s covariates and disability incidence measure as predictors. From this 
regression, a predicted probability of non-attrition was generated for each observation and each 
year. The inverse of this probability was then multiplied by the PSID-provided weight to 
generate the attrition-adjusted weights applied in all models.  
 
Regressions also took into account sample stratification, repeat observations, and (using Taylor 
Series linearization) heteroskedasticity (Heeringa et al., 2011). Lack of convergence precluded 
correction for family-level clustering.  
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Appendix A-7. Interactions between education and the mediators 
The regression models assume independence between education and the mediators, but 
interactions could exist such that the association between each mediator and incident ADL/IADL 
difficulty varies by educational attainment. For example, excess BMI may be more likely to 
contribute to ADL/IADL difficulty among people with less education, e.g., due to higher risk of 
developing and fewer resources for managing health conditions such as diabetes, cardiovascular 
disease, and arthritis. Alternatively, intensity of current and former smoking may vary by 
educational status, such that these indicators are more strongly associated with incident 
ADL/IADL difficulty in less educated groups.  
 
I tested the assumption of independence by assessing whether additive interactions between 
educational attainment and each mediator existed in each regression model. In order to compare 
the expected difference in incidence between two educational groups given a one-unit change in 
the mediator in each, I calculated the double derivative with respect to the two predictors and 
then conducted a Wald test of the null hypothesis that the double derivative was equal to zero. 
This approach was required because, in logit models, the coefficient on an interaction term is not 
equivalent to the interaction effect (Ai & Norton, 2003; Norton et al., 2004). It corresponded to 
40 tests (five mediator indicators, including both measures of excess BMI and two comparison 
levels of smoking; two comparison levels of educational attainment; and four age-gender 
groups). 
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Table 5-7 shows the estimated interaction effects—i.e., the estimated difference between the 
marginal effect of the mediator in the educational group of interest and that in the reference 
group, those without a high school degree—as well as the p-value from the corresponding Wald 
tests. Of the 40 tests and given a conservative alpha of 0.10, four interactions were detected: in 
younger women, evidence that both current and former smoking are less associated with incident 
ADL/IADL difficulty in the most compared to the least educated group; in older women, 
evidence that former smoking is less associated with incidence in the most compared to the least 
educated group; and in older men, evidence that current smoking is more associated with 
incidence in the middle compared to the least educated group. No interactions were identified 
between education and either excess BMI or manual labor.  
 
In women ages 33-64, being a current or former smoker appeared less associated with incidence 
among those with a college degree than among those with less than a high school degree. The 
marginal effect of former smoking (compared to never smoking) was estimated to be -0.017 
(95% CI: 0. -0.055, 0.021) in those with a college degree and 0.075 (95% CI: -0.005, 0.155) in 
those with less than a high school degree (interaction effect: -0.092, p=0.041). The marginal 
effect of current smoking (compared to never smoking) was estimated to be -0.021 (95% CI: 0. -
0.085, 0.0429) in those with a college degree and 0.172 (95% CI: 0.066, 0.278) in those with less 
than a high school degree (interaction effect: -0.193, p=0.002). 
 
In older women, being a former smoker appeared less associated with incidence among those 
with a college degree compared to those with less than a high school degree. The marginal effect 
of former smoking (compared to never smoking) was estimated to be -0.042 (95% CI: -0.143, 
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0.060) in those with a college degree and 0.221 (95% CI: 0.075, 0.367) in those with less than a 
high school degree (interaction effect: -0.262, p=0.004). 
 
In older men, being a current smoker may have been more associated with incidence among 
those with a high school degree compared to those with less than a high school degree. The 
marginal effect of current smoking (compared to never smoking) was estimated to be 0.150 
(95% CI: 0.010, 0.290) in those with a high school degree and -0.017 (95% CI: -0.157, 0.122) in 
those with less than a high school degree (interaction effect: 0.168, p=0.090). 
 
Appendix A-8. Supplementary analyses 
In the analysis including sedentariness in the regressions, I used sedentariness in year of study 
entry to alleviate potential reverse causation. Time-varying alcohol consumption (0, 1-2, more 
than 2 drinks per day) was also examined but did not significantly predict incidence and was 
excluded from analyses. 
 
The analysis examining incidence of persistent ADL/IADL difficulty was limited to ADL/IADL 
difficulty lasting two or more waves. In younger women, 54.5% of those who (a) experienced 
ADL/IADL difficulty incidence in a given wave, and (b) met inclusion criteria in the subsequent 
wave, reported no ADL/IADL difficulty in the subsequent wave. This percentage was 54.5% in 
younger men, 42.9% in older women, and 33.2% in older men. Across groups, 18-24% reported 
ADL/IADL difficulty in the subsequent wave only (i.e., a total of two consecutive waves); and 
27-44% reported ADL/IADL difficulty in three or more consecutive waves. Disability was most 
likely to be persistent in older men. 
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A.  
Figure 5-1. Prevalence of each ADL and IADL by age and gender 
 
 
B.  
  
Note: Estimates are weighted.  
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Table 5-1. Bivariate relationships between education and mediators of interest 
 
    Under 65 65 and over 
    Women Men Women Men 
Mediator Education     
Ever smoked 
Less than HS Ref. Ref. Ref. Ref. 
HS degree -0.157* -0.175** 0.092 -0.035 
College degree -0.253*** -0.386*** 0.109 -0.232** 
Excess BMI Less than HS Ref. Ref. Ref. Ref. 
 HS degree -1.456* 0.467 -0.838 1.604*** 
 College degree -2.481*** -0.210 -1.547** 1.192*** 
Ever manual 
Less than HS Ref. Ref. Ref. Ref. 
HS degree -0.252*** -0.223*** -0.290*** -0.282*** 
College degree -0.518*** -0.604*** -0.452*** -0.531*** 
 
Note: * p<0.05, ** p<0.01, *** p<0.001. Estimates are unadjusted linear regression coefficients 
and are weighted. 
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Figure 5-2. Mediators by educational attainment 
A.  
 
 
B.  
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Note: Panel A: Education and contemporaneous BMI; Panel B: Education and percent ever 
smoked; Panel C: Education and percent ever conducted manual labor.  
71
49
10
63
37
11
57
29
4
58
29
13
0
20
40
60
80
P
er
ce
nt
 e
ve
r i
nv
ol
ve
d 
in
 m
an
ua
l l
ab
or
Under 65 65 and over
Men Women Men Women
Notes: Estimates weighted
Less than HS HS degree College degree
 144 
 
Table 5-2. Inclusion of sedentariness as a mediator: Observed disparities and estimates of percent 
explained 
Under 65 Women Men 
  
Most vs. 
least 
Middle vs. 
least 
Most vs. 
middle 
Most vs. 
least 
Middle vs. 
least 
Most vs. 
middle 
Observed disparity (per 100 PY) 4.6 3.2 1.5 2.9 1.7 1.3 
Percent explained       
Smoking 21.7 20.1 25.3 27.4 31.2 22.4 
Excess BMI 34.4 34.8 33.6 14.6 5.4 26.7 
Manual 5.8 5.7 6.2 32.7 30.3 35.7 
All 56.2 55.6 57.5 61.4 55.0 69.8 
Sedentariness 12.6 10.3 17.8 9.3 17.4 11.0 
All + 
sedentariness 64.1 62.6 67.5 68.7 64.3 74.5 
       
65 and over Women Men 
  
Most vs. 
least 
Middle vs. 
least 
Most vs. 
middle 
Most vs. 
least 
Middle vs. 
least 
Most vs. 
middle 
Observed disparity (per 100 PY) 6.0 3.6 2.4 1.2 2.0 -0.8 
Percent explained       
Smoking 0.0 -2.8 4.3 70.8 22.5 N/A 
Excess BMI 27.7 26.4 29.8 -16.7 -10.0 N/A 
Manual 8.4 9.7 6.4 25.0 10.0 N/A 
All 33.6 33.3 34.0 62.5 17.8 N/A 
Sedentariness 14.3 13.9 14.9 20.8 15.0 N/A 
All + 
sedentariness 46.2 45.8 46.8 75.0 29.3 N/A 
 
 
Note: PY = person-years. "Least" education = less than high school degree; "middle" = at least a 
high school degree; "most" = at least a college degree. N/A indicates excluded value due to a 
negative disparity. “Percent explained” refers to estimated percentage of educational disparities 
explained by the mediator of interest or the relevant combination of them. 
 
Including sedentariness in the models appeared to reduce the total percentage explained by the 
three mediators of interest, reflecting their correlation. However, the proportion of disparities 
explained by each of the main mediators fell only slightly. Being sedentary in the year of study 
entry explained an estimated 9-21% of disparities.  
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Table 5-3. Difficulty with walking and heavy housework: Observed disparities and estimates of 
percent explained 
Under 65 Women Men 
  Most vs. least Middle vs. least Most vs. middle Most vs. least Middle vs. least Most vs. middle 
Observed disparity 
(per 100 PY) 5.1 4.0 1.1 1.9 0.5 1.4 
Percent explained        
Smoking 23.4 20.9 32.4 35.0 67.9 22.0 
Excess BMI 39.6 38.6 43.2 17.9 -10.1 28.9 
Manual 2.8 2.5 3.6 23.6 33.0 19.9 
All 59.0 56.2 69.4 61.9 67.9 59.6 
       
65 and over Women Men 
  Most vs. least Middle vs. least Most vs. middle Most vs. least Middle vs. least Most vs. middle 
Observed disparity 
(per 100 PY) 5.6 2.8 2.9 0.3 0.7 -0.4 
Percent explained       
Smoking 1.8 -1.8 5.3 222.9 32.9  N/A  
Excess BMI 35.7 41.8 29.8 -85.7 -64.3  N/A  
Manual 3.6 5.5 1.8 28.6 7.1  N/A  
All 40.0 41.8 38.2 150.0 -4.3  N/A  
 
 
Note: PY = person-years. "Least" education = less than high school degree; "middle" = at least a 
high school degree; "most" = at least a college degree. N/A indicates excluded value due to a 
negative disparity. “Percent explained” refers to estimated percentage of educational disparities 
explained by the mediator of interest or the relevant combination of them. 
 
In the supplementary analysis of difficulty with walking and heavy housework—i.e., defining 
disability incidence as new difficulty with one or both of these, patterns were similar to those in 
the main analysis. The estimated proportion of disparities explained by manual labor tended to 
fall.  
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Table 5-4. Persistent disability: Observed disparities and estimates of percent explained 
 
Under 65 Women Men 
  
Most vs. 
least 
Middle vs. 
least 
Most vs. 
middle 
Most vs. 
least 
Middle vs. 
least 
Most vs. 
middle 
Observed disparity 
(per 100 PY) 2.3 1.8 0.5 2.2 1.1 1.1 
Percent explained       
Smoking 23.0 17.8 42.4 36.1 44.2 27.6 
Excess BMI 38.9 35.0 53.5 9.6 7.1 12.3 
Manual 25.2 21.9 37.4 31.2 35.0 27.3 
All 70.5 61.2 105.1 61.9 68.1 55.5 
       
65 and over Women Men 
  
Most vs. 
least 
Middle vs. 
least 
Most vs. 
middle 
Most vs. 
least 
Middle vs. 
least 
Most vs. 
middle 
Observed disparity 
(per 100 PY) 4.4 3.7 0.7 1.1 0.7 0.4 
Percent explained       
Smoking 0.0 0.0 0.0 35.5 20.8 57.5 
Excess BMI 44.1 39.6 66.9 -3.7 -31.5 37.9 
Manual -1.0 -1.4 0.7 44.2 42.3 47.1 
All 44.5 40.0 66.9 58.1 26.2 105.7 
 
 
Note: PY = person-years. "Least" education = less than high school degree; "middle" = at least a 
high school degree; "most" = at least a college degree. “Percent explained” refers to estimated 
percentage of educational disparities explained by the mediator of interest or the relevant 
combination of them. Persistent disability is defined as reporting of disability for at least two 
consecutive waves. 
 
In the supplementary analysis of persistent disability (i.e., disability lasting at least two 
consecutive waves), the mediators tended to explain a greater proportion of disparities in women. 
In younger women, this was largely due to an increase in the percent explained by manual labor. 
In older women, it was due to an increase in the contribution of excess weight. 
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Table 5-5. Separate prediction of ADL and IADL difficulty: Observed disparities and estimates 
of percent explained 
 
A. ADLs 
 
Under 65 Women Men 
  
Most vs. 
least 
Middle vs. 
least 
Most vs. 
middle 
Most vs. 
least 
Middle vs. 
least 
Most vs. 
middle 
Observed disparity (per 100 PY) 4.0 3.2 0.8 2.3 1.2 1.1 
Percent explained       
Smoking 23.3 21.6 30.1 38.0 46.7 28.2 
Excess BMI 41.5 41.0 43.4 21.8 11.2 33.8 
Manual 16.1 15.4 18.7 29.7 29.3 30.1 
All 66.8 64.8 74.1 69.2 66.1 72.7 
       
65 and over Women Men 
  
Most vs. 
least 
Middle vs. 
least 
Most vs. 
middle 
Most vs. 
least 
Middle vs. 
least 
Most vs. 
middle 
Observed disparity (per 100 PY) 5.7 2.9 2.8 0.5 1.0 -0.5 
Percent explained       
Smoking 1.7 0.0 3.4 119.0 30.0 N/A 
Excess BMI 22.4 24.1 20.5 -61.0 -30.5 N/A 
Manual 3.9 5.2 2.7 100.0 28.0 N/A 
All 27.4 28.1 26.6 132.0 30.5 N/A 
 
B. IADLs 
Under 65 Women Men 
  
Most vs. 
least 
Middle vs. 
least 
Most vs. 
middle 
Most vs. 
least 
Middle vs. 
least 
Most vs. 
middle 
Observed disparity (per 100 PY) 3.4 2.5 0.9 2.1 1.3 0.8 
Percent explained       
Smoking 26.8 23.7 36.0 31.7 35.1 26.2 
Excess BMI 39.7 39.8 39.4 9.9 5.3 17.1 
Manual 11.9 11.0 14.3 37.6 34.4 42.7 
All 66.6 63.5 75.4 64.8 60.7 71.3 
       
65 and over Women Men 
  
Most vs. 
least 
Middle vs. 
least 
Most vs. 
middle 
Most vs. 
least 
Middle vs. 
least 
Most vs. 
middle 
Observed disparity (per 100 PY) 4.9 3.1 1.8 1.2 1.8 -0.6 
Percent explained       
Smoking 1.7 -1.6 7.7 38.8 17.4 N/A 
Excess BMI 24.9 25.8 23.3 -0.4 -0.3 N/A 
Manual 23.9 25.8 20.5 -19.2 -8.8 N/A 
All 46.3 47.6 44.0 20.8 9.4 N/A 
 
Note: PY = person-years. "Least" education = less than high school degree; "middle" = at least a 
high school degree; "most" = at least a college degree. N/A indicates excluded value due to a 
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negative disparity. “Percent explained” refers to estimated percentage of educational disparities 
explained by the mediator of interest or the relevant combination of them. 
 
Patterns in the percent of disparities explained were generally similar to those from the main 
analysis on ADLs and IADLs jointly. Disparities in ADLs and IADLs individually tended to be 
smaller compared to those in the joint analysis, and the estimated overall percent explained 
tended to be larger. 
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Table 5-6. Analysis of excess BMI and smoking as mediators of the manual labor-disability 
relationship in men ages 33-64 
  Estimate Standard error 
Confounding 
percent 
Association, manual labor 
and incident disability (OR)    
  Reduced model 1.653 0.260  
  Full model 1.481 0.231  
  Difference 1.116 0.403  
Mediator coefficients (β)    
  1986 BMI 0.022 0.018 3.08 
  Concurrent BMI 0.015 0.012 4.41 
  Former smoker 0.002 0.004 0.34 
  Current smoker 0.071 0.027 14.06 
  All -- -- 21.89 
 
Note: Estimates were produced using Stata’s -khb- command, which implements Karlson, Holm, 
and Breen’s method for comparing coefficients among same-sample nested logit and probit 
models (Karlson et al., 2012). Errors are clustered at the individual level; estimates are 
unweighted. The confounding percent estimates the percentage of the association between 
manual labor and incidence that is explained by excess BMI and smoking. 
 
Excess BMI and smoking were estimated to explain 22% of the association among younger men 
between manual labor and disability incidence in the reduced model (p=0.002). Being a current 
smoker appeared to be the largest mediator, explaining an estimated 14% of the association. 
Contrary to my hypothesis, manual labor was estimated to be positively associated with excess 
BMI, such that the latter appeared to be a mediator rather than a suppressor of the manual labor-
disability relationship. 
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Table 5-7. Estimated additive interaction effects between education and the mediators of interest 
  Women 33-64 years Men 33-64 years Women 65-94 years Men 65-94 years 
  Est. p Est. p Est. p Est. p 
Contemporaneous BMI         
  Less than high school Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
  High school degree 0.000 0.933 -0.008 0.188 0.000 0.975 -0.002 0.869 
  College degree 0.006 0.239 -0.006 0.321 0.001 0.931 -0.015 0.319 
1986 BMI         
  Less than high school Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
  High school degree 0.003 0.594 0.001 0.931 0.030 0.133 0.011 0.388 
  College degree -0.007 0.413 0.000 0.952 0.026 0.284 0.013 0.365 
Former smoker         
  Less than high school Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
  High school degree -0.039 0.370 -0.088 0.113 -0.174 0.031 -0.023 0.721 
  College degree -0.092 0.041 -0.064 0.250 -0.262 0.004 -0.082 0.282 
Current smoker         
  Less than high school Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
  High school degree -0.118 0.038 -0.022 0.678 -0.228 0.140 0.168 0.090 
  College degree -0.193 0.002 -0.014 0.803 -0.245 0.234 0.022 0.911 
Manual labor         
  Less than high school Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
  High school degree -0.044 0.261 0.020 0.683 0.088 0.273 0.029 0.608 
  College degree -0.025 0.620 -0.029 0.562 0.178 0.107 0.210 0.114 
 
Note. Estimated interaction effects are the difference between (a) the marginal effect of the mediator at the 
educational group of interest; and (b) the marginal effect of the mediator in the reference group, those without a high 
school degree. A negative estimate therefore indicates a larger association in those without a high school degree. 1P-
values refer to Wald tests of the null hypothesis that the interaction effect equals zero. Bold indicates a p-value less 
than 0.10.   
 
 
 
 
 
 
1 Dear reader: if you have made it to and are actually reading this page, I am impressed, grateful, and rather 
surprised! In return, I owe you a gift of your choice: champagne, succulent, or methods textbook. 
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Appendix B. Supplementary Material for Chapter 3 (Opioid Prescribing) 
 
Table 5-8. International Classification of Disease codes used to identify certain mental health and 
substance use disorders 
Diagnosis Category ICD-9 Diagnostic Codes ICD-10 Diagnostic Codes 
Psychotic and bipolar disorders 295, 296.0, 296.1, 296.4-296.7, 
297-298 
F29, F28, F24, F23, F22, F333, F323, F319, 
F315, F314, F312, F304, F303, F302, F259, 
F209, F205, F202, F201, F200, F310, F309, 
F258, F251, F250, F203, F4489, F3178, 
F3177, F3176, F3175, F3174, F3173, F3164, 
F3163, F3162, F3161, F3160, F3132, F3131, 
F3130, F3113, F3112, F3111, F3110, F3013, 
F3012, F3011, F3010, F2089, F2081, F3189, 
F3172, F3171, F3170 
Major depression 296.2, 296.3 F339, F333, F332, F331, F330, F329, F325, 
F324, F323, F322, F321, F320, F3342, F3341, 
F3340 
Anxiety disorders (includes 
PTSD) 
300.0, 300.2, 300.3, 309.81 F419, F418, F411, F410, F409, F408, F413, 
F4312, F4310, F4010, F4002, F4001, F4311, 
F4011, F4000, F40241, F40240, F40218, 
F40298, F40291, F40290, F40248, F40243, 
F40242, F40233, F40232, F40231, F40230, 
F40228, F40220, F40210 
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Substance use disorders 2911, 2912, 2913, 2914, 2915, 
2919, 2922, 2929, 3039, 3041, 
3042, 3043, 3044, 3045, 3046, 
3047, 3048, 3049, 3051, 3052, 
3053, 3054, 3055, 3056, 3057, 
3058, 3059, 29181, 29182, 
29189, 29211, 29212, 29281, 
29282, 29283, 29284, 29285, 
29289, 30301, 30302, 30303, 
30391, 30392, 30393, 30401, 
30402, 30403, 30411, 30412, 
30413, 30421, 30422, 30423, 
30431, 30432, 30433, 30441, 
30442, 30443, 30451, 30452, 
30453, 30461, 30462, 30463, 
30471, 30472, 30473, 30481, 
30482, 30483, 30491, 30492, 
30493, 30501, 30502, 30503, 
30521, 30522, 30523, 30531, 
30532, 30533, 30541, 30542, 
30543, 30551, 30552, 30553, 
30561, 30562, 30563, 30571, 
30572, 30573, 30581, 30582, 
30583, 30591, 30592, 30593 
F1026, F1096, F1097, F1027, F1014, F1024, 
F1019, F1029, F1094, F1099, F1123, F1193, 
F1423, F1523, F1593, F10121, F10221, 
F10231, F10921, F10151, F10251, F10951, 
F10920, F10929, F10150, F10250, F10950, 
F10230, F10232, F10239, F10182, F10282, 
F10982, F10159, F10180, F10181, F10188, 
F10259, F10280, F10281, F10288, F10959, 
F10980, F10981, F10988, F13230, F13231, 
F13232, F13239, F13930, F13931, F13932, 
F13939, F19230, F19231, F19232, F19239, 
F19930, F19931, F19932, F19939, F11150, 
F11250, F11950, F12150, F12250, F12950, 
F13150, F13250, F13950, F14150, F14250, 
F14950, F15150, F15250, F15950, F16150, 
F16250, F16950, F18150, F18250, F18950, 
F19150, F19250, F19950, F11151, F11251, 
F11951, F12151, F12251, F12951, F13151, 
F13251, F13951, F14151, F14251, F14951, 
F15151, F15251, F15951, F16151, F16251, 
F16951, F18151, F18251, F18951 
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Table 5-9. Quasi-likelihood index criterion (QIC) values corresponding to each model selection step (osteoarthritis) 
Osteoarthritis Any fill  Average MME MME > 90 Overlap Fills Days supplied Days overlapped 
Link function Identity Identity Identity Identity Negative binomial Negative binomial Negative binomial 
Distributional family Gaussian Gaussian Gaussian Gaussian Negative binomial Negative binomial Negative binomial 
Correlation structure        
  Unstructured     229,628   N.C.   N.C.             N.C.               887,678   N.C.   N.C.  
  Exchangeable     229,784  
   
1,841,992,405             316,004             307,849.57               887,530            2,519,465           680,418  
        
Fibromyalgia Any fill  Average MME MME > 90 Overlap Fills Days supplied Days overlapped 
Link function Identity Identity Identity Log Negative binomial Negative binomial Negative binomial 
Distributional family Gaussian Gaussian Gaussian Binomial Negative binomial Negative binomial Negative binomial 
Correlation structure        
  Unstructured   1,090,400   N.C.   N.C.             246,880               660,410   N.C.   N.C.  
  Exchangeable   1,093,155  
   
1,488,311,429             245,346             248,758               660,290            1,901,575           609,991  
 
Note: MME = morphine milligram equivalents. N.C. = No convergence. Bold indicates minimum QIC value and therefore the 
selected specification. 
 
 
 154 
 
Table 5-10. Sociodemographic and clinical measures by race/ethnicity in osteoarthritis patients 
 
  White Black Hispanic Asian 
  Estimate 95% CI  Estimate  95% CI Estimate 95% CI  Estimate  95% CI 
Observations 1,001,737   147,540   114,146   21,045   
Individuals 68,579   9,663   8,032   1,708   
Age (mean) 53.8 (53.78 to 53.89) 53.6 (53.46 to 53.74) 53.1 (52.93 to 53.25) 52.9 (52.53 to 53.29) 
Female (%) 57.5 (57.15 to 57.89) 65.4 (64.46 to 66.35) 58.7 (57.61 to 59.77) 61.7 (59.34 to 63.96) 
Education (%)             
High school degree or less 26.7 (26.34 to 27.00) 49.6 (48.64 to 50.63) 45.3 (44.23 to 46.41) 18.3 (16.49 to 20.16) 
Less than college 55.5 (55.14 to 55.88) 45.9 (44.88 to 46.87) 46.3 (45.21 to 47.39) 49.2 (46.81 to 51.55) 
College degree 17.8 (17.53 to 18.11) 4.5 (4.08 to 4.90) 8.4 (7.77 to 8.99) 32.5 (30.27 to 34.72) 
Income (%)             
<$40K 16.9 (16.63 to 17.19) 44.8 (43.81 to 45.79) 28.6 (27.65 to 29.62) 10.9 (9.47 to 12.43) 
$40K-$59K 10.8 (10.59 to 11.06) 17.9 (17.15 to 18.68) 18.0 (17.17 to 18.86) 8.3 (6.95 to 9.56) 
$60K-$74K 9.3 (9.08 to 9.52) 10.2 (9.55 to 10.75) 11.9 (11.16 to 12.57) 10.3 (8.86 to 11.75) 
$75K-$99K 18.4 (18.11 to 18.69) 11.9 (11.25 to 12.54) 16.6 (15.79 to 17.42) 18.2 (16.38 to 20.04) 
$100K+ 44.6 (44.19 to 44.94) 15.2 (14.53 to 15.96) 24.9 (23.93 to 25.82) 52.3 (49.91 to 54.65) 
Any mental health diagnosis 6.3 (6.15 to 6.52) 5.4 (4.95 to 5.85) 5.5 (5.03 to 6.03) 3.7 (2.85 to 4.65) 
SUD diagnosis 2.9 (2.75 to 3.00) 3.6 (3.19 to 3.93) 2.2 (1.89 to 2.54) 1.4 (0.85 to 1.96) 
Other pain-related diagnosis 42.5 (42.17 to 42.91) 40.1 (39.11 to 41.07) 41.0 (39.95 to 42.10) 39.8 (37.49 to 42.14) 
Elixhauser score (max per month. mean) 0.9 (0.85 to 0.87) 1.2 (1.21 to 1.27) 1.1 (1.04 to 1.09) 0.8 (0.77 to 0.87) 
Days since last pain visit 42.9 (42.46 to 43.30) 44.4 (43.19 to 45.53) 42.9 (41.67 to 44.16) 45.2 (42.22 to 48.19) 
Pain visits per month 2.9 (2.85 to 2.89) 2.8 (2.77 to 2.88) 2.8 (2.78 to 2.89) 2.8 (2.71 to 2.94) 
Months between first and last pain 
diagnosis 32.9 (32.78 to 32.95) 33.4 (33.19 to 33.65) 32.5 (32.25 to 32.77) 31.4 (30.82 to 32.01) 
 
Note: Estimates include individuals for whom data is not missing on any model predictor
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Table 5-11. Sociodemographic and clinical measures by race/ethnicity in fibromyalgia patients 
 
  White Black Hispanic Asian 
  Estimate 95% CI  Estimate  95% CI Estimate 95% CI  Estimate  95% CI 
Observations 685,748   75,673   77,205   16,745   
Individuals 44,761  
 4,724   5,380   1,429   
Age (mean) 48.1 (47.96 to 48.16)  48.8 (48.54 to 49.12) 47.4 (47.1 to 47.64) 44.7 (44.2 to 45.28) 
Female (%) 71.7 (71.30 to 72.13) 77.1 (75.90 to 78.29) 71.5 (70.3 to 72.69) 64.9 (62.4 to 67.35) 
Education (%)             
High school degree or less 22.5 (22.11 to 22.89) 44.0 (42.55 to 45.38) 36.8 (35.6 to 38.14) 11.1 (9.4 to 12.68) 
Less than college 56.6 (56.11 to 57.03) 50.0 (48.59 to 51.45) 52.1 (50.8 to 53.46) 45.7 (43.1 to 48.28) 
College degree 20.9 (20.55 to 21.31) 6.0 (5.33 to 6.69) 11.0 (10.2 to 11.86) 43.2 (40.7 to 45.82) 
Income (%)             
<$40K 15.6 (15.29 to 15.96) 41.3 (39.90 to 42.70) 25.8 (24.6 to 26.93) 9.3 (7.8 to 10.82) 
$40K-$59K 10.3 (10.06 to 10.63) 16.9 (15.84 to 17.98) 16.9 (15.9 to 17.95) 7.7 (6.3 to 9.08) 
$60K-$74K 
9.0 (8.70 to 9.23) 10.5 (9.65 to 11.40) 10.6 (9.8 to 11.40) 7.1 (5.7 to 8.40) 
$75K-$99K 16.9 (16.58 to 17.28) 13.3 (12.37 to 14.31) 16.9 (15.9 to 17.95) 15.2 (13.3 to 17.05) 
$100K+ 48.1 (47.67 to 48.60) 17.9 (16.84 to 19.02) 29.8 (28.5 to 30.98) 60.7 (58.2 to 63.28) 
Any mental health diagnosis 9.0 (8.72 to 9.25) 7.7 (6.96 to 8.49) 8.3 (7.6 to 9.07) 7.1 (5.8 to 8.47) 
SUD diagnosis 3.0 (2.82 to 3.14) 4.1 (3.50 to 4.63) 2.7 (2.2 to 3.08) 1.7 (1.0 to 2.35) 
Other pain-related diagnosis 36.6 (36.13 to 37.03) 37.3 (35.88 to 38.64) 36.5 (35.2 to 37.82) 36.9 (34.4 to 39.38) 
Elixhauser score (max per month. 
mean) 0.7 (0.69 to 0.71) 1.0 (1.00 to 1.08) 0.8 (0.8 to 0.88) 0.6 (0.5 to 0.62) 
Days since last pain visit 38.0 (37.48 to 38.45) 40.0 (38.51 to 41.57) 39.5 (38.1 to 40.96) 39.7 (36.4 to 42.99) 
Pain visits per month 2.9 (2.91 to 2.95) 2.9 (2.83 to 2.98) 2.9 (2.9 to 3.00) 3.3 (3.1 to 3.39) 
Months between first and last pain 
diagnosis 33.1 (32.94 to 33.17) 33.4 (33.1 to 33.77) 32.3 32.0 to 32.624 30.0 29.3 to 30.73) 
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Table 5-12. Comparison of individuals with missing versus complete race/ethnicity data 
  Osteoarthritis Fibromyalgia 
  Missing Complete p Missing Complete p 
 Distinct individuals  27,449 98,043  22,331 63,580 
 
 Total monthly observations  511,828 1,804,480 414,272 1,201,438  
 Months with pain visits  18.6 18.4 0.002 18.6 18.9 <0.001 
 Age (%)        
 18-25  0.7 0.6 0.069 4.4 4.0 0.007 
 25-34  3.5 1.9 <0.001 14.9 9.2 <0.001 
 35-44  13.4 8.8 <0.001 25.4 20.3 <0.001 
 45-54  35.5 34.2 <0.001 31.1 34.4 <0.001 
 55-64  46.9 54.6 <0.001 24.2 32.1 <0.001 
 Female (%)  59.0 58.6 0.183 72.5 72.1 0.228 
 Education (%)        
 High school degree or less  27.3 31.4 <0.001 22.0 26.0 <0.001 
 Less than college  51.1 53.0 <0.001 52.9 54.8 <0.001 
 College degree  16.0 15.4 0.016 20.5 19.0 <0.001 
 Missing  5.5 0.2 <0.001 4.6 0.2 <0.001 
 Income (%)        
 <$40K  15.7 19.1 <0.001 13.2 16.7 <0.001 
 $40K-$59K  9.4 11.1 <0.001 9.8 10.3 0.025 
 $60K-$74K  6.4 8.8 <0.001 6.6 8.3 <0.001 
 $75K-$99K  7.9 15.9 <0.001 8.0 14.9 <0.001 
 $100K+  14.9 36.1 <0.001 16.3 39.6 <0.001 
 Missing  45.8 9.0 <0.001 46.0 10.3 <0.001 
 Mental health diagnosis        
 Anxiety  6.2 5.3 <0.001 8.6 7.6 <0.001 
 Depression  5.5 4.8 <0.001 6.9 6.4 <0.001 
 Psychosis/PTSD  2.4 1.8 <0.001 2.5 2.1 <0.001 
 SUD diagnosis  2.3 1.9 <0.001 2.4 2.2 <0.001 
 Elixhauser score 1.3 1.2 <0.001 1.0 1.0 <0.001 
 Days since last pain visit  23.6 24.6 <0.001 22.7 23.1 <0.001 
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 Pain visits per month  3.4 3.3 <0.001 3.3 3.2 <0.001 
 Months between first and last 
 pain diagnosis  32.5 32.8 0.001 32.4 32.8 <0.001 
 Any opioid fill in month (%)  16.9 15.5 <0.001 17.2 16.7 <0.001 
 Fills per month, if any 1.27 1.26 0.004 1.27 1.26 <0.001 
 Days supplied per month, if any  28.5 28.1 <0.001 30.4 30.6 0.120 
 Morphine milligram equivalents (MME), if any      
 Average per day  77.8 74.4 <0.001 80.4 78.4 <0.001 
 Receiving > 100 MME (%)  25.0 22.9 <0.001 25.6 24.4 <0.001 
 Concurrent opioid/benzodiazepine prescription, if any opioid      
 Any (%)  28.6 27.0 <0.001 33.6 32.4 <0.001 
 Number of overlapping days  8.1 7.8 <0.001 28.6 29.0 0.001 
Note: SUD = substance use disorder
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Table 5-13. Marginal effects of main predictors from Stage I model, osteoarthritis 
 
  Any fill (%) Average dose (MME) High dose (%) Concurrent (%) Fills Days supplied 
Days with 
concurrent 
prescriptions 
Secular trend               
  Time 0.0313*** 0.0469 -8.75E-03 -0.170*** -0.00034 0.00706 -0.00353 (0.0181, 0.0445) (-0.0441, 0.138) (-0.0572, 0.0397) (-0.212, -0.127) (-0.00101, 0.000333) (-0.0137, 0.0279) (-0.0363, 0.0293) 
Race/ethnicity        
  White Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
  Black -1.263*** -9.922***  -4.315***  -4.711*** -0.0385*** -1.110*** -1.331*** 
(-1.705, -0.821) (-11.48, -8.361)  (-5.184, -3.446)  (-5.687, -3.735) (-0.0492, -0.0279) (-1.517, -0.704) (-2.067, -0.594) 
  Hispanic -2.028*** -10.41*** -4.268*** -2.920*** -0.0383*** 0.094 -0.662 
(-2.480, -1.576) (-12.20, -8.621) (-5.257, -3.279) (-4.017, -1.823) (-0.0504, -0.0261) (-0.438, 0.626) (-1.572, 0.248) 
  Asian -3.820*** 
-5.217* -2.333 -6.875*** -0.0267 -2.009** 0.98 
(-4.568, -3.073) (-10.03, -0.402) (-4.989, 0.324) (-9.110, -4.641) (-0.0576, 0.00419) (-3.330, -0.689) (-2.394, 4.355) 
Level change 
-0.214 0.905 0.625 0.733 0.014 0.238 0.0627 
(-0.541, 0.113) (-0.922, 2.731) (-0.437, 1.686) (-0.273, 1.738) (-0.00235, 0.0303) (-0.211, 0.688) (-0.734, 0.859) 
Trend change -0.0308* -0.563*** -0.229*** -0.0578 -0.00133* -0.0381* -0.0435 
(-0.0557, -0.00587) (-0.716, -0.411) (-0.317, -0.140) (-0.136, 0.0207) (-0.00259, -7.65e-05) (-0.0740, -0.00214) (-0.104, 0.0168) 
Observations 1,284,468 191,970 191,970 194,045 194,045 194,045 51,143 
 
Note: *** p<0.001, ** p<0.01, * p<0.05. Estimates are marginal effects from model in which the exposure variables were not interacted with race/ethnicity. 95% 
confidence intervals are in parentheses. 
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Table 5-14. Marginal effects of main predictors from Stage I model, fibromyalgia 
  Any fill (%) Average dose (MME) High dose (%) 
Concurrent 
prescriptions (%) Fills Days supplied 
Days with 
concurrent 
prescriptions 
Secular trend              
  Time 0.035*** -0.084 -0.031 -0.209*** -0.001 -0.030* 0.016 
(0.018, 0.051) (-0.193, 0.024) (-0.087, 0.025) (-0.261, -0.156) (-0.001, 0.000) (-0.054, -0.005) (-0.018, 0.051) 
Race/ethnicity        
  White Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
  Black 
-1.069** -9.243*** -2.323** -4.786*** -0.038*** -1.528*** -1.160** 
(-1.732, -0.407) (-11.466, -7.020) (-3.823, -0.823) (-6.287, -3.285) (-0.052, -0.025) 
(-2.133, -
0.923) (-2.039, -0.281) 
  Hispanic 
-1.774*** -7.344*** -3.522*** -3.484*** -0.020** 0.068 -0.579 
(-2.364, -
1.185) (-9.879, -4.808) (-5.087, -1.957) (-4.984, -1.985) (-0.035, -0.005) (-0.642, 0.777) (-1.593, 0.435) 
  Asian -3.830*** -3.118 -1.602 -7.818*** -0.029 -1.435 -1.365 
(-4.689, -2.971) (-10.244, 4.007) (-5.450, 2.247) (-11.208, -4.427) (-0.065, 0.007) (-3.472, 0.603) (-4.173, 1.442) 
Level change 0.149 1.946 0.925 -0.307 0.019* 0.319 -0.397 
(-0.259, 0.558) (-0.226, 4.118) (-0.356, 2.206) (-1.530, 0.915) (0.000, 0.039) (-0.213, 0.850) (-1.197, 0.404) 
Trend change -0.059*** -0.569*** -0.237*** -0.077 -0.001 -0.013 -0.03 
(-0.090, -0.028) (-0.751, -0.387) (-0.350, -0.124) (-0.172, 0.018) (-0.003, 0.000) (-0.055, 0.029) (-0.091, 0.031) 
Observations 855,371 137,984 137,984 139,484 139,484 139,484 44,939 
 
Note: *** p<0.001, ** p<0.01, * p<0.05. Estimates are marginal effects from model in which the exposure variables were not interacted with race/ethnicity. 95% 
confidence intervals are in parentheses. 
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Table 5-15. Marginal effects from Stage II (interacted) model, osteoarthritis 
  Any fill (probability) 
Average dosage 
(MMEs) 
High dosage 
(probability) 
Concurrent 
prescriptions  
(probability) 
Prescription fills Days supplied Days of concurrent prescriptions 
Secular trend 
0.000313*** 0.0465 -5.12E-05 -0.00170*** -0.00034 0.00709 -0.00318 
(0.000181 - 
0.000445) (-0.0445 - 0.138) (-0.000541 - 0.000438) (-0.00212, -0.00127) (-0.00101 - 0.000333) (-0.0137 - 0.0279) (-0.0360 - 0.0296) 
Level change 
0.207* 380.4*** 1.297*** 0.398 1.017 -772.7 16.85 
(0.0376 - 
0.376) (277.4 - 483.4) (0.691 - 1.902) (-0.134 - 0.930) (-3.088 - 5.123) (-7.507e+09 - 7.507e+09) (-109.5 - 143.2) 
  By race/ethnicity        
    White 
0.238* 386.6*** 1.366*** 0.416 1.592 -979.1 24.94 
(0.0524 - 
0.425) (273.1 - 500.2) (0.699 - 2.033) (-0.174 - 1.007) (-2.859 - 6.044) (-9.508e+09 - 9.508e+09) (-130.6 - 180.5) 
    Black 
0.156 265.8* 1.159 -0.0733 0.884 -2.35 -15.01*** 
(-0.283 - 
0.594) (53.95 - 477.6) (-0.106 - 2.425) (-1.254 - 1.107) (-3.174 - 4.942) (-53.26 - 48.56) (-23.31, -6.700) 
    Hispanic 
0.0281 502.3*** 0.852 0.815 -4.337 -16.99* -20.15 
(-0.434 - 
0.490) (231.2 - 773.5) (-0.803 - 2.507) (-0.631 - 2.261) (-24.27 - 15.59) (-32.83, -1.154) (-52.92 - 12.62) 
    Asian 
0.0262 310.8 1.059 1.358 0.444 0.321 -27.52 
(-0.782 - 
0.835) (-535.7 - 1,157) (-4.138 - 6.256) (-3.281 - 5.998) (-1.687 - 2.575) (-13.00 - 13.64) (-181.5 - 126.4) 
Trend change 
-0.000310* -0.563*** -0.00192*** -0.00058 -0.00133* -0.0381* -0.0437 
(-0.000559, -
6.05e-05) (-0.715, -0.411) (-0.00281, -0.00102) (-0.00137 - 0.000206) (-0.00259, -8.02e-05) (-0.0741, -0.00224) (-0.104 - 0.0166) 
  By race/ethnicity        
    White 
-0.000356* -0.572*** -0.00202*** -0.000606 -0.0013 -0.0407* -0.0217 
(-0.000630, -
8.22e-05) (-0.740, -0.404) (-0.00300, -0.00104) (-0.00148 - 0.000264) (-0.00269 - 8.43e-05) (-0.0798, -0.00167) (-0.0850 - 0.0416) 
    Black 
-0.000234 -0.393* -0.00171 0.000109 -0.000931 0.00324 -0.161 
(-0.000875 - 
0.000408) (-0.704, -0.0824) (-0.00357 - 0.000142) (-0.00162 - 0.00184) (-0.00371 - 0.00185) (-0.0731 - 0.0795) (-0.332 - 0.00924) 
    Hispanic 
-5.41E-05 -0.746*** -0.00126 -0.00119 -0.00303 -0.0931 -0.108 
(-0.000729 - 
0.000621) (-1.144, -0.349) (-0.00369 - 0.00116) (-0.00331 - 0.000921) (-0.00629 - 0.000228) (-0.197 - 0.0104) (-0.329 - 0.112) 
    Asian 
-3.76E-05 -0.452 -0.00152 -0.00196 0.00507 0.103 -0.0789 
(-0.00122 - 
0.00114) (-1.693 - 0.790) (-0.00914 - 0.00609) (-0.00876 - 0.00484) (-0.00505 - 0.0152) (-0.143 - 0.349) (-0.426 - 0.268) 
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Race        
  White Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
  Black 
-0.0126*** -9.848*** -0.0417*** -0.0471*** -0.0383*** -1.101*** -1.338*** 
(-0.0170, -
0.00815) (-11.40, -8.295) (-0.0503, -0.0332) (-0.0568, -0.0373) (-0.0490, -0.0277) (-1.507, -0.695) (-2.075, -0.601) 
  Hispanic 
-0.0206*** -10.63*** -0.0413*** -0.0294*** -0.0387*** 0.104 -0.676 
(-0.0252, -
0.0161) (-12.40, -8.861) (-0.0511, -0.0316) (-0.0404, -0.0184) (-0.0508, -0.0265) (-0.430 - 0.637) (-1.592 - 0.239) 
  Asian 
-0.0378*** -4.849 -0.0208 -0.0680*** -0.0234 -1.907** 1.045 
(-0.0453, -
0.0303) (-9.718 - 0.0200) (-0.0472 - 0.00551) (-0.0907, -0.0453) (-0.0551 - 0.00827) (-3.255, -0.558) (-2.311 - 4.402) 
Age 
-0.000851*** -0.0411 -0.00022 0.000189 -0.00107*** 0.0996*** 0.0500** 
(-0.00104, -
0.000665) (-0.159 - 0.0774) (-0.000630 - 0.000189) (-0.000241 - 0.000619) (-0.00157, -0.000565) (0.0773 - 0.122) (0.0158 - 0.0843) 
Female 
-0.0104*** -8.382*** -0.0370*** 0.0393*** -0.0226*** 0.0518 -0.131 
(-0.0131, -
0.00765) (-9.556, -7.209) (-0.0433, -0.0307) (0.0329 - 0.0457) (-0.0303, -0.0148) (-0.264 - 0.367) (-0.645 - 0.382) 
Education        
  High school degree 
 or less Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
  Some college 
-0.00104 5.079*** 0.0208*** 0.000465 0.0219*** -0.589*** -0.851** 
(-0.00438 - 
0.00231) (3.847 - 6.311) (0.0140 - 0.0275) (-0.00697 - 0.00790) (0.0136 - 0.0302) (-0.922, -0.256) (-1.387, -0.315) 
  College degree 
-0.0193*** 5.966*** 0.0288*** -0.0104 0.0317*** -2.924*** -2.347*** 
(-0.0238, -
0.0149) (4.033 - 7.899) (0.0178 - 0.0398) (-0.0216 - 0.000770) (0.0176 - 0.0457) (-3.498, -2.350) (-3.385, -1.308) 
Income        
  <$40K Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
  $40K-$59K 
-0.0182*** -1.327 -0.00087 -0.0185*** 0.0113 -1.346*** -0.241 
(-0.0233, -
0.0131) (-3.141 - 0.487) (-0.0106 - 0.00887) (-0.0295, -0.00751) (-0.000565 - 0.0232) (-1.817, -0.874) (-0.970 - 0.488) 
  $60K-$74K 
-0.0198*** -1.627 0.000973 -0.0284*** 0.0228** -1.599*** -0.134 
(-0.0254, -
0.0143) (-3.675 - 0.422) (-0.00997 - 0.0119) (-0.0404, -0.0164) (0.00854 - 0.0370) (-2.149, -1.049) (-0.973 - 0.704) 
  $75K-$99K 
-0.0292*** -2.191* 0.00167 -0.0313*** 0.0133* -2.497*** -0.870* 
(-0.0339, -
0.0245) (-4.013, -0.368) (-0.00792 - 0.0113) (-0.0419, -0.0208) (0.00181 - 0.0248) (-2.975, -2.020) (-1.604, -0.135) 
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  $100K+ 
-0.0433*** -4.191*** -0.00318 -0.0518*** 0.0113* -4.250*** -1.767*** 
(-0.0477, -
0.0389) (-5.974, -2.408) (-0.0123 - 0.00594) (-0.0615, -0.0421) (0.000228 - 0.0223) (-4.687, -3.813) (-2.519, -1.014) 
Mental health 
diagnosis 
  
     
  Anxiety, PTSD 
0.00894*** -2.921* -0.00257 0.0215*** -1.54E-05 0.229 0.772** 
(0.00561 - 
0.0123) (-5.149, -0.694) (-0.0135 - 0.00835) (0.0118 - 0.0312) (-0.0116 - 0.0115) (-0.177 - 0.636) (0.301 - 1.243) 
  Depression 
0.0121*** -0.0327 0.00488 0.117*** 0.00767 0.743*** 1.078*** 
(0.00928 - 
0.0149) (-2.237 - 2.171) (-0.00469 - 0.0145) (0.108 - 0.126) (-0.00209 - 0.0174) (0.343 - 1.142) (0.530 - 1.627) 
  Psychosis, 
  schizophrenia,  
  or bipolar disorder 
0.00202 -2.509 -0.0113 0.0446*** -0.0094 -0.0769 -0.0267 
(-0.00431 - 
0.00835) (-6.774 - 1.756) (-0.0292 - 0.00665) (0.0255 - 0.0636) (-0.0280 - 0.00915) (-0.739 - 0.586) (-0.655 - 0.602) 
Substance use disorder 
diagnosis 
0.0526*** 0.6 0.0331*** 0.0489*** 0.0441*** 2.044*** 1.357*** 
(0.0488 - 
0.0563) (-2.355 - 3.555) (0.0227 - 0.0435) (0.0400 - 0.0577) (0.0347 - 0.0536) (1.598 - 2.489) (0.863 - 1.852) 
Elixhauser 
comorbidity score 
0.00893*** 1.561*** 0.00643*** 0.00741*** 0.0119*** 0.0707* 0.0577 
(0.00837 - 
0.00949) (1.297 - 1.824) (0.00497 - 0.00789) (0.00608 - 0.00874) (0.00979 - 0.0141) (0.0131 - 0.128) (-0.0518 - 0.167) 
Other pain-related 
diagnosis 
0.0389*** 4.914*** 0.0232*** 0.0199*** 0.0868*** 0.729*** 0.834*** 
(0.0377 - 
0.0402) (4.330 - 5.498) (0.0198 - 0.0266) (0.0165 - 0.0232) (0.0815 - 0.0922) (0.582 - 0.875) (0.545 - 1.123) 
Days since last visit 
-0.000211*** -0.0519*** -0.000288*** -0.000914*** -0.00113*** -0.00614*** -0.0264*** 
(-0.000226, -
0.000196) (-0.0645, -0.0394) (-0.000356, -0.000220) (-0.000998, -0.000831) (-0.00124, -0.00101) (-0.00968, -0.00260) (-0.0380, -0.0149) 
Number of visits 
0.0125*** 1.830*** 0.00858*** 0.00362*** 0.0196*** 0.0808*** 0.0226 
(0.0122 - 
0.0129) (1.673 - 1.987) (0.00774 - 0.00941) (0.00296 - 0.00428) (0.0185 - 0.0207) (0.0516 - 0.110) (-0.0310 - 0.0762) 
        
Observations 1,284,468 191,970 194,045 194,045 194,045 194,045 51,143 
 
*** p<0.001, ** p<0.01, * p<0.05 
Note:  Estimates are marginal effects. 95% confidence intervals are in parentheses. 
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Table 5-16. Marginal effects from Stage II (interacted) model, fibromyalgia 
  Any fill (probability) 
Average dosage 
(MMEs) 
High dosage 
(probability) 
Concurrent prescriptions  
(probability) Fills Days supplied 
Days of concurrent 
prescriptions 
Secular trend 
0.000346*** -0.084 -0.000161 -0.00202*** -0.000528 -0.0296* 0.0161 
(0.000181 - 
0.000512) (-0.193 - 0.0244) (-0.000730 - 0.000407) (-0.00253, -0.00151) (-0.00134 - 0.000285) (-0.0542, -0.00494) (-0.0187 - 0.0508) 
  By race/ethnicity         
    White 
-0.000676*** -0.594*** -0.00236*** -0.000727 -0.00117 -0.0104 -0.0053 
(-0.00101, -
0.000337) (-0.792, -0.395) (-0.00358, -0.00114) (-0.00181 - 0.000359) (-0.00286 - 0.000524) (-0.0556 - 0.0349) (-0.0702 - 0.0596) 
    Black 
0.000745 -0.395 -0.00149 -0.00091 -7.48E-05 0.0111 -0.0684 
(-0.000213 - 
0.00170) (-0.809 - 0.0193) (-0.00440 - 0.00142) (-0.00346 - 0.00164) (-0.00346 - 0.00331) (-0.0898 - 0.112) (-0.227 - 0.0898) 
    Hispanic 
-0.00117** -0.580* -0.00218 -0.00143 -0.00106 -0.0547 -0.253* 
(-0.00198, -
0.000364) (-1.067, -0.0925) (-0.00550 - 0.00114) (-0.00431 - 0.00144) (-0.00501 - 0.00290) (-0.177 - 0.0676) (-0.464, -0.0429) 
    Asian 
-0.000571 -0.43 -0.000105 0.00314 -0.00704 -0.105 0.0887 
(-0.00213 - 
0.000989) (-1.572 - 0.711) (-0.00995 - 0.00974) (-0.00248 - 0.00876) (-0.0178 - 0.00368) (-0.370 - 0.160) (-0.330 - 0.508) 
Level change 0.401*** 386.9*** 3,654 -110 1.114 1.722 -1.575 
(0.190 - 0.613) (263.7 - 510.1) (-22,712 - 30,021) (-2,529 - 2,309) (-1.838 - 4.066) (-184.3 - 187.8) (-44.94 - 41.79) 
  By race/ethnicity         
    White 0.459*** 402.5*** 3,055 0.959 1.275 8.657 3.103 (0.229 - 0.688) (268.1 - 536.9) (-13,204 - 19,314) (-1.914 - 3.832) (-2.161 - 4.712) (-38.09 - 55.40) (-45.68 - 51.89) 
    Black -0.516 266.8 140.7 1.855 0.0556 -7.535 -34.59 (-1.171 - 0.139) (-15.67 - 549.3) (-1,929 - 2,210) (-12.07 - 15.78) (-2.312 - 2.424) (-87.95 - 72.88) (-172.6 - 103.5) 
    Hispanic 0.792** 391.7* 13,966 7.559 1.122 -51.5 -13.93*** (0.238 - 1.345) (59.65 - 723.8) (-242,748 - 270,680) (-51.98 - 67.10) (-6.000 - 8.245) (-2,145 - 2,042) (-17.91, -9.952) 
    Asian 0.388 289.6 0.049 -10,156 -1.288* -15.03 1.063 (-0.679 - 1.455) (-489.9 - 1,069) (-8.107 - 8.205) (-230,394 - 210,082) (-2.373, -0.203) (-42.63 - 12.58) (-58.71 - 60.84) 
Trend change 
-0.000593*** -0.571*** -0.00223*** -0.000762 -0.00112 -0.013 -0.0296 
(-0.000905, -
0.000281) (-0.753, -0.389) (-0.00336, -0.00111) (-0.00175 - 0.000228) (-0.00266 - 0.000427) (-0.0551 - 0.0290) (-0.0905 - 0.0312) 
Race        
  White Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
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  Black -0.0114*** -9.234*** -0.0269*** -0.0470*** -0.0383*** -1.529*** -1.154* 
(-0.0180, -0.00480) (-11.46, -7.012) (-0.0399, -0.0138) (-0.0633, -0.0308) (-0.0518, -0.0248) (-2.135, -0.922) (-2.034, -0.273) 
  Hispanic -0.0183*** -7.415*** -0.0339*** -0.0257** -0.0189* 0.0626 -0.606 
(-0.0242, -0.0124) (-9.914, -4.916) (-0.0474, -0.0203) (-0.0423, -0.00906) (-0.0338, -0.00405) (-0.647 - 0.772) (-1.621 - 0.409) 
  Asian -0.0382*** -3.169 -0.0244 -0.0906*** -0.0289 -1.411 -1.44 
(-0.0469, -0.0296) (-10.33 - 3.995) (-0.0578 - 0.00893) (-0.136, -0.0452) (-0.0655 - 0.00763) (-3.452 - 0.630) (-4.227 - 1.347) 
Age 
0.00110*** 0.299*** 0.00143*** 0.00187*** -0.000909*** 0.254*** 0.158*** 
(0.000945 - 
0.00125) (0.224 - 0.374) (0.000957 - 0.00190) (0.00134 - 0.00240) (-0.00139, -0.000433) (0.229 - 0.279) (0.125 - 0.190) 
Female 
0.003 -8.787*** -0.0385*** 0.0481*** -0.0321*** 0.179 0.339 
(-0.000916 - 
0.00692) (-10.65, -6.923) (-0.0487, -0.0283) (0.0350 - 0.0613) (-0.0436, -0.0206) (-0.309 - 0.668) (-0.320 - 0.999) 
Education        
  High school 
degree or less Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
  Some college -0.00582* 3.350*** 0.00785 0.00158 0.0170*** -0.490* -0.184 
(-0.0106, -0.00109) (1.616 - 5.084) (-0.00258 - 0.0183) (-0.0102 - 0.0133) (0.00692 - 0.0271) (-0.951, -0.0287) (-0.775 - 0.407) 
  College degree -0.0290*** 1.889 -0.00291 0.00416 0.0158 -3.064*** -1.345* 
(-0.0348, -0.0232) (-0.741 - 4.520) (-0.0189 - 0.0131) (-0.0144 - 0.0227) (-0.00136 - 0.0330) (-3.824, -2.303) (-2.388, -0.303) 
Income        
  <$40K Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
  $40K-$59K -0.0157*** -2.299 -0.0158* -0.00452 0.00224 -0.3 -0.00295 
(-0.0229, -0.00850) (-4.866 - 0.267) (-0.0312, -0.000449) (-0.0213 - 0.0123) (-0.0128 - 0.0173) (-0.932 - 0.333) (-0.809 - 0.803) 
  $60K-$74K -0.0273*** -7.268*** -0.0251** -0.0253** 0.00574 -0.999** -0.445 
(-0.0351, -0.0196) (-9.979, -4.556) (-0.0419, -0.00829) (-0.0437, -0.00685) (-0.0116 - 0.0231) (-1.700, -0.297) (-1.402 - 0.511) 
  $75K-$99K -0.0372*** -7.031*** -0.0226** -0.0166* -0.00333 -0.818* -1.003* 
(-0.0436, -0.0308) (-9.511, -4.550) (-0.0372, -0.00804) (-0.0328, -0.000300) (-0.0174 - 0.0108) (-1.471, -0.165) (-1.798, -0.208) 
  $100K+ -0.0534*** -9.274*** -0.0249*** -0.0300*** -0.0037 -2.383*** -0.821* 
(-0.0592, -0.0475) (-11.63, -6.921) (-0.0383, -0.0114) (-0.0447, -0.0153) (-0.0169 - 0.00951) (-2.973, -1.792) (-1.594, -0.0471) 
Mental health 
diagnosis 
  
     
  Anxiety, PTSD 
0.00262 -0.563 0.00631 0.0231*** 0.0128 0.283 0.314 
(-0.00129 - 
0.00653) (-2.986 - 1.859) (-0.00621 - 0.0188) (0.0133 - 0.0329) (-0.00173 - 0.0273) (-0.181 - 0.746) (-0.209 - 0.838) 
  Depression 0.0106*** -0.264 -0.000726 0.128*** -0.00252 0.332 0.258 
(0.00731 - 0.0139) (-2.680 - 2.152) (-0.0123 - 0.0108) (0.116 - 0.139) (-0.0140 - 0.00899) (-0.106 - 0.769) (-0.320 - 0.835) 
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  Psychosis,  
schizophrenia,  
  or bipolar disorder 
-0.00297 -2.244 -0.0132 0.0389*** -0.0116 -0.453 -0.293 
(-0.0102 - 0.00425) (-7.025 - 2.537) (-0.0336 - 0.00718) (0.0245 - 0.0534) (-0.0324 - 0.00916) (-1.185 - 0.280) (-0.918 - 0.333) 
Substance use 
disorder diagnosis 
0.0619*** 2.657 0.0238*** 0.0336*** 0.0604*** 2.605*** 1.409*** 
(0.0570 - 0.0668) (-0.629 - 5.944) (0.0106 - 0.0371) (0.0231 - 0.0441) (0.0475 - 0.0732) (2.115 - 3.094) (0.894 - 1.924) 
Elixhauser 
comorbidity score 
0.00908*** 1.024*** 0.00262** 0.00636*** 0.00905*** 0.0532 0.126* 
(0.00832 - 0.00984) (0.692 - 1.356) (0.000998 - 0.00425) (0.00492 - 0.00780) (0.00639 - 0.0117) (-0.0212 - 0.127) (0.00704 - 0.245) 
Other pain-related 
diagnosis 
0.0345*** 3.574*** 0.0140*** 0.0252*** 0.0765*** 1.166*** 0.983*** 
(0.0330 - 0.0361) (2.890 - 4.257) (0.00993 - 0.0180) (0.0212 - 0.0292) (0.0700 - 0.0829) (0.986 - 1.345) (0.668 - 1.298) 
Days since last visit 
-0.000201*** -0.0341*** -0.000295*** -0.00246*** -0.00103*** -0.0129*** -0.0225*** 
(-0.000222, -
0.000180) (-0.0495, -0.0187) (-0.000416, -0.000174) (-0.00271, -0.00220) (-0.00117, -0.000899) (-0.0180, -0.00789) (-0.0344, -0.0107) 
Number of visits 0.0105*** 1.609*** 0.00421*** 0.00192*** 0.0193*** 0.112*** 0.0655* 
(0.0101 - 0.0109) (1.403 - 1.815) (0.00340 - 0.00503) (0.00110 - 0.00275) (0.0178 - 0.0208) (0.0734 - 0.151) (0.00477 - 0.126) 
        
Observations 855,371 137,984 137,984 139,484 139,484 139,484 44,939 
 
*** p<0.001, ** p<0.01, * p<0.05 
Note:  Estimates are marginal effects. 95% confidence intervals are in parentheses. 
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Table 5-17. Predicted means from Stage I models: Sensitivity analysis with narrowed 
implementation period      
  Any fill (%) 
Average dose 
(MME) High dose (%) Concurrent prescriptions (%) 
Osteoarthritis     
  Observed 
14.03 48.26 12.35 18.99 
13.76, 14.30 46.66, 49.85 11.45, 13.25 18.15, 19.82 
  Counterfactual 15.04 58.94 15.76 19.20 
14.52, 15.57 55.62, 62.25 13.94, 17.59 17.60, 20.81 
Fibromyalgia     
  Observed 
14.67 47.85 11.30 23.45 
14.32, 15.01 45.94, 49.76 10.22, 12.39 22.48, 24.41 
  Counterfactual 
15.87 56.32 15.83 24.52 
15.21, 16.53 52.44, 60.20 13.64, 18.02 22.66, 26.38 
 
Note: MME = morphine milligram equivalents. 95% confidence intervals below estimates. Estimates refer to 
predicted means for December 2017. Bold indicates observed and counterfactual estimates with non-overlapping 
confidence intervals. The counterfactual scenario is that in which the guidelines were not released but all other 
predictors were as observed.
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Table 5-18. Predicted means from Stage I models: Sensitivity analysis excluding observations 
after September 2017 (following the President’s declaration of a public health emergency) 
 Any fill (%) 
Average dose 
(MME) 
High dose 
(%) 
Concurrent prescriptions 
(%) 
Osteoarthritis     
  Observed 
13.73 49.39 13.01 19.93 
13.47, 14.00 47.82, 50.95 12.12, 13.90 19.12, 20.75 
  Counterfactual 14.15 56.60 15.78 19.99 
13.77, 14.54 54.22, 58.99 14.47, 17.10 18.83, 21.15 
Fibromyalgia     
  Observed 
14.43 49.66 12.25 23.92 
14.09, 14.77 47.83, 51.49 11.19, 13.31 22.96, 24.88 
  Counterfactual 
15.38 56.51 15.21 24.91 
14.89, 15.87 53.68, 59.35 13.62, 16.79 23.61, 26.22 
 
Note: MME = morphine milligram equivalents. 95% confidence intervals below estimates. Estimates refer to 
predicted means for September 2017. Bold indicates observed and counterfactual estimates with non-overlapping 
confidence intervals. The counterfactual scenario is that in which the guidelines were not released but all other 
predictors were as observed.
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Table 5-19. Three-month predicted means from Stage I models (October-December 2017) 
  Any fill (%) 
Average dose 
(MME) 
High dose 
(%) 
Concurrent 
prescriptions (%) 
Osteoarthritis     
  Observed 
13.99 48.89 12.25 19.22 
13.73, 14.25 47.34, 50.44 11.38, 13.12 18.41, 20.03 
  Counterfactual 14.82 59.23 16.19 19.64 
14.34, 15.30 56.19, 62.27 14.52, 17.86 18.17, 21.12 
Fibromyalgia     
  Observed 
14.67 48.44 11.19 23.86 
14.34, 15.01 46.57, 50.30 10.15, 12.24 22.91, 24.82 
  Counterfactual 
15.7 57.85 15.6 25.5 
15.09, 16.30 54.27, 61.44 13.60, 17.60 23.75, 27.25 
 
Note: MME = morphine milligram equivalents. 95% confidence intervals below estimates. Estimates refer to 
predicted means for October through December 2017. Bold indicates observed and counterfactual estimates with 
non-overlapping confidence intervals. The counterfactual scenario is that in which the guidelines were not released 
but all other predictors were as observed.
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Table 5-20. Impact inventory: Impacts considered in analyses of health sector perspective and 
societal perspective 
   
 
Sector Type of impact Included in this reference case from…perspective?  
   Healthcare sector Societal 
Formal health care sector 
Health Health outcomes (effects)   
 Longevity effects X X 
 Health-related quality-of-life 
effects X X 
 
Other health effects (e.g., 
adverse events and secondary 
transmissions of infections) 
    
 Medical costs   
 Paid for by third-party-payers X X 
 Paid for by patients out-of-
pocket X X 
 Future related medical costs 
(payers and patients) X X 
  Future unrelated medical costs (payers and patients) X X 
Informal healthcare sector 
Health Patient time costs  X 
 Unpaid caregiver time costs  Only for caretaking of minors 
  Transportation costs   
Non-healthcare sectors (with examples of possible items) 
Productivity    
 Labor market earnings  X 
 Cost of unpaid lost 
productivity due to illness 
 X 
 Cost of uncompensated 
household production 
 X 
 Criminal justice  X 
 Other consumption  X 
 Other social services   
 
Decision-analytic model and parameter estimates 
 
Table 5-21 shows the base case estimates and ranges corresponding to each model parameter. 
The annual probability of overdose depended on whether the individual had overdosed 
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previously. However, it did not vary with time; that is, an individual with opioid use disorder 
(OUD) for ten years without a prior overdose is, in my model, as likely to overdose the following 
year as an individual in their first year of misuse.  
 
The extent to which a dose of naloxone reduces mortality likely depends on whether it is the first 
or a subsequent dose the victim has received. However, prior research has not examined the 
exact nature of this relationship. In the base case analysis, I treat all doses equally. In a threshold 
analysis, I vary the effectiveness of subsequent EMS and police and fire doses from high (as 
effective as if it were the first dose) to low (no further reduction in mortality). I conduct two-way 
sensitivity analysis to identify any joint thresholds of effectiveness at which the model 
conclusions change. 
 
In the base case, laypeople and first responders were assumed to obtain a new kit after every use 
and every two years, to reflect naloxone expiration. However, sensitivity analyses considering 
wide variation in the probability that a layperson has obtained naloxone account for the 
possibility that laypeople do not immediately obtain a new kit when needed. 
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Table 5-21. Base case parameter point estimates and ranges 
Probabilities and Relative Risks   
Parameter Point Estimate Range Rationale References  
Per capita 
number of 
police and 
firefighters in 
the US 
0.003 (0.001-0.005) 
The Bureau of Labor Statistics reported 657,690 police 
and sheriff's patrol officers and 315,910 firefighters 
nationwide in 2016, corresponding to a per capita 
estimate of 0.003. In my hypothetical community of 
50,000, this corresponds to 150 police and firefighters. 
Occupational Outlook Handbook. US Bureau of Labor 
Statistics; 2018. Available from: https://www.bls.gov/ooh. 
Per capita 
number of 
EMTs and 
paramedics in 
the US 
0.0008 (0.0002-0.032) 
The Bureau of Labor Statistics reported 244,960 
EMTs and paramedics nationwide in 2016, 
corresponding to a per capita estimate of 0.0008. In 
my hypothetical community of 50,000, this 
corresponds to 40 EMTs. 
Occupational Outlook Handbook. US Bureau of Labor 
Statistics; 2018. Available from: https://www.bls.gov/ooh. 
Prevalence of 
opioid use 
disorder in the 
US 
0.008 (0.004-0.012) 
The 2016 National Survey on Drug Use and Health 
(NSDUH) estimated that 2.1 million people aged 12 
and older had an opioid use disorder in 2016. This 
includes pain reliever use disorder and heroin use 
disorder, and corresponds to approximately 0.8% of 
the US population. In my hypothetical community of 
50,000, this corresponds to 400 people with OUD. 
Substance Abuse and Mental Health Services Administration. 
Key Substance Use and Mental Health Indicators in the United 
States: Results from the 2016 National Survey on Drug Use and 
Health (HHS Publication No. SMA 17-5044, NSDUH Series H-
52) [Internet]. Vol. 7. Rockville, MD; 2017. Available from: 
https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR1-
2016/NSDUH-FFR1-
2016.pdf%0Ahttps://store.samhsa.gov/shin/content//SMA17-
5044/SMA17-5044.pdf 
Proportion of 
people with 
OUD who have 
previously 
overdosed at 
initialization of 
model 
0.4 N/A 
The model begins with a population of opioid users 
who have been misusing for ten years. Starting with an 
annual probability of overdose of 0.05 (see 
justification below), in ten years roughly 40% of this 
population will have experienced at least one prior 
overdose and 60% of the population will never have 
overdosed. 
Darke S, Williamson A, Ross J, Mills KL, Havard A, Teesson 
M. Patterns of nonfatal heroin overdose over a 3-year period: 
findings from the Australian treatment outcome study. J Urban 
Health. United States; 2007 Mar;84(2):283–91.   
Annual 
probability of 
initial 
overdose+ 
0.07 (0.0125-0.125) 
This is the annual probability that a person with OUD 
will overdose, given that they have never overdosed. 
Probability of overdose in scientific studies is often 
reported over the lifetime of the user, and little 
longitudinal data on overdose probability exists. 
However, a 2007 longitudinal cohort study following 
users over a three-year period found an annual 
overdose rate of approximately 5% among study 
participants who had not overdosed in the past year 
(Darke, Williamson, Ross, Mills, Havard, & Teesson, 
Darke S, Williamson A, Ross J, Mills KL, Havard A, Teesson 
M. Patterns of nonfatal heroin overdose over a 3-year period: 
findings from the Australian treatment outcome study. J Urban 
Health. United States; 2007 Mar;84(2):283–91.  
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2007). In the past decade, overdose rates have 
increased sharply. During calibration, this estimate 
was increased to 0.07 so that, in line with the 
literature, 50-60% of people with OUD will have 
overdosed at least once by 15-20 years after initiation.  
Annual 
probability of 
subsequent 
overdose+ 
0.30 (0.15-0.45) 
This is the annual probability that a person with OUD 
will overdose, given that they have overdosed 
previously. Prior overdose is a risk factor for future 
overdose. The aforementioned longitudinal cohort 
study found that the odds of overdosing over the three-
year follow-up were 3.5 times as high for participants 
with a history of overdose. During calibration, this 
estimate was increased to 0.30, which reflects the 
sharply increased rates of overdose over the past 
decade.  
Darke S, Williamson A, Ross J, Mills KL, Havard A, Teesson 
M. Patterns of nonfatal heroin overdose over a 3-year period: 
findings from the Australian treatment outcome study. J Urban 
Health. United States; 2007 Mar;84(2):283–91.  
Probability 
overdose is 
witnessed+ 
0.79 (0.55-0.9) 
Most estimates place the proportion of overdoses 
witnessed at 0.8. However, these estimates tend to be 
collected via self-report. Such data select for nonfatal 
overdoses; the true proportion of overdoses witnessed 
is thus likely to be lower. 
 
Zador, Sunjic, & Darke (1996) examined coronial files 
of all cases of heroin-related deaths, and found that 
58% of heroin overdose deaths occurred in the 
presence of others. That study selected for fatal 
overdoses, likely underestimating the true value. After 
weighting by the probability that an overdose is/is not 
fatal (which takes into account the probability that it is 
a first-time vs. subsequent overdose, and the fatality 
rates of each), I estimate a probability of 0.79 that an 
overdose is witnessed. 
Zador D, Sunjic S, Darke S. Heroin-related deaths in New South 
Wales, 1992: Toxicological findings and circumstances. Med J 
Aust. 1996 Feb 19;164(4):204-6. 
 
Darke S, Ross J, Hall W. Overdose among heroin users in 
Sydney, Australia: I. Prevalence and correlates of non-fatal 
overdose. Addiction. England; 1996 Mar;91(3):405–11.  
 
Lagu T, Anderson BJ, Stein M. Overdoses among friends: drug 
users are willing to administer naloxone to others. J Subst 
Abuse Treat. United States; 2006 Mar;30(2):129–33.  
 
Powis B, Strang J, Griffiths P, Taylor C, Williamson S, 
Fountain J, et al. Self-reported overdose among injecting drug 
users in London: extent and nature of the problem. Addiction. 
1999;94(0965–2140 (Print)):471–8.  
 
Sergeev B, Karpets A, Sarang A, Tikhonov M. Prevalence and 
Circumstances of Opiate Overdose among Injection Drug Users 
in the Russian Federation. J Urban Heal. 2003;80(2):212–9.  
 
Sherman SG, Cheng Y, Kral AH. Prevalence and correlates of 
opiate overdose among young injection drug users in a large 
U.S. city. Drug Alcohol Depend. 2007;88:182–7.  
 
Strang J, Powis B, Best D, Vingoe L, Griffiths P, Taylor C, et 
al. Preventing opiate overdose fatalities with take-home 
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naloxone: pre-launch study of possible im pact and 
acceptability. Addiction. 1999;94(2):199–204.  
Probability that 
witness 
administers 
naloxone+ 
0.7 (0.4-0.9) 
When asked, 75-90% of laypeople with a history of 
opioid misuse express capability and willingness to 
administer naloxone in cases of overdose (Strang, 
Powis, Best, Vingoe et al., 1999; Galea, Worthington, 
et al; Lagu, Anderson, & Stein, 2006). However, 
individuals may not have their naloxone at all times 
(Galea, Worthington, et al., 2006), reducing the 
probability that a witness with naloxone administers. 
Empirical studies suggest that laypeople equipped with 
and trained to use naloxone will administer it in 44%-
80% of overdose events (Seal, Thawley, Gee, 
Bamberger, Kral, et al., 2005; Sherman, Gann, Scott, 
Carlberg, Bigg, & Heimer, 2008; Tobin, Sherman, 
Beilenson, et al., 2009). Because, in reality, the 
possibility that a given witness will not have their 
naloxone available at an overdose may be in part 
counterbalanced by the possibility that another witness 
has obtained naloxone, I estimate this parameter as 
0.7. 
Galea S, Worthington N, Piper TM, Nandi V V, Curtis M, 
Rosenthal DM. Provision of naloxone to injection drug users as 
an overdose prevention strategy: early evidence from a pilot 
study in New York City. Addict Behav. England; 2006 
May;31(5):907–12.  
 
Seal KH, Thawley R, Gee L, Bamberger J, Kral AH, Ciccarone 
D, et al. Naloxone distribution and cardiopulmonary 
resuscitation training for injection drug users to prevent heroin 
overdose death: A pilot intervention study. J Urban Heal. 
2005;82(2):303–11.  
 
Sherman SG, Gann DS, Scott G, Carlberg S, Bigg D, Heimer R. 
A qualitative study of overdose responses among Chicago 
IDUs. Harm Reduct J. England; 2008 Jan;5:2.  
 
Strang J, Powis B, Best D, Vingoe L, Griffiths P, Taylor C, et 
al. Preventing opiate overdose fatalities with take-home 
naloxone: pre-launch study of possible impact and acceptability. 
Addiction. 1999;94(2):199–204.  
 
Tobin KE, Sherman SG, Beilenson P, Welsh C, Latkin CA. 
Evaluation of the Staying Alive programme: training injection 
drug users to properly administer naloxone and save lives. Int J 
Drug Policy. Netherlands; 2009 Mar;20(2):131–6.  
 
Wagner KD, Valente TW, Casanova M, Partovi SM, 
Mendenhall BM, Hundley JH, et al. Evaluation of an Overdose 
Prevention and Response Training Programme for Injection 
Drug Users in the Skid Row Area of Los Angeles, California. 
Int J Drug Policy. 2010;21(3):581–6.   
Probability that 
witness calls 
911 given that 
lay naloxone 
was not 
administered+ 
0.5 (0.3-0.85) 
Many of the studies estimating the proportion of 
overdose witnesses who call 911 do not differentiate 
by whether naloxone was administered. Those that do 
tend to be smaller studies or retrospective. For 
example, of 43 participants in the Staying Alive 
program in Baltimore, MD, 65% reported calling 911 
when they witnessed an overdose and did not 
Banta-Green C, Kuszler P, Coffin P, Schoeppe J. Washington’s 
911 Good Samaritan Drug Overdose Law: Initial Evaluation 
Results [Internet]. 2011. Available from: 
http://adai.uw.edu/pubs/infobriefs/ADAI-IB-2011-
05.pdf%0AFind 
Galea S, Worthington N, Piper TM, Nandi V V, Curtis M, 
Rosenthal DM. Provision of naloxone to injection drug users as 
 174 
administer naloxone (Tobin, Sherman, Beilenson, 
Welsh, & Latkin, 2009). In a similar study, Bennett, 
Bell, et al., 2011 found that, prior to participating in an 
overdose prevention program, participants reported 
calling 911 in 34% of overdose events. Other 
estimates range from 46% to 58%  (Galea, 
Worthington, et al., 2006; Seal, Downing, et al., 2003; 
Sherman, Gann, et al., 2008). Some evidence suggests 
that Good Samaritan Laws may increase the 
probability of calling 911 (Banta-Green, Kuszler, 
Coffin, & Schoeppe, 2011; McClellan, Lambdin, Ali, 
et al., 2018), although barriers to these policies' 
effectiveness remain (Koester, Mueller, Raville, et al., 
2017; Zadoretzky et al., 2017). 
an overdose prevention strategy: early evidence from a pilot 
study in New York City. Addict Behav. England; 2006 
May;31(5):907–12.  
 
Koester S, Mueller SR, Raville L, Langegger S, Binswanger IA. 
Why are some people who have received overdose education 
and naloxone reticent to call Emergency Medical Services in the 
event of overdose? Int J Drug Policy [Internet]. Elsevier B.V.; 
2017;48:115–24. Available from: 
http://dx.doi.org/10.1016/j.drugpo.2017.06.008 
 
Lankenau SE, Wagner KD, Silva K, Kecojevic A, Iverson E, 
McNeely M, et al. Injection drug users trained by overdose 
prevention programs: responses to witnessed overdoses. J 
Community Health. Netherlands; 2013 Feb;38(1):133–41.  
 
Mcclellan C, Lambdin BH, Ali MM, Mutter R, Davis C, 
Wheeler E, et al. Opioid-overdose laws association with opioid 
use and overdose mortality. Addict Behav [Internet]. 
2018;(December 2017)  
 
Seal KH, Downing M, Kral AH, Singleton-Banks S, Hammond 
J-P, Lorvick J, et al. Attitudes about prescribing take-home 
naloxone to injection drug users for the management of heroin 
overdose: a survey of street-recruited injectors in the San 
Francisco Bay Area. J Urban Health. United States; 2003 
Jun;80(2):291–301.  
 
Sherman SG, Gann DS, Scott G, Carlberg S, Bigg D, Heimer R. 
A qualitative study of overdose responses among Chicago 
IDUs. Harm Reduct J. England; 2008 Jan;5:2.  
 
Tobin KE, Sherman SG, Beilenson P, Welsh C, Latkin CA. 
Evaluation of the Staying Alive programme: training injection 
drug users to properly administer naloxone and save lives. Int J 
Drug Policy. Netherlands; 2009 Mar;20(2):131–6.  
 
Tracy M, Piper TM, Ompad D, Bucciarelli A, Coffin PO, 
Vlahov D, et al. Circumstances of witnessed drug overdose in 
New York City: implications for intervention. Drug Alcohol 
Depend. Ireland; 2005 Aug;79(2):181–90.  
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Zadoretzky C, McKnight C, Bramson H, Des Jarlais D, Phillips 
M, Hammer M, et al. The New York 911 Good Samaritan Law 
and Opioid Overdose Prevention Among People Who Inject 
Drugs. World Med Heal Policy [Internet]. 2017;9(3):318–40. 
Available from: http://doi.wiley.com/10.1002/wmh3.234  
Probability that 
witness calls 
911 given lay 
naloxone 
administered+  
0.5 (0.1-0.85) 
Several studies suggest that overdose witnesses are 
less likely to call 911 if they have administered 
naloxone. For example, Doe-Simkins, Quinn, Xuan, et 
al. (2014) found in a retrospective cohort study that in 
about 25% of overdose events in which participants 
administered naloxone, 911 was called or emergency 
medical services were present. Walley, Xuan, et al. 
(2013) found that 911 was called or emergency 
medical services were present in 32.5% of events in 
which naloxone was administered by participants in 
San Francisco's DOPE project. Other studies have 
reported similar results, with estimates ranging from 
10% to 29% (Koester et al., 2017; Lankenau et al., 
2013; Sherman et al., 2008; Seal et al., 2005; Enteen et 
al., 2010; Bennett et al., 2011). 
 
However, many of these studies only capture 
individuals who return to community-based programs 
to report their experience administering naloxone, a 
non-representative group. Selection bias may thus 
threaten the validity of these estimates. Given a lack of 
high-quality data and conflicting experiences among 
experts on the ground, I estimate that the probability of 
calling 911 does not depend on naloxone 
administration, but conduct sensitivity analyses to 
investigate the possibility that it does.   
Bennett AS, Bell A, Tomedi L, Hulsey EG, Kral AH. 
Characteristics of an overdose prevention, response, and 
naloxone distribution program in Pittsburgh and Allegheny 
County, Pennsylvania. J Urban Health. United States; 2011 
Dec;88(6):1020–30.  
 
Doe-Simkins M, Quinn E, Xuan Z, Sorensen-Alawad A, 
Hackman H, Ozonoff A, et al. Overdose rescues by trained and 
untrained participants and change in opioid use among 
substance-using participants in overdose education and 
naloxone distribution programs: a retrospective cohort study. 
BMC Public Health. England; 2014 Apr;14:297.  
 
Enteen L, Bauer J, McLean R, Wheeler E, Huriaux E, Kral AH, 
et al. Overdose prevention and naloxone prescription for opioid 
users in San Francisco. J Urban Health. United States; 2010 
Dec;87(6):931–41.  
 
Koester S, Mueller SR, Raville L, Langegger S, Binswanger IA. 
Why are some people who have received overdose education 
and naloxone reticent to call Emergency Medical Services in the 
event of overdose? Int J Drug Policy [Internet]. Elsevier B.V.; 
2017;48:115–24. Available from: 
http://dx.doi.org/10.1016/j.drugpo.2017.06.008 
 
Lankenau SE, Wagner KD, Silva K, Kecojevic A, Iverson E, 
McNeely M, et al. Injection drug users trained by overdose 
prevention programs: responses to witnessed overdoses. J 
Community Health. Netherlands; 2013 Feb;38(1):133–41.  
 
Seal KH, Thawley R, Gee L, Bamberger J, Kral AH, Ciccarone 
D, et al. Naloxone distribution and cardiopulmonary 
resuscitation training for injection drug users to prevent heroin 
overdose death: A pilot intervention study. J Urban Heal. 
2005;82(2):303–11.  
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Sherman SG, Gann DS, Scott G, Carlberg S, Bigg D, Heimer R. 
A qualitative study of overdose responses among Chicago 
IDUs. Harm Reduct J. England; 2008 Jan;5:2.  
 
Walley, A. Y., Xuan, Z., Hackman, H. H., Quinn, E., Doe-
simkins, M., Sorensen-alawad, A., … Ozonoff, A. (2013). 
Opioid overdose rates and implementation of overdose 
education and nasal naloxone distribution in Massachusetts : 
interrupted time series analysis, 174(January), 1–13. 
https://doi.org/10.1136/bmj.f174 
 
Zadoretzky C, McKnight C, Bramson H, Des Jarlais D, Phillips 
M, Hammer M, et al. The New York 911 Good Samaritan Law 
and Opioid Overdose Prevention Among People Who Inject 
Drugs. World Med Heal Policy [Internet]. 2017;9(3):318–40. 
Available from: http://doi.wiley.com/10.1002/wmh3.234 
Probability that 
police and fire 
arrive before 
EMS, if 911 is 
called+ 
0.5 (0-1) 
The probability that police and fire arrive first to the 
scene of an overdose will vary widely depending on 
the community, and there is a dearth of research 
estimating the distribution of this parameter. 
Therefore, I arbitrarily set the base case estimate at 
0.5, and, in sensitivity analyses, examine the full range 
of zero to one. 
 
Probability that 
first responders 
(EMS/police 
and fire) 
administer 
naloxone if 
available 
0.89 (0.8-1) 
First responders may not always recognize an 
overdose as such or may fail to administer naloxone 
for other reasons. Sumner, Mercado-Crespo, Spelke, et 
al. (2016) find that Sumner et al. find that, out of 124 
fatal overdose cases in which EMS attempted 
resuscitation, they administered naloxone 66% of the 
time. Women, older individuals, and those without 
clear evidence of illicit drug use were less likely to 
receive naloxone. Since Sumner et al. (2016) only 
looked at fatal cases, I adjust my estimate to account 
for the estimated 6% of overdoses that are fatal, 
assuming that first responders administer naloxone 
90% of the time in ultimately nonfatal cases. Police 
and fire may differ from EMS on this parameter, but 
due to a lack of available dataIassume that it is the 
same for all first responders. 
Sumner, S. A., Mercado-Crespo, M. C., Spelke, M. B., 
Paulozzi, L., Sugerman, D. E., Hillis, S. D., & Stanley, C. 
(2016). Use of Naloxone by Emergency Medical Services 
during Opioid Drug Overdose Resuscitation Efforts. Prehospital 
Emergency Care: Official Journal of the National Association 
of EMS  Physicians and the National Association of State EMS 
Directors, 20(2), 220–225. 
https://doi.org/10.3109/10903127.2015.1076096 
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Probability of 
mortality due to 
overdose, given 
initial overdose 
and that (a) the 
victim is alone 
or (b) the 
witness does 
not administer 
naloxone or call 
emergency 
services 
0.054 (0.0125-0.12) 
Although the overall increase in mortality due to 
overdose for opioid users over a lifetime is significant, 
the probability of an individual overdose being fatal is 
low. In a large cohort study of Australian heroin users, 
the probability of mortality given first overdose was 
0.03. This is a conservative estimate of mortality given 
no medical intervention, because unwitnessed 
mortalities or deaths outside of hospitals cannot be 
ascertained from emergency room records or surveys 
of living users of opioids, and are therefore highly 
dependent on death records. During calibration, I thus 
adjusted this value upward to 0.054, in order to 
approximate the 47,600 opioid overdose deaths in 
2017. The upper bound is high to account for the 
uncertainty in this parameter, as well as rising 
fatalities and fentanyl prevalence in recent years. 
Darke S, Mills KL, Ross J, Teesson M. Rates and correlates of 
mortality amongst heroin users: findings from the Australian 
Treatment Outcome Study (ATOS), 2001-2009. Drug Alcohol 
Depend. Ireland; 2011 Jun;115(3):190–5.  
 
Darke S, Ross J, Hall W. Overdose among heroin users in 
Sydney, Australia: I. Prevalence and correlates of non-fatal 
overdose. Addiction. England; 1996 Mar;91(3):405–11.  
 
Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, 
Hackman HH, et al. Opioid overdose rates and implementation 
of overdose education and nasal naloxone distribution in 
Massachusetts: interrupted time series analysis. 
2013;346(7894).   
Probability of 
mortality due to 
overdose, given 
it is a 
subsequent 
overdose and 
that (a) the 
victim is alone 
or (b) the 
witness does 
not administer 
naloxone or call 
emergency 
services 
0.164 (0.06-0.38) 
In a large cohort study of Australian heroin users, the 
adjusted hazard ratio for mortality compared to first 
overdose was 3.03 (1.22-7.52). Using the estimate of 
probability of mortality given first overdose (0.03), the 
probability of overdose from subsequent overdose was 
calculated using this relative risk, and adjusted upward 
to 0.164 during calibration. The upper bound is high to 
account for the considerable uncertainty in this 
parameter, as well as rising fatalities and fentanyl 
prevalence in recent years. 
Darke S, Mills KL, Ross J, Teesson M. Rates and correlates of 
mortality amongst heroin users: findings from the Australian 
Treatment Outcome Study (ATOS), 2001-2009. Drug Alcohol 
Depend. Ireland; 2011 Jun;115(3):190–5.  
 
Galea S, Worthington N, Piper TM, Nandi V V, Curtis M, 
Rosenthal DM. Provision of naloxone to injection drug users as 
an overdose prevention strategy: early evidence from a pilot 
study in New York City. Addict Behav. England; 2006 
May;31(5):907–12.  
 
Strang J, Powis B, Best D, Vingoe L, Griffiths P, Taylor C, et 
al. Preventing opiate overdose fatalities with take-home 
naloxone: pre-launch study of possible im pact and 
acceptability. Addiction. 1999;94(2):199–204.   
Relative risk of 
mortality due to 
overdose, given 
that one of the 
three parties 
(layperson, 
police and fire, 
or EMS) 
administers 
naloxone.+ 
0.48 (.3-.7) 
Studies of lay naloxone distribution programs have 
found between 89% and 100% overdose survival 
following naloxone administration (Bennett, Bell, 
Tomedi, et al., 2011; Enteen, Bauer, McLean, et al., 
2010; Strang, Manning, Mayet, et al., 2008). A meta-
analysis of lay naloxone programs found the odds of 
overdose reversal to be 8.58 times higher when lay 
naloxone was administered, compared to no 
administration (Giglio, Li, & DiMaggio, 2015).  
 
 
Belz, D. et al., 2006. Naloxone use in a tiered-response 
emergency medical services system. Prehospital Emergency 
Care, 10(4), pp.468–471. 
 
Bennett AS, Bell A, Tomedi L, Hulsey EG, Kral AH. 
Characteristics of an overdose prevention, response, and 
naloxone distribution program in Pittsburgh and Allegheny 
County, Pennsylvania. J Urban Health. United States; 2011 
Dec;88(6):1020–30.  
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Research on naloxone administration by EMS (both 
basic and advanced life support personnel) has found 
overdose survival rates of between 45 and 80% 
following administration (Belz, Lieb, Rea, et al., 2006; 
Gulec, Lahey, Suozzi, et al., 2018). 
 
Because some of these cases may not have been fatal 
without naloxone, the relative risk of mortality 
following administration is estimated to be 0.6 in the 
base case analysis. However, because of the potential 
importance of this estimate to the model results, I vary 
it from zero (no mortality when naloxone is 
administered) to one (no reduction in mortality when 
naloxone is administered) in sensitivity analysis. 
 
There are actually three separate relative risk 
parameters in the model, each describing mortality 
reduction due to administration by a different group 
(laypeople, police and fire, and EMS). 
 
Lay naloxone administration occurs before first 
responder administration, saving time and reducing 
mortality. However, this advantage may be offset by 
the medical care that first responders can provide; 
moreover, first responders may be more likely to 
possess multiple doses of naloxone than laypeople 
(i.e., a full kit), improving their ability to reduce 
mortality since multiple doses are often required for 
successful reversal (Belz et al., 2006; Gulec et al., 
2018).  
 
Given the dearth of data examining the net effect of 
these competing factors, I assume in the base case that 
the mortality benefit is equal across the three groups. 
However, this may not be accurate, and in particular 
may underestimate the effectiveness of lay 
distribution. One-way sensitivity analysis on the 
effectiveness of naloxone distribution by laypeople 
allows evaluation of this possibility. Moreover, in the 
probabilistic sensitivity analysis, I allow each 
parameter to independently vary at the same time, in 
Enteen L, Bauer J, McLean R, Wheeler E, Huriaux E, Kral AH, 
et al. Overdose prevention and naloxone prescription for opioid 
users in San Francisco. J Urban Health. United States; 2010 
Dec;87(6):931–41.  
 
Giglio RE, Li G, DiMaggio CJ. Effectiveness of bystander 
naloxone administration and overdose education programs: a 
meta-analysis. Inj Epidemiol [Internet]. Cham: Springer 
International Publishing; 2015 Dec 22;2(1):10. Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005759/ 
 
Gulec, N. et al., 2018. Basic and Advanced EMS Providers Are 
Equally Effective in Naloxone Administration for Opioid 
Overdose in Northern New England. Prehospital Emergency 
Care, 22(2), pp.163–169. Available at: 
https://doi.org/10.1080/10903127.2017.1371262. 
 
Strang J, Manning V, Mayet S, Best D, Titherington E, Santana 
L, et al. Overdose training and take-home naloxone for opiate 
users: prospective cohort study of impact on knowledge and 
attitudes and subsequent management of overdoses. Addiction. 
England; 2008 Oct;103(10):1648–57. 
  
Walley, A. Y., Xuan, Z., Hackman, H. H., Quinn, E., Doe-
simkins, M., Sorensen-alawad, A., … Ozonoff, A. (2013). 
Opioid overdose rates and implementation of overdose 
education and nasal naloxone distribution in Massachusetts : 
interrupted time series analysis, 174(January), 1–13. 
https://doi.org/10.1136/bmj.f174 
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order to examine a wider range of possible 
circumstances.  
 
There is no combination of interventions in which the 
base case probability of mortality is zero; this accounts 
for cases in which the victim is not reached in time or 
the overdose cannot be reversed by naloxone (e.g., 
some cases of polydrug toxicity). 
 
These mortality parameters are also applied to the 
probability of developing hypoxia if an overdose is 
survived. 
 
As described below, regardless of whether EMS have 
naloxone available, they reduce mortality by an 
estimated 20% by managing cardiac and breathing 
conditions. Thus, the 52% reduction due to 
administration of naloxone by EMS is on top of this 
existing 20% reduction, and is thus applied to the 
smaller remaining risk of mortality. The situation is 
analogous for naloxone administered by police and 
fire.   
Relative risk of 
mortality, given 
that EMS arrive 
but do not have 
naloxone.+ 
0.8 (.65-.95) 
EMS who arrive at the scene of an overdose without 
naloxone can other provide medical assistance before 
the victim receives naloxone at the emergency 
department. I assume that, compared to receiving no 
naloxone or other medical assistance, this reduces 
mortality by 20%.  
 
Yokell, Delgado, Zaller, et al. (2014) report that 0.2% 
of emergency room visits for overdose that resulted in 
death. This would correspond to a relative risk of 
0.067 if these were first overdoses. However, this is an 
underestimate of mortality given EMS assistance 
without naloxone, because it does not account for 
victims who died before reaching the hospital, and 
because some of these victims will have received 
naloxone. I increase the relative risk accordingly. 
Yokell M, Delgado M, Zaller N, Wang N, McGowan S, Green 
T. Presentation of prescription and nonprescription opioid 
overdoses to us emergency departments. JAMA Intern Med 
[Internet]. 2014 Dec 1;174(12):2034–7. Available from: 
http://dx.doi.org/10.1001/jamainternmed.2014.5413  
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Relative risk of 
mortality, given 
that police and 
fire arrive first 
but do not have 
naloxone.+ 
.95 (.8-1) 
If police and fire arrive to the scene before EMS but 
are not equipped with naloxone, they may still reduce 
average mortality via rescue breathing or ventilation 
by bag-valve. I assume that, compared to receiving no 
naloxone or other medical assistance, this reduces 
mortality by 5%. 
Belz, D., Lieb, J., Rea, T., & Eisenberg, M. S. (2006). Naloxone 
use in a tiered-response emergency medical services system. 
Prehospital Emergency Care, 10(4), 468–471. 
https://doi.org/10.1080/10903120600885134 
Probability of 
cessation given 
no recent 
overdose 
0.15 (0.05-0.3) 
In a prospective study of injection drug users in San 
Francisco (Evans, Hahn, Lum, et al., 2009), 28.8% 
ceased injecting for three months or more during 
follow-up; median time to cessation from initial 
interview was 331 days. In a similar study in Canada, 
Bruneau, Brogly, Tyndall, et al. (2004) found that 
18.5% ceased injection for seven months or more. In 
both studies, however, heroin users were less likely to 
quit. Huo, Bailey, and Ouellet (2006) found that 16% 
of their sample ceased injection for a median of 16 
months. I estimate that 15% of individuals in my 
cohort who have not recently overdosed cease use for 
at least 12 months. 
Bruneau J, Brogly SB, Tyndall MW, Lamothe F, Franco EL. 
Intensity of drug injection as a determinant of sustained 
injection cessation among chronic drug users: the interface with 
social factors and service utilization. Addiction. 2004 
Jun;99(6):727–37.  
  
Evans JL, Hahn JA, Lum PJ, Stein ES, Page K. Predictors of 
injection drug use cessation and relapse in a prospective cohort 
of young injection drug users in San Francisco, CA (UFO 
Study). Drug Alcohol Depend. 2009;101(3):152-157. 
doi:10.1016/j.drugalcdep.2008.12.007. 
 
Huo D, Bailey SL, Ouellet LJ. Cessation of injection drug use 
and change in injection frequency: the Chicago Needle 
Exchange Evaluation Study. Addiction. 2006;101(11):1606-
1613. doi:10.1111/j.1360-0443.2006.01577.x. 
Probability of 
cessation, given 
recent overdose 
0.15 (0.025-0.3) 
 
Evans et al. (2009) found that the individuals who had 
recently overdosed were 76% less likely to cease 
injection than those who had not recently overdosed. 
However, Huo et al. (2006) found that overdose was 
not a significant predictor of cessation. A study by 
Shah, Galai, Celentano, et al. (2006) of the ALIVE 
cohort found that median time to cessation was longer 
for individuals who had experienced overdose in the 
prior 6 months (time ratio = 1.48, 95% CI: 1.12-1.96). 
 
However, given the limited available data and the 
contrasting experiences of experts on the ground, 
Evans JL, Hahn JA, Lum PJ, Stein ES, Page K. Predictors of 
injection drug use cessation and relapse in a prospective cohort 
of young injection drug users in San Francisco, CA (UFO 
Study). Drug Alcohol Depend. 2009;101(3):152-157. 
doi:10.1016/j.drugalcdep.2008.12.007. 
 
Huo D, Bailey SL, Ouellet LJ. Cessation of injection drug use 
and change in injection frequency: the Chicago Needle 
Exchange Evaluation Study. Addiction. 2006;101(11):1606-
1613. doi:10.1111/j.1360-0443.2006.01577.x. 
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estimate the post-overdose cessation rate as equal to 
the rate not following overdose. I reduce the lower 
bound on this parameter in order to examine the 
possibility that cessation rates are lower among those 
who recently overdosed. 
Pollini RA, McCall L, Mehta SH, Celentano DD, Vlahov D, 
Strathdee SA. Response to overdose among injection drug 
users. Am J Prev Med.; 2006 Sep;31(3):261–4.  
Shah, N. G., Galai, N., Celentano, D. D., Vlahov, D., & 
Strathdee, S. A. (2006). Longitudinal predictors of injection 
cessation and subsequent relapse among a cohort of injection 
drug users in Baltimore , MD , 1988 – 2000, 83, 147–156. 
https://doi.org/10.1016/j.drugalcdep.2005.11.007  
Relative risk of 
cessation, given 
Emergency 
Department 
visit 
1 (1-1.2) 
 
Individuals who receive treatment for overdose in the 
Emergency Department (ED) may receive Screening, 
Brief Intervention, and Referral to Treatment  
(SBIRT) to address opioid misuse and use disorder; in 
addition, they may receive ED-initiated 
buprenorphine/naloxone (Suboxone) to begin treating 
OUD. However, evidence suggests that SBIRT 
interventions do not improve substance use outcomes. 
Moreover, D’Onofrio, O’Connor, Pantalon, et al. 
(2017) find that ED-initiated buprenorphine/naloxone 
entails no difference in outcomes at six or twelve 
months follow-up. However, ED-initiated therapy may 
improve and become more widespread in the future; to 
account for this possibility, I set the upper bound of 
this parameter to 1.2 (20% higher “risk” of cessation 
given ED visit).        
Bogenschutz, M. P., Donovan, D. M., Mandler, R. N., Perl, H. 
I., Forcehimes, A. A., Crandall, C., … Douaihy, A. (2014). 
Brief intervention for patients with problematic drug use 
presenting in emergency departments: A randomized clinical 
trial. JAMA Internal Medicine, 174(11), 1736–1745. 
https://doi.org/10.1001/jamainternmed.2014.4052 
 
D’Onofrio, G., O’Connor, P. G., Pantalon, M. V., Chawarski, 
M. C., Busch, S. H., Owens, P. H., … Fiellin, D. A. (2015). 
Emergency department-initiated buprenorphine/naloxone 
treatment for opioid dependence: A randomized clinical trial. 
JAMA, -Journal of the American Medical Association, 313(16), 
1636–1644. https://doi.org/10.1001/jama.2015.3474 
 
Roy-Byrne, P., Bumgardner, K., Krupski, A., Dunn, C., Ries, 
R., Donovan, D., … Zarkin, G. A. (2014). Brief intervention for 
problem drug use in safety-net primary care settings: A 
randomized clinical trial. JAMA, -Journal of the American 
Medical Association, 312(5), 492–501. 
https://doi.org/10.1001/jama.2014.7860 
 
Saitz, R., Palfai, T. P. A., Cheng, D. M., Alford, D. P., 
Bernstein, J. A., Lloyd-Travaglini, C. A., … Samet, J. H. 
(2014). Screening and brief intervention for drug use in primary 
care: The ASPIRE randomized clinical trial. JAMA, -Journal of 
the American Medical Association, 312(5), 502–513. 
https://doi.org/10.1001/jama.2014.7862 
Annual 
probability of 
relapse given 
cessation  
0.15 (0.13-0.18) 
Using an 8-year observational study of heroin users in 
Chicago, I calculated an approximate probability of 
relapse for a former user in recovery. The probability 
of relapse falls dramatically with increased time in 
recovery; following Coffin & Sullivan (2013), I 
assumed that the probability of relapse falls by half 
after 10 years in recovery, and again after 15 years. I 
Dennis ML, Foss MA, Scott CK. An eight-year perspective on 
the relationship between the duration of abstinence and other 
aspects of recovery. Eval Rev. 2007;31(6):585-612. 
doi:10.1177/0193841X07307771. 
 
Giglio RE, Li G, DiMaggio CJ. Effectiveness of bystander 
naloxone administration and overdose education programs: a 
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accounted for this by back-calculating a single annual 
probability that results in the correct proportion of the 
population remaining in recovery after 20 years. 
meta-analysis. Inj Epidemiol. 2015;2(1):10. 
doi:10.1186/s40621-015-0041-8. 
 
Gossop M, Marsden J, Stewart D. Dual dependence: assessment 
of dependence upon alcohol and illicit drugs, and the 
relationship of alcohol dependence among drug misusers to 
patterns of drinking, illicit drug use and health problems. 
Addiction. 2002;97(2):169-178. 
 
Parmar MKB, Strang J, Choo L, Meade AM, Bird SM. 
Randomized controlled pilot trial of naloxone-on-release to 
prevent post-prison opioid overdose deaths. Addiction. 
2017;112(3):502-515. doi:10.1111/add.13668. 
 
Seal KH, Downing M, Kral AH, et al. Attitudes about 
prescribing take-home naloxone to injection drug users for the 
management of heroin overdose: a survey of street-recruited 
injectors in the San Francisco Bay Area. J Urban Health. 
2003;80(2):291-301. doi:10.1093/jurban/jtg032. 
Relative risk of 
overdose given 
that person has 
received 
naloxone 
(hypothetical 
moral hazard)+ 
1 (0.8-1.2) 
While some people with substance abuse disorder 
report that they might use more intensively if naloxone 
were available (e.g., Kirane, Ketteringham, Bereket, et 
al., 2016), a review of lay naloxone distribution 
programs, finds no empirical evidence of this 
hypothesis. In fact, several studies show a reduction in 
opioid use following naloxone training. I thus use a 
base-case relative risk at 1 and vary the parameter in 
both a promotional and restrictive direction. In 
threshold analyses, I vary this parameter even more 
widely.  
Kirane H, Ketteringham M, Bereket S, et al. Awareness and 
attitudes toward intranasal naloxone rescue for opioid overdose 
prevention. J Subst Abuse Treat. 2016;69:44-49. 
doi:10.1016/j.jsat.2016.07.005. 
 
McDonald R, Strang J. Are take-home naloxone programmes 
effective? Systematic review utilizing application of the 
Bradford Hill criteria. Addiction. 2016;111(7):1177-1187. 
doi:10.1111/add.13326. 
Costs and cost inputs   
      Parameter Value Range  References 
Hourly wage of 
health 
professional 
trainer ($) 
58.00 (48-70) 
$29.42 is the Medicare reimbursement for 15 to 30 
minutes of alcohol and/or substance abuse structured 
screening and brief intervention services (G0396). 
Reimbursement for SBIRT. Substance Abuse and Mental 
Health Services Organization. Available from: https://www. I 
ntegration.samhsa.gov/sbirt/Reimbursement_for_SBIRT.pdf  
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Hourly wage of 
person with 
OUD ($) 
18.11 (14.50-27.70) 
Calculated by reducing the average hourly wage for 
Americans in 2017 by 17.5%, in order to account for 
low labor participation by people using illicit 
substances. 
Inocencio TJ, Carroll N V, Read EJ, Holdford DA. The 
economic burden of opioid-related poisoning in the United 
States. Pain Med. 2013;14(10):1534-1547. 
doi:10.1111/pme.12183. 
 
U.S. Department of Justice National Drug Intelligence Center. 
(2011). The Economic Impact of Illicit Drug Use on American 
Society. Washington, D.C. Available from: 
https://www.justice.gov/archive/ndic/pubs44/44731/44731p.pdf 
 
Employment, hours, and earnings from the current employment 
statistics survey (National). US Bureau of Labor Statistics; 
2018. Available from: 
https://data.bls.gov/pdq/SurveyOutputServlet?request_action=w
h&graph_name=CE_cesbref3. 
Hourly wage of 
police and fire 
($) 
27.30 (13.70-41) 
Weighted average of median hourly income for 
firefighters and patrol officers in 2016, inflated to 
2017. 
Occupational Outlook Handbook. US Bureau of Labor 
Statistics; 2018. Available from: https://www.bls.gov/ooh. 
Hourly wage of 
EMS personnel 
($) 
16.05 (8-24) The median pay for EMTs & paramedics was $15.71 in 2016, whichIinflate to July 2017 dollars. 
Occupational Outlook Handbook. US Bureau of Labor 
Statistics; 2018. Available from: https://www.bls.gov/ooh. 
Number of 
trainees per 
trainer (first 
responder 
trainings) 
20 (5-100) 
This parameter scales the cost of trainer wages to 
account for the fact that multiple first responders 
(police and fire/EMS) will typically be trained 
simultaneously.  
 
Number of 
trainers per 
training 
(layperson 
trainings) 
5 (1-20) 
This parameter scales the cost of trainer wages to 
account for the fact that multiple laypeople will 
sometimes be trained simultaneously—e.g., by 
community-based programs. Other times, laypeople 
will receive one-on-one training, for instance when 
obtaining naloxone at a pharmacy. This parameter 
takes both types of circumstance into account.  
 
 184 
Duration of 
layperson 
trainings 
(minutes) 
15 (5-60) 
Training length varies. Some community-based 
programs may last thirty minutes or an hour and 
involve broader training (e.g., in CPR administration), 
while naloxone obtained from a pharmacist via 
standing order may involve less training. 
Guide to developing and managing overdose prevention and 
take-home naloxone projects [Internet]. Harm Reduction 
Coalition; 2012 [cited 2018 May 8]. Available from: 
http://www.overdosepreventionstrategies.org/wp-
content/uploads/2015/03/od-manual-final-links.pdf.  
Personal communication with Lemont Gore (Michigan Unified), 
Leo Beletsky (Northeastern University), and Dominick Zurlo 
(New Mexico Department of Health). 
Duration of 
trainings for 
police and fire 
(minutes) 
60 (15-90) 
Training length varies. In the DOPE project,  provider 
trainings typically lasted 90 minutes, while others last 
about an hour. Overall, training in naloxone 
administration may be growing shorter as easier-to-use 
naloxone becomes available, and as police and fire 
become increasingly familiar with signs and 
management of overdose. 
Guide to developing and managing overdose prevention and 
take-home naloxone projects [Internet]. Harm Reduction 
Coalition; 2012 [cited 2018 May 8]. Available from: 
http://www.overdosepreventionstrategies.org/wp-
content/uploads/2015/03/od-manual-final-links.pdf.  
Personal communication with Gina Dahlem (University of 
Michigan). 
Duration of 
trainings for 
EMS (minutes) 
30 (7.5-45) 
Training EMS personnel in naloxone administration is 
assumed to take roughly half as long as training for 
fire and law enforcement, because it is subsumed in 
their broader medical training.  
 
Cost of 
naloxone kit 
(two doses) 
61.50 (6-300) 
Gupta et al. report that the average price of injectable 
naloxone from the four dominant manufacturers was 
$24 per dose in 2016, while the cost of nasal spray 
(NarcanÒ) was $150. However, ADAPT Pharma offers 
a public interest price of $37.50 per intranasal dose. In 
the base case analysis, I assume that 50% of naloxone 
is injectable and that 50% is nasal spray (at $37.50 per 
dose), corresponding to a weighted average price of 
$30.75 per dose, or $61.50 per kit.  
 
Some community-based programs report lower prices 
per kit; for instance, Yokell, Green, Bowman, et al., 
(2011) report a cost of approximately $3 per dose. I 
adjust the range of possible costs accordingly. A wide 
range accounts for a large variety of possible 
circumstances. The lower bound reflects a situation in 
which all naloxone is injectable or the public interest 
price of NarcanÒ falls. The upper bound reflects a 
situation in which all naloxone is NarcanÒ and there is 
no public interest pricing. 
ADAPT Pharma® Expands Program Offering Free NARCAN® 
(naloxone HCl) Nasal Spray to Eligible Schools and 
Universities. Adapt Pharma; 2018. Available from: 
http://adaptpharma.com/adapt_press_release/march-19-2018-
adapt-pharma-expands-program-offering-free-narcan/. 
 
Gupta R, Shah N, Ross JS. The Rising Price of Naloxone — 
Risks to Efforts to Stem Overdose Deaths. N Engl J Med. 
2016;373(25):1-3. doi:10.1056/NEJMp1002530. 
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While the average price of a naloxone kit is assumed 
to be equal regardless of the distribution target, 
laypeople may be more likely to receive injectable 
naloxone from community-based programs because of 
its affordability, while police and fire and basic life 
support personnel may be more likely to receive 
intranasal naloxone because of its ease of 
administration. As a result, naloxone kit prices for 
each group are allowed to vary independently in 
sensitivity analyses.  
 
Note that a threshold analysis is also conducted to 
examine the effect of further price increases in 
naloxone.    
Cost of 
ambulance 
transport ($) 
500 (470-530) National median Medicare payment per transport with add-on payments. 
Ambulance providers: costs and Medicare margins varied 
widely; transports of beneficiaries have increased; 2012. United 
States Government Accountability Office. Available from: 
https://www.gao.gov/assets/650/649018.pdf.  
Cost of 
Emergency 
Department 
visit ($) 
16,760 (13,410-20,110) 
Yokell, Delgado, Zaller, et al. (2014) tabulate charges 
associated with Emergency Department visits due to 
prescription and non-prescription opioid overdose, as 
well as subsequent inpatient stays. my estimate is a 
weighted average of expenditures for patients who are 
versus are not subsequently hospitalized ($29,807 and 
$3,397, respectively; proportion hospitalized is 0.506). 
Yokell, M., Delgado, M., Zaller, N., Wang, N., McGowan, S., 
& Green, T. (2014). Presentation of prescription and 
nonprescription opioid overdoses to us emergency departments. 
JAMA Internal Medicine, 174(12), 2034–2037. Retrieved from 
http://dx.doi.org/10.1001/jamainternmed.2014.5413  
Productivity 
cost per 
overdose ($) 
610 (550-670) 
Market and household productivity costs due to 
overdose. This does not include the productivity cost 
of mortality due to overdose, which is reflected in the 
model when an individual dies.  
Inocencio TJ, Carroll N V, Read EJ, Holdford DA. The 
economic burden of opioid-related poisoning in the United 
States. Pain Med. 2013;14(10):1534-1547. 
doi:10.1111/pme.12183. 
Average annual 
market and 
non-market 
productivity of 
the general 
population 
25-34: 64,686 
Grosse, Krueger, and Pike (2018) estimated age-
specific annual market and non-market productivity 
for Americans in 2016. I inflated these to 2017 dollars 
and, in sensitivity analysis, varied them by up to 20% 
in each direction. 
Grosse, S. D., Krueger, K. V, & Pike, J. (2018). Estimated 
annual and lifetime labor productivity in the United States , 
2016 : implications for economic evaluations. Journal of 
Medical Economics, 0(0), 1–8. 
https://doi.org/10.1080/13696998.2018.1542520 
 
35-34: 87,023 
45-54: 83,354 
55-64: 67,990 
65-74: 38,504 
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75+: 16,017 
Average per 
person annual 
consumption 
for the general 
population 
25-34: 24,665 The 2017 Bureau of Labor Statistics’ Consumer 
Expenditure Survey estimates average consumption 
per consumer unit. This includes average health care 
consumption. I use this to calculate per-person 
consumption and, in sensitivity analyses, varied them 
by up to 20% in each direction.  
Consumer Expenditure Survey. U.S. Bureau of Labor Statistics. 
Available from: 
https://www.bls.gov/cex/2017/combined/age.pdf 
35-34: 25,524 
45-54: 35,790 
55-64: 38,653 
65-74: 30,547 
75+: 19,230 
Productivity 
cost due to 
OUD for 
individual not 
in treatment 
12,100 (9,680-14,520) 
On average, individuals with OUD have lower societal 
productivity due to factors such as greater 
unemployment, lower earnings, and absenteeism due 
to incarceration. This estimate was obtained by 
averaging the 2017-inflated results of three costing 
papers. 
Birnbaum, H. G., White, A. G., Schiller, M., Waldman, T., 
Cleveland, J. M., & Roland, C. L. (2011). Societal Costs of 
Opioid Abuse, Dependence and Misuse in The United States. 
Pain Medicine, 12, 657–667. https://doi.org/10.1016/S1098-
3015(10)72532-8 
 
Florence, C., Luo, F., Xu, L., & Zhou, C. (2016). The Economic 
Burden of Prescription Opioid Overdose, Abuse and 
Dependence in the United States, 2013 Curtis. Medical Care, 
54(10), 901–906. 
https://doi.org/10.1097/MLR.0000000000000625. 
 
Mark, T. L., Woody, G. E., Juday, T., & Kleber, H. D. (2001). 
The economic costs of heroin addiction in the United States. 
Drug and Alcohol Dependence, 61, 195–206. 
 
Criminal justice 
system costs 5,000 (4,000-6,000) 
This estimate captures the policing, legal, and 
incarceration costs associated with opioid misuse, as 
well as costs to victims of crimes committed by 
individuals (e.g., due to lost property). Incarceration 
costs exclude those associated with absenteeism, 
which are captured in productivity costs. The estimate 
reflects an average of the 2017-inflated results of three 
costing papers.  
Birnbaum, H. G., White, A. G., Schiller, M., Waldman, T., 
Cleveland, J. M., & Roland, C. L. (2011). Societal Costs of 
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Excess health 
care costs for 
individual with 
11,000 (8,800-13,200) 
Excess medical costs beyond those of a typical 
American are generated by people with OUD who are 
not in treatment, including costs due to septicemia, 
Birnbaum, H. G., White, A. G., Schiller, M., Waldman, T., 
Cleveland, J. M., & Roland, C. L. (2011). Societal Costs of 
Opioid Abuse, Dependence and Misuse in The United States. 
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OUD, not in 
treatment 
HIV and Hepatitis C, and others. Direct health care 
expenditures due to overdose are not included here, as 
these are parameterized elsewhere in the model. This 
estimate was obtained by averaging the 2017-inflated 
results of two costing papers, excluding the direct 
medical costs of overdose used elsewhere in this 
model. In the model, individuals who are currently 
misusing accrue these costs. 
Pain Medicine, 12, 657–667. https://doi.org/10.1016/S1098-
3015(10)72532-8 
 
Mark, T. L., Woody, G. E., Juday, T., & Kleber, H. D. (2001). 
The economic costs of heroin addiction in the United States. 
Drug and Alcohol Dependence, 61, 195–206. 
Excess health 
care costs for 
individual with 
OUD, in 
treatment 
5,800 (4,640-6,960) 
Individuals receiving treatment for OUD may generate 
fewer medical costs on average; in addition to 
treatment costs, however, costs due to chronic 
complications such as HIV and Hepatitis C persist. 
This estimate was obtained by averaging the 2017-
inflated results of three costing papers, as well as a 
U.S. Department of Defense estimate of annual 
methadone treatment cost. In the model, individuals 
who are not currently misusing accrue these costs. 
Birnbaum, H. G., White, A. G., Schiller, M., Waldman, T., 
Cleveland, J. M., & Roland, C. L. (2011). Societal Costs of 
Opioid Abuse, Dependence and Misuse in The United States. 
Pain Medicine, 12, 657–667. https://doi.org/10.1016/S1098-
3015(10)72532-8 
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The economic costs of heroin addiction in the United States. 
Drug and Alcohol Dependence, 61, 195–206. 
 
U.S. Department of Defense Office of the Secretary. (2016). 
TRICARE; Mental Health and Substance Use Disorder 
Treatment (Vol. 81). Washington, D.C. Retrieved from 
https://www.govinfo.gov/content/pkg/FR-2016-09-02/pdf/2016-
21125.pdf 
Utilities     
Parameter Value Range  References 
Currently 
misusing 
opioids 
0.8 (0.73-0.9) 
Individuals misusing opioids experience lower health-
related quality of life on average, due to a variety of 
complications of substance use. 
 
Nosyk B, Sun H, Guh DP, et al. The quality of eight health 
status measures were compared for chronic opioid dependence. 
J Clin Epidemiol. 2010;63(10):1132-1144. 
doi:http://dx.doi.org/10.1016/j.jclinepi.2009.12.003. 
 
Pyne JM, Tripathi S, French M, McCollister K, Rapp RC, Booth 
BM. Longitudinal association of preference-weighted health-
related quality of life measures and substance use disorder 
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outcomes. Addiction. 2011;106(3):507-515. doi:10.1111/j.1360-
0443.2010.03299.x. 
 
Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the 
cost-effectiveness of methadone maintenance. Am J Public 
Health. 2000;90(7):1100-1111. 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1446290/. 
Relative 
increase for 
recovery health 
state utility 
1.07 (1-1.123) 
On average, health-related quality of life increases 
upon cessation from opioid misuse, but—due to 
chronic conditions related to opioid misuse—does not 
recover entirely. 
Nosyk B, Sun H, Guh DP, et al. The quality of eight health 
status measures were compared for chronic opioid dependence. 
J Clin Epidemiol. 2010;63(10):1132-1144. 
doi:http://dx.doi.org/10.1016/j.jclinepi.2009.12.003. 
 
Pyne JM, Tripathi S, French M, McCollister K, Rapp RC, Booth 
BM. Longitudinal association of preference-weighted health-
related quality of life measures and substance use disorder 
outcomes. Addiction. 2011;106(3):507-515. doi:10.1111/j.1360-
0443.2010.03299.x. 
 
Vanagas G, Padaiga Z, Bagdonas E. Cost-utility analysis of 
methadone maintenance treatment in Lithuania. Medicina 
(Kaunas). 2010;46(4):286-292. 
 
Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the 
cost-effectiveness of methadone maintenance. Am J Public 
Health. 2000;90(7):1100-1111. 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1446290/. 
Absolute 
reduction in 
utility due to 
long-term 
effects of 
severe hypoxia 
0.119 (0-0.2) 
The effects of hypoxia exist on a continuum. I estimate 
that, on average, individuals with severe hypoxia will 
experience a decline in utility equivalent to moving 
from a modified Rankin scale score of 0 (no 
symptoms) to a score of 1 (no significant disability, 
but some symptoms). 
Rivero-Arias O, Ouellet M, Gray A, Wolstenholme J, Rothwell 
PM, Luengo-Fernandez R. Mapping the modified Rankin scale 
(mRS) measurement into the generic EuroQol (EQ-5D) health 
outcome. Med Decis Making. 2010;30(3):341-354. 
doi:10.1177/0272989X09349961. 
Other     
     Parameter    References 
Start age of 
cohort 35 (25-45) 
Using data from the 2016 National Survey on Drug Use 
and Health, Lipari, Ahrnsbrak, Pemberton, and Porter 
(2017) found that the average age of initiating heroin use 
was 25.5, and that the average aeg of initiating 
prescription pain reliever misuse was 24.4. I thus estimate 
the average age of nonmedical opioid use overall to be 
25. Best, Ghufran, Day, et al. (2008) found the average 
Best, D. W., Ghufran, S., Day, E. D., Ray, R., & Loaring, J. 
(2008). Breaking the habit: a retrospective analysis of desistance 
factors among formerly problematic heroin users. Drug and 
Alcohol Review, (July 2007), 619–624. 
https://doi.org/10.1080/09595230802392808 
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length of heroin use to be roughly ten years. To 
approximate a cross-sectional population of individuals 
with opioid use disorder, I thus model a cohort of 
individuals starting at age 35. I use the annual probability 
of first overdose to adjust the proportion who, at ten 
years, will have previously overdosed. 
Lipari, R. N., Ahrnsbrak, R. D., Pemberton, M. R., & Porter, J. 
D. (2017). Risk and Protective Factors and Estimates of 
Substance Use Initiation: Results from the 2016 National 
Survey on Drug Use and Health. NSDUH Data Review, 
(September). Retrieved from 
https://www.samhsa.gov/data/sites/default/files/NSDUH-DR-
FFR3-2016/NSDUH-DR-FFR3-2016.pdf 
Mortality rate 
of long-term 
opioid user, 
excluding 
mortality due to 
overdose (per 
person-year) 
Mean age less than 35 and 
out of treatment: 0.0187 
 
Mean age less than 35 and in 
treatment: 0.0073 
 
Mean age 35 or over and out 
of treatment: 0.0298 
 
Mean age 35 or over and in 
treatment: 0.0113 
A systematic review and meta-analysis by Sordo, 
Barrio, Bravo, et al. (2017) estimates crude mortality 
rates (CMRs) for individuals with opioid dependence 
who are in vs. out of medication-assisted treatment. 
Because mortality due to overdose is accounted for 
elsewhere in the model, the CMRs included reflect 
rates of mortality due to all other causes of death. 
Sordo et al. break down the reviewed studies by 
whether the average age of the population studied was 
less than 35 years or 35+. I apply their estimates 
accordingly; however, given the sharp rise in all-cause 
mortality at older ages, I also incorporate age-specific 
mortality rates for the general population: when the 
relevant estimate from Sordo et al. is smaller than the 
age-specific mortality rates, I apply the latter. In 
sensitivity analyses, I vary these rates from 20% below 
to 20% above the base case estimates. 
Murphy, S. L., Xu, J., Kochanek, K. D., & Arias, E. (2018). 
Mortality in the United States, 2017. Hyattsville, MD. Retrieved 
from https://www.cdc.gov/nchs/data/databriefs/db328-h.pdf 
 
Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, 
L., Wiessing, L., … Pastor-barriuso, R. (n.d.). Mortality risk 
during and after opioid substitution treatment : systematic 
review and meta-analysis of cohort studies. 
https://doi.org/10.1136/bmj.j1550  
Note: + indicates that, in addition to the main sensitivity analyses, a threshold analysis was conducted for that parameter given its uncertainty and/or potential to 
influence the results; that is, the parameter was varied from zero to one to identify any thresholds at which the preferred strategy changed.  
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Table 5-22. Distribution assumptions and distribution parameters used in probabilistic sensitivity 
analysis 
Description of Variable Base case estimate Low High Distribution Mean 
Standard 
Deviation 
Starting age of cohort 35 25 45 Normal 35 5 
Probability of overdose given no 
prior overdose 0.07 0.0125 0.125 Beta 0.07 0.028 
Probability of overdose given 
prior overdose 0.3 0.15 0.45 Beta 0.3 0.075 
Probability that overdose is 
witnessed 0.79 0.55 0.9 Beta 0.79 0.1 
Probability that layperson witness 
would administer naloxone, if 
available 
0.7 0.4 0.9 Beta 0.7 0.15 
Probability that witness will call 
FRs 0.5 0.3 0.85 Beta 0.5 0.17 
Probability that witness will call 
FRs if administered naloxone 0.5 0.1 0.85 Beta 0.5 0.175 
Probability that police and fire 
arrive first 0.5 0 1 Beta 0.5 0.25 
Probability that first responders 
administer naloxone given it is 
available 
0.89 0.8 1 Beta 0.89 0.05 
Mortality due to first overdose 
(given no naloxone, no first 
responders) 
0.054 0.013 0.12 Beta 0.054 0.03 
Mortality due to subsequent 
overdose (given no naloxone, no 
first responders) 
0.164 0.06 0.38 Beta 0.108 0.108 
Relative risk of mortality given 
administration of layperson 
naloxone (compared to no 
naloxone, no FRs) 
0.48 0.3 0.7 Beta 0.48 0.2 
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Relative risk of mortality if police 
and fire come but do not 
administer naloxone (compared to 
no naloxone, no FRs) 
0.95 0 1 Beta 0.95 0.2 
Relative risk of mortality if police 
and fire come and do administer 
naloxone (compared to no 
naloxone, no FRs) 
0.48 0.3 0.7 Beta 0.48 0.2 
Relative risk of mortality if EMS 
come but do not administer 
naloxone (compared to no 
naloxone, no FRs) 
0.8 0 1 Beta 0.8 0.2 
Relative risk of mortality if EMS 
come and do administer naloxone 
(compared to no naloxone, no 
FRs) 
0.48 0.3 0.7 Beta 0.48 0.2 
Probability of experiencing 
hypoxia due to overdose 0.05 0 0.3 Beta 0.05 0.125 
Reduction in utility due to 
experience of hypoxia  0.119 0 0.2 Beta 0.119 0.041 
Probability of cessation following 
overdose 0.15 0.025 0.3 Beta 0.15 0.063 
Probability of cessation if no 
overdose 0.15 0.05 0.3 Beta 0.15 0.05 
Probability of relapse if in 
recovery/treatment 0.15 0.13 0.18 Beta 0.15 0.015 
Relative risk of cessation if the 
individual interacts with FRs 1 0.8 1.2 Normal 1 0.1 
Utility if not in treatment 0.8 0.73 0.9 Beta 0.8 0.05 
Relative increase in utility for 
individual in treatment/recovery 1.07 1 1.123 Normal 1.07 0.005 
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Hourly wage of EMS receiving 
naloxone training 16.05 8 24 Gamma 16.05 3.995 
Hourly wage of layperson 
receiving naloxone training 18.11 24.5 27.7 Gamma 18.11 4.811 
Hourly wage of police and fire 
receiving naloxone training 27.3 13.65 40.95 Gamma 27.3 6.825 
Hourly wage of individual 
conducting naloxone training 58 48 70 Gamma 58 6 
Length of naloxone training for 
laypersons (hours) 0.25 0.083 1 Gamma 0.25 0.375 
Length of naloxone training for 
police and fire (hours); length of 
training for EMS is estimated to 
be half of this value 
1 0.25 1.5 Gamma 1 0.25 
Ratio of trainer to laypeople 
(inverse of number of trainees per 
trainer) 
0.2 0.1 1 Beta 0.2 0.05 
Ratio of trainer to EMS  0.05 0.01 0.2 Beta 0.05 0.02 
Ratio of trainer to police and fire 0.05 0.01 0.2 Beta 0.05 0.02 
Cost of naloxone kit (laypeople) 61.5 6 300 Gamma 61.5 27.75 
Cost of naloxone kit (police and 
fire) 61.5 6 300 Gamma 61.5 6.7 
Cost of naloxone kit (EMS) 61.5 6 300 Gamma 61.5 6.7 
Criminal justice costs 5000 4000 6000 Gamma 5000 500 
Excess health care costs, not in 
treatment 11000 8800 13200 Gamma 11000 1100 
Excess health care costs, in 
treatment 5800 4640 6960 Gamma 5800 580 
Excess productivity costs, not in 
treatment 12100 9680 14520 Gamma 12100 1210 
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Multiplier, consumption  1 .8 1.2 Normal 1 .1 
Multiplier, productivity 1 .8 1.2 Normal 1 .1 
 
Cost calculations 
Costs are inflated to 2017 dollars using a CPI-based calculator. 
Health care costs 
Both the societal and the health sector perspective took into account the annual health care costs accrued 
by individuals in the model. Health costs reflect direct health care costs, including expenditures related to 
treatment, emergency transport, health insurance administration, and research and prevention efforts to 
address opioid use disorder (time costs of lay naloxone training were considered productivity costs). 
Health costs were calculated as the sum of (a) age-specific consumer expenditures on health care for the 
general population, and (b) estimated excess health care costs for individuals with opioid use disorder 
who are in or out of treatment (where treatment refers to any specialty treatment for opioid addiction). 
Individuals not currently misusing accrue costs associated with treatment, while those misusing accrue 
costs associated with not being in treatment. Tabale 5-21 details these parameters.  
 
Productivity and criminal justice system costs 
In the societal perspective, market and non-market productivity costs due to absenteeism (such as that 
caused by incarceration or overdose), greater unemployment, and lower earnings were taken into account. 
Following the recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine, 
productivity costs were calculated as productivity costs due to OUD minus average, annual, age-specific 
productivity for the general population plus consumption (note that health care consumption was not 
double-counted). 
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Criminal just system costs due to policing, legal adjudication, incarceration, and victimization were also 
included in the societal perspective.  
 
Naloxone training and distribution costs 
The cost of training one first responder (police and fire or EMS) in naloxone use was calculated as the 
sum of first responder wages and trainer wages, multiplied by the length of training (taking into account 
that multiple first responders may be trained simultaneously). The initial cost of first responder 
distribution was equal to the total cost of a single first responder training and naloxone kit, multiplied by 
the number of first responders receiving naloxone nationwide. This parameter varied depending on the 
proportion of first responders equipped with naloxone (i.e., depending on which strategy was under 
consideration). Further costs accrued in subsequent years, as first responders received new naloxone kits 
and training refreshers.  
 
The cost of training one layperson in naloxone use was calculated as the sum of layperson and trainer 
wages, multiplied by the length of training (taking into account that multiple laypeople may be trained 
simultaneously). The initial cost of lay distribution was equal to the total cost of a single layperson 
training and naloxone kit, multiplied by the number of laypeople receiving naloxone in the entire 
population—which depended on the strategy under consideration. In high layperson strategies in the base 
case analysis, this number was estimated as .75 times the number of people with OUD. However, because 
of positive spillover in which naloxone distributed to one person may be administered to someone else, 
this may be an overestimate of reality: ensuring that, at 75% of overdose scenes, the victim or at least one 
witness has at some time obtained naloxone can likely be achieved by distributing naloxone to fewer than 
75% of people using (or their loved ones). This slightly disadvantages the high lay distribution strategies; 
however, sensitivity analyses on the cost parameters suggest that this error in distribution costs does not 
importantly influence the results. Further costs accrued in subsequent years, as laypeople received new 
naloxone kits and training refreshers.  
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Model calibration and validation 
In step one of calibration, I adjusted the annual probability of overdose (given no prior 
overdoses) such that 50-60% of those surviving at 10-20 years after initiation would have a 
lifetime history of overdose (Darke et al., 1996, 2011; Sherman et al., 2007; Alexander Y Walley 
et al., 2013). I did so by modelling a cohort of novice individuals misusing opioids (age 25; 
holding all else in the model equal) and calculating the proportion of those surviving at years 10, 
15, and 20 who had previously overdosed (Table 5-23). Since none of the strategies truly 
represents the status quo, I calibrated across strategies. By adjusting the probability of overdose 
(given no prior overdoses) from a starting value of 0.04 to 0.07, I found that, depending on the 
strategy, 36-38% of surviving model participants have overdosed at 10 years, 48-50% at 15 
years, and 58-64% at 20 years.  
 
In step two of calibration, I adjusted several parameters—the probability of subsequent overdose, 
the mortality rates associated with first and subsequent overdoses (absent intervention), and the 
relative risk of mortality due to naloxone administration—in order to approximate the estimated 
47,600 opioid overdose deaths nationwide in 2017. WhileIreport my main results in terms of a 
hypothetical community, for this step of calibration, I scale the model up to the national 
population level. Since none of the strategies truly represents the status quo, I sought parameter 
estimates such that the number of deaths would be too high in the low LP/low PF/low EMS 
condition and too low in the other strategies. Table 5-23 details the changes made during each 
step.  
 
 
  196 
Table 5-23. Model calibration 
Step 1: Calibrate probability of first overdose to get percent of those still alive at 10-20 years who 
have ever overdosed close to 50-60%. 
Parameter Starting Value Adjustment factor New Value 
Probability of overdose 
given no prior 
overdose 
0.04 1.75 0.07 
Step 2: Calibrate to number of  2017 opioid overdose deaths (47,600 in 2017) 
Parameter Starting Value Adjustment factor New Value 
Probability of overdose 
given prior overdose 
  
0.175 1.7 0.30 
Probability of mortality 
due to overdose absent 
intervention, given no 
prior overdose 
  
0.03 1.8 0.054 
Probability of mortality 
due to overdose absent 
intervention, given 
prior overdose 
  
0.0909 1.8 0.164 
Relative risk of 
mortality due to 
naloxone 
administration 
0.6 0.8 0.48 
 
To validate the model, I first checked that the lifetime percentage of overdose deaths averted in 
the high LP/low EMS/low PF strategy was similar to that in two modelling studies of lay 
naloxone distribution (Coffin & Sullivan, 2013b; Uyei et al., 2017a) and one empirical study of 
the effect of naloxone access laws on mortality (Rees et al., 2017). To compare with Coffin and 
Sullivan (2013), I set the proportion of laypersons who have obtained naloxone in the “high LP” 
strategy to 0.2; in this case, 5.1% of fatal overdoses were averted over five years and 3.6% over 
the lifetime, compared to that study’s 10.6% and 6.5%, respectively. To compare with Uyei, 
Fiellin, Buchelli, et al. (2017), I set the proportion of laypersons who have obtained naloxone in 
the “high LP” strategy to 0.3; then, 6.7% of fatal overdoses were averted over 20 years, 
  197 
compared to that study’s 6.3%. I hypothesize that Coffin and Sullivan’s estimate was higher than 
ours because they made higher estimates on two parameters: (a) the probability that a witness is 
overdosed and (b) the probability that, given that the witness had obtained naloxone, they would 
have it available and administer it. Based on my assessment of the literature, I believe that 70% 
and 79%, respectively, are appropriate estimates.  
 
Rees, Sabias, Argys, et al. (2017) find that Naloxone Access Laws correspond to a 21% 
reduction in opioid deaths after two years. When I set the proportion of laypersons who have 
obtained naloxone to 0.75 (as in the base case analysis), 20% of fatal overdoses were averted 
after two years.  
 
Second, I compared the percentage of lay naloxone kits used with that in three empirical studies 
(Doe-Simkins et al., 2014; Enteen et al., 2010; Alexander Y Walley et al., 2013). At two years 
after distribution, Walley et al. (2013) found that approximately 11% of kits of lay kits had been 
used, while in my model 6.2% had. At roughly five years after distribution, Enteen et al. (2010) 
and Doe-Simkins et al. (2014) found that 18.5% and 5.9%, respectively, of lay kits had been 
used, compared to 7.0% in my model. I suspect that my model is underestimating the share of 
kits that will be used because I assumed that a lay kit will be replaced every two years or as soon 
as it is used, which is optimistic. Because this underestimation would cause my main results to 
be somewhat conservative but would not be expected to change the ranking of strategies, I did 
not change the model further.  
 
Results 
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Results of varying the proportion of each group receiving naloxone in “high” strategies 
In sensitivity analyses, I examined the level of distribution to each target group as a continuous 
variable (between 0% and 100% coverage). The net monetary benefit associated with each 
strategy increased monotonically with the percentage of each target group receiving naloxone 
(Figure 5-3). That is, there was no point at which the health gains due to increased distribution to 
any group are outweighed by increased costs. However, the validity of this analysis may be 
limited by the fact that I model costs as linearly increasing with greater levels of distribution, 
which does not capture the effects of non-random distribution in the target population and 
increasing costs as target individuals become harder to reach.  
 
 
Figure 5-3. Net monetary benefit as a function of proportion in each target group receiving 
naloxone, given high distribution to the other groups 
 
 
Note: In this model, net monetary benefit increases monotonically with the percentage of each target 
group receiving naloxone. That is, there is no point at which the health gains of increased distribution are 
outweighed by increased costs. 
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Threshold analyses (societal perspective) 
 
Table 5-24 details the results of varying some parameters from zero to one, to identify thresholds 
at which the preferred strategy changes, and to account for the possibility that the true parameter 
value could be outside of my estimated range. Threshold analyses identified thresholds in nine 
parameters that influenced the preferred strategy: the probability an overdose is witnessed, 
naloxone kit costs, the reduction in mortality associated with each possible intervention, and 
(hypothetical) moral hazard (Table 5-24). Each of these thresholds occurred at an extreme or 
unlikely value. 
  
Table 5-24. Results of threshold analyses 
Parameter Threshold Value  Preferred Strategy Below Preferred Strategy Above 
Probability of overdose given no 
prior overdoses None  N/A N/A 
Probability of overdose given 
prior overdoses None  N/A N/A 
Probability that the overdose is 
witnessed 0.049 High LP, low PF, high EMS Maximum 
Probability witness administers 
naloxone, if available 0.008 Low LP, high PF, high EMS Maximum 
Probability that witness will call 
911 None  N/A N/A 
Probability that EMS have 
naloxone in “low EMS” 
strategies 
None  N/A N/A 
Probability that police and fire 
arrive before EMS 0.030 High LP, low PF, high EMS Maximum 
Probability that PF have 
naloxone in “low PF” strategies None  N/A N/A 
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Relative risk of mortality: lay 
naloxone 0.986 Maximum Low LP, high PF, high EMS 
Relative risk of mortality: PF, 
without naloxone 0.092 High LP, low PF, high EMS Maximum 
Relative risk of mortality: PF 
naloxone 0.954 Maximum High LP, low PF, high EMS 
Relative risk of mortality: EMS, 
without naloxone 0.020 High LP, low PF, low EMS Maximum 
Relative risk of mortality: EMS 
naloxone 0.994 Maximum High LP, high PF, low EMS 
Cost of naloxone kit distributed 
to all parties ($) 1,432 Maximum High LP, low PF, high EMS 
Cost of lay naloxone kit ($)a 5,264 Maximum High LP, low PF, high EMS 
Relative risk of overdose given 
availability of lay naloxone 
(hypothetical moral hazard) 
1.23 Maximum Low LP, high PF, high EMS 
 
Note: A strategy is preferred if it maximizes net monetary benefit compared to the other strategies. WTP 
set at $50,000. Some thresholds that do not affect the preferred strategy are excluded. Two thresholds on 
the probability that an overdose is witnessed are excluded because they occur at probabilities less than 
0.005.  
a This threshold analysis can also be used to evaluate greater costs of naloxone distribution more 
broadly—due, e.g., to difficulty reaching target laypeople.  
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